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Preface
Biotechnology is often considered to be one of the key technologies that will help enable the long-
term sustainable development of the European Union (EU), particularly in terms of economic growth, 
environmental protection and public health. However, despite the high levels of research funding, both 
public and private, and the high expectations, especially regarding biotechnology-enabled medical 
advances, there has been a lack of reliable information on the contribution that biotechnology is really 
making and on its economic, social and environmental consequences.
The “Bio4EU study”, which had its origins in a request from the European Parliament, intents to 
contribute to closing that knowledge gap.
The study was developed by the European Commission’s Joint Research Centre (JRC), working in 
harmony with a group of other services of the Commission concerned with biotechnology, and coordinated 
by the Commission’s Secretariat-General. The work was led by a team at the JRC’s Institute for Prospective 
Technological Studies (JRC/IPTS). Much of the data was gathered by the European Techno-Economic Policy 
Support Network (ETEPS), a consortium of highly regarded European policy studies institutes linked to the 
JRC/IPTS, which also provided valuable input to the analysis.
Throughout the study, the JRC has involved stakeholder groups, keeping them abreast of progress 
and inviting them to provide input and comments. We are grateful for their participation. Also, a public 
website (http://bio4eu.jrc.es/) has provided a wider platform for publishing up-to-date information on the 
study and for receiving feedback.
I would also like to thank the Bio4EU Advisory Committee of distinguished scientists, chaired by 
Professor Patrick Cunningham, for their support. They have followed the study from its beginning and have 
been instrumental in guiding it to a successful conclusion.
The present document, the Bio4EU synthesis report, sets out the main findings of the study. It presents 
the first comprehensive picture of the applications of modern biotechnology and their contribution to 
the EU’s chief policy goals. We hope that it will become a valuable basis for a better understanding of 
biotechnology and its impacts and challenges. It has already been used by the Commission to help draw 
up its mid-term review of the EU Strategy on Life Sciences and Biotechnology.
For those wishing to delve into this interesting subject in more detail, the full report and all its 
supporting documents can be found on our Bio4EU website (http://bio4eu.jrc.es/).
Roland Schenkel
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Executive Summary
This report sets out the main findings of the Bio4EU study. It is based on a series of more detailed 
background documents that are available on the Bio4EU website (http://bio4eu.jrc.es/). The study provides 
the first comprehensive evaluation of the contributions that modern biotechnology is making in the context 
of major European Union (EU) policies.
The policy context
The study was set in the context of the EU’s Lisbon Strategy and Sustainable Development Strategy. 
At its March 2000 Lisbon summit the European Council endorsed the objective of making the EU “the 
most competitive and dynamic knowledge-based economy in the world, capable of sustainable economic 
growth with more and better jobs and greater social cohesion”. In 2005 the Lisbon Strategy was refocused 
on economic growth and more and better jobs1. In 2001, one year after the Lisbon summit, the Sustainable 
Development Strategy was adopted by the Gothenburg European Council, complementing the Lisbon 
Agenda2. It was revised in 2005, identifying key challenges such as climate change, clean energy, public 
health and sustainable consumption and production3.
Biotechnology in general, and modern biotechnology4 in particular, is considered one of the key 
enabling technologies of the 21st century to support the Lisbon Strategy and sustainable development. 
However, there are few data on the actual availability and uptake of modern biotechnology products and 
processes. As a result, there is a lack of reliable information on the contribution that modern biotechnology 
is making to the Union’s objectives.
The genesis of the Bio4EU study
Against this background, in response to a request from the European Parliament, the European 
Commission decided to carry out a study assessing applications of modern biotechnology. The study was 
designed to provide input for the reflection on the role of life sciences and biotechnology in the renewed 
Lisbon Strategy and to help increase public awareness and understanding of them5.
1 European Commission (2000) DOC/00/7: The Lisbon European Council – An agenda of economic and social renewal for 
Europe. Contribution of the European Commission to the special European Council in Lisbon, 23-24 March 2000; European 
Commission COM (2005) 24: Communication to the Spring European Council – Working together for growth and jobs – a new 
start for the Lisbon Strategy.
2 European Commission COM (2001) 264 final: Communication from the Commission – a sustainable Europe for a better world: a 
European Union Strategy for Sustainable Development (Commission’s proposal to the Gothenburg European Council).
3 European Commission COM (2005) 658 final: Communication from the Commission to the Council and the European 
Parliament on the review of the Sustainable Development Strategy – A platform for action.
4 Modern biotechnology can be defined as use of cellular, molecular and genetic processes in production of goods and services. 
Its beginnings date back to the early 1970s when recombinant DNA technology was first developed. Unlike traditional 
biotechnology – which includes fermentation and plant and animal hybridisation – modern biotechnology involves a different 
set of technologies, including industrial use of recombinant DNA, cell fusion and tissue engineering amongst others.
5 European Commission COM (2005) 286 final: Report from the Commission to the European Parliament, the Council, the 
Committee of the Regions and the European Economic and Social Committee Life sciences and biotechnology – a strategy for 
Europe. Third progress report and future orientations.
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The study was conducted between autumn 2005 and spring 20076 under the leadership of the European 
Commission’s Joint Research Centre. It focused on current applications of modern biotechnology in its 
three main fields: medicine and health care; primary production and agro-food; and industrial production 
processes, energy and the environment.
Modern biotechnology in medicine and health care
Human medicine and health care is the most prominent field of application of modern biotechnology, 
as the high share of biotechnology publications and patent applications targeted at this sector confirms. 
Modern biotechnology has widespread applications in human medicine and health care which make a 
significant contribution to the EU economy. Modern biotechnology directly contributes to around 0.04% 
of the EU’s gross value added (GVA)7 (based on 2002 data). The main product groups are:
•	 biopharmaceuticals, with a share of 9% of turnover from all pharmaceuticals in the EU in 2005. 
Examples include recombinant insulin or monoclonal antibodies for cancer treatment;
•	 recombinant vaccines, with a share of 17% of turnover from all vaccines in the EU in 2005. Most 
recombinant vaccines are targeted at hepatitis B;
•	 modern biotechnology-based in vitro diagnostics (IVD), mainly immunoassays and nucleic-acid-
based tests, with a share of about 30% of turnover from all IVD in the EU in 2005. Examples 
include detection of HIV by nucleic-acid-based tests and cardiac diagnostic assays for detecting 
biomarkers associated with heart attacks.
Beyond that, modern biotechnology provides powerful tools for research and development work 
on biopharmaceuticals, but also on small molecule drugs, vaccines and diagnostics. These and indirect 
effects stemming from use of modern biotechnology products and the potentially improved state of health 
of EU citizens would add to the contribution to GVA.
The USA takes the largest market shares (in terms of value) for biopharmaceuticals, vaccines and 
modern biotechnology-based in vitro diagnostics. However, the similar numbers of modern biotechnology 
products available on the EU and US markets indicate that EU citizens are also able to reap the benefits 
which modern biotechnology can yield, for example:
•	 unique therapeutic and diagnostic solutions (e.g. enzyme replacement therapy and genetic 
testing);
•	 unlimited supplies of potentially safer products (e.g. insulin and hepatitis B vaccine);
•	 superior therapeutic and diagnostic approaches (e.g. monoclonal antibodies and cardiac 
diagnostic assays).
Mounting health care costs are a challenge for many European health care systems. Applications 
of modern biotechnology could contribute to reducing health care costs by virtue of their superior cost-
effectiveness over alternative products. Often, however, appropriate cost-effectiveness studies are missing 
or no alternative treatments are available. Apart from a few examples, such as nucleic-acid-based HIV 
testing which appears to be cost-effective, a conclusive overall assessment is therefore difficult.
6 The ETEPS network carried out a large part of the data gathering and provided input to the analysis, whereas DG JRC/IPTS was 
responsible for design and coordination of the study and overall data analysis.
7 Modern biotechnology can be either a core technology or just a supporting technology in production processes or products. 
In every application of modern biotechnology, 100% of the product value added or turnover was considered a contribution by 
modern biotechnology.
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Modern biotechnology products tend to be relatively high-value products. For example, 
biopharmaceuticals and recombinant vaccines are dynamic market components displaying higher average 
growth rates than conventional products. The EU shows less development activity on biopharmaceuticals: 
only 15% of the biopharmaceuticals currently available were developed by EU companies compared with 
54% by US companies. Moreover, US companies have about twice as many drug candidates in clinical 
trials as EU companies, whereas the share of biopharmaceuticals out of all drugs in clinical trials has been 
similar in both regions in recent years.
Modern biotechnology in primary production and agro-food
Modern biotechnology affects large parts of primary production and the agro-food sector. It is mainly 
applied in the input sectors and contributes to 13% to 23% of their turnover and 0.01% to 0.02% of the 
EU’s GVA (based on 2002 data). This includes:
•	 breeding and propagation of crops, livestock and fish, e.g. use of genetic markers, genetic 
modification and embryo transfer;
•	 feed additive production, e.g. the amino acid lysine and the enzyme phytase;
• veterinary and food diagnostics, e.g. detection of BSE8, salmonella, genetically modified crops 
and food;
•	 veterinary vaccines, e.g. for pseudorabies eradication;
•	 enzymes for food production, e.g. in fruit juice production.
However, uptake of modern biotechnology depends on the application and subsector. The EU holds 
large shares of the global markets for which biotechnology-derived products are relevant (e.g. breeding 
and propagation material, veterinary products and feed additives), with he notable exception of GM 
crops. Use of biotechnology-derived products further downstream by the EU agro-food sector contributes 
to about 32% to 38% of its turnover and to 1.3% to 1.55% of the EU’s GVA (based on 2002 data).
Modern biotechnology-based veterinary and diagnostic applications help to monitor and control 
some of the major animal diseases (e.g. pseudorabies or foot and mouth disease), zoonoses and food 
safety concerns (e.g. salmonella and BSE) and maintain consumer confidence (e.g. GMO traceability).
The applications of modern biotechnology in primary production and agro-food mostly affect 
production efficiency, leading to lower use of resources and emissions per unit output (e.g. improved crop 
varieties or phytase and the amino acid lysine in feed additives).
Modern biotechnology in industrial production, energy and the environment
Industrial biotechnology (including modern biotechnology in industrial production processes, energy 
and the environment) in EU manufacturing industry is currently limited to specific processes and individual 
steps in the production process, including:
•	 textile finishing (e.g. enzyme-based de-sizing of cotton fabric);
•	 pulp and paper manufacturing (e.g. enzyme-supported pulp bleaching);
•	 detergents (e.g. enzymes in laundry and automatic dishwasher detergents);
8 BSE: bovine spongiform encephalopathy.
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•	 certain chemical products, e.g. enzymes, biotechnology-based polymers, antibiotics, amino 
acids, drug compounds (individual steps in the production process or fully biotechnological 
production);
•	 bioethanol production.
In bioremediation, approaches based on traditional biotechnology still predominate.
Industrial biotechnology contributes to around 0.08% of the EU's GVA (based on 2002 data, without 
the chemical sector, due to lack of data, and without food processing, which is included in the agro-
food sector). However, wherever industrial biotechnology is applied it has positive economic and 
environmental implications:
•	 industrial biotechnology increases labour productivity by 10% to 20% compared with 
conventional processes;
•	 industrial biotechnology reduces energy and water consumption and emissions, including the 
greenhouse gas CO2.
The EU is the leading producer of enzymes (75%), the prerequisite for many industrial biotechnology 
processes. However, in many industrial applications of biotechnology the USA (e.g. bioethanol and 
biotechnology-based polymers) and Asian countries, in particular China (chemicals), are outperforming 
the EU or strongly increasing their market shares.
The economic, social and environmental impact of modern biotechnology
Overall, modern biotechnology products and processes are an integral part of the EU economy, 
particularly in manufacturing, including pharmaceuticals, agro-food and health care. While some products 
are invisible to the general public (e.g. use of genetic markers in livestock breeding), others are used on a 
daily basis (detergents with enzymes and recombinant insulin) or have become a topic of public discussion 
(e.g. genetically modified crops).
Production and use of products derived from modern biotechnology products supports the generation 
of around 1.43% to 1.69% of the EU’s GVA (based on 2002 data). Pharmaceutical R&D and further 
induced economic benefits would add to this estimate. This is in the same order of magnitude as entire 
sectors of the economy, such as agriculture (1.79%) or chemicals (1.95%).
Modern biotechnology bolsters the competitiveness of EU companies, in particular on more 
traditional markets, renewing their competitive base, e.g. in breeding crops and livestock or in enzyme 
production. However, on new expanding markets the EU is often not at the forefront of development, 
e.g. in the cases of biopharmaceuticals, bioethanol, biotechnology-based polymers and GM crops. Patent 
applications and bibliometric data confirm this trend. In particular, the USA seems to embark on new 
developments much quicker and with strong policy support. China and other Asian countries are also 
strongly increasing their involvement.
Modern biotechnology contributes to employment, mainly in the form of “better jobs”, reflecting the 
higher level of training often necessary to develop and deal with biotechnology products and processes. 
However, by supporting competitiveness, it also helps to safeguard jobs. The effect in terms of “more jobs” 
is unclear because of lack of data and replacement effects.
Turning to sustainable development in the EU, including both the environmental and the public 
health aspects, modern biotechnology contributes via a variety of applications. Industrial biotechnology, 
along with applications in primary production and agro-food targeting production efficiency, reduces use 
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of resources and emissions. The energy savings offered by these applications and the potential to replace 
fossil fuels by renewable sources (bioethanol) address challenges such as global warming and security of 
energy supply and provide an opportunity to break the link between economic growth and pressure on 
the environment.
Modern biotechnology in human and animal medicine and in veterinary and food diagnostics provides 
effective, better or unique treatments and diagnostics and facilitates control of zoonoses such as BSE or 
salmonella. In this way, modern biotechnology contributes to reducing the burden which disease places 
on EU citizens and potentially supports the health of an ageing population. However, the effect on health 
care costs is less clear because of the lack of conclusive cost-effectiveness studies on several applications 
of modern biotechnology and the dependence of cost-effectiveness calculations on the specific product 
and specific indication analysed.
Although modern biotechnology provides a wide range of beneficial applications, some of them 
also raise new challenges and concerns that demand attention. Examples include human embryonic 
stems cells, use of genetic data for non-medical purposes, animal welfare in R&D and farming, potential 
environmental risks of new applications or the implications of large-scale use of agricultural food and 
feed products for non-food industrial purposes. Considering the rapid conversion of advances in research 
into products and processes, monitoring of developments in modern biotechnology seems necessary to 
identify policy-relevant emerging issues and carefully assess the risks and benefits early on in the process.
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1 Introduction
Given the potential of modern biotechnology 
applications in many different sectors, such 
as biopharmaceuticals, plant breeding, and 
biotechnological production of chemicals, 
modern biotechnology is seen as one of the 
key enabling technologies of the 21st century. 
At the same time it has contributed to major 
advances in basic science and is the subject of 
EU and national research funding programmes. 
Modern biotechnology potentially offers new 
opportunities to address many needs and is thus 
regarded as a major contributor to achieving 
EU policy goals on economic growth and job 
creation, public health, environmental protection 
and sustainable development.9
On the other hand, modern biotechnology 
has raised high expectations, in particular 
regarding novel therapeutic approaches (e.g. gene 
therapy), which have not materialised as quickly 
as anticipated. Furthermore, certain modern 
biotechnology applications raise new issues and 
spark controversial discussions involving the 
broader public (e.g. genetically modified crops, 
human embryonic stem cells, or use of personal 
genetic data). However, data on the actual uptake 
of modern biotechnology by the various sectors 
and its socio-economic and environmental 
consequences in the EU is still scarce.
Against this background, and in response 
to a request from the European Parliament, the 
European Commission, in its third progress report 
on the strategy on life sciences and biotechnology, 
announced that it would carry out this Bio4EU 
study for two main purposes: “First of all, an 
evaluation of the consequences, opportunities and 
challenges of modern biotechnology for Europe, 
in terms of economic, social and environmental 
aspects, is important both for policy-makers and 
industry. The study would therefore constitute 
the primary input to [the reflection on the role 
of the Life Sciences and Biotechnology in the 
renewed Lisbon Agenda]. Secondly, this kind of 
independent study should help to increase public 
awareness and understanding of life sciences and 
biotechnology.”10
The Commission assigned the 
“Biotechnology for Europe” (Bio4EU) study 
to its Joint Research Centre, where the study 
was carried out by the Institute for Prospective 
Technological Studies (JRC-IPTS). It focused on 
current applications of modern biotechnology, 
i.e. analysing the successful developments of 
modern biotechnology in the EU until the present 
day. The study was designed in a way that allows 
identifying and quantifying as far as possible the 
economic, social and environmental implications 
of modern biotechnology applications in different 
sectors, and the contributions they make to 
major EU policy goals. A representative set of 
29 in-depth case studies provided the basis for 
the analysis. Data were collected between April 
and December 2006 by the European Techno-
Economic Policy Support Network11 and JRC-
IPTS. Details regarding the methodology are 
described in Annex 2. Throughout the study, 
the JRC involved European-level stakeholder 
organisations to inform about the study and 
to provide an opportunity for input12 and 
9 European Commission COM (2002) 27: Communication form the Commission to the European Parliament, the Council, the 
Economic and Social Committee and the Committee of the Regions Life Sciences and Biotechnology – a strategy for Europe.
10 European Commission COM (2005) 286 final: Report from the Commission to the European Parliament, the Council, the 
Committee of the Regions and the European Economic and Social Committee Life sciences and biotechnology – a strategy for 
Europe. Third progress report and future orientations.
11 European Techno-Economic Policy Support Network (ETEPS; http://www.eteps.net/). Participating institutes are listed with the 
Preface. References to ETEPS reports refer either to the main report or to the application sector specific case study reports in 
which 28 case studies are presented in detail. 
12 The submissions by stakeholder organisations are available on the Bio4EU website http://bio4eu.jrc.es/stakeholders.html.
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comments. The Bio4EU Advisory Committee 
of distinguished scientists, chaired by Professor 
Patrick Cunningham, provided guidance on the 
approach, methodology, scope and results of the 
study13.
This report summarises the data gathered 
and the analysis carried out in the course of the 
study. The detailed background documents are 
available on the Bio4EU study website (http://
bio4eu.jrc.es/).
Chapter 2 will assess the direct and indirect 
uptake of modern biotechnology and the 
resulting socio-economic implications for the 
three main application sectors, i.e. medicine and 
health care, primary production and agro-food, 
and industrial production processes, energy and 
environment. While the analysis of the social 
and environmental implications is more of a 
qualitative nature, the economic significance was 
quantified using a common methodology.
Modern biotechnology may play different 
roles where adopted, i.e. it may be the core 
technology employed (e.g. biopharmaceuticals, 
genetically modified seeds), it may have a key 
function (e.g. the use of enzymes in individual 
stages in the textile finishing process), or it 
may have more of a supportive character in 
production processes or products (e.g. the use 
of molecular markers assisting in the breeding 
of plants/animals). Moreover, the nature of the 
different applications will affect the way in which 
adoption may be measured and presented. Thus, 
in medicine and health care, it is straightforward 
to reason in terms of shares of products, whereas 
in agriculture, it is more appropriate to talk 
about shares of total output. Furthermore, data 
are available to varying degrees for the different 
application sectors, data coverage being best for 
health applications.
The direct contribution of modern 
biotechnology adoption to the EU economy is 
measured in terms of gross value added (GVA, 
or turnover if GVA data were not available) 
attributable to output for which modern 
biotechnology was used in the production 
process. The relative contribution of modern 
biotechnology to the reported GVA/turnover 
differs depending on its use: it is highest where 
biotechnology is a core technology, and the GVA 
generated may be allocated 100% to modern 
biotechnology; it is lowest where it is a supportive 
technology, and its main role is in improving the 
efficiency of production processes and hence 
overall competitiveness. However, the relative 
contribution to GVA is usually not quantifiable, so 
in all cases 100% of the product value added or 
turnover was considered a contribution of modern 
biotechnology. The same approach was used to 
measure the indirect contribution to the economy 
of modern biotechnology adoption, attributable to 
output for which modern biotechnology-derived 
inputs were used in the production process: e.g. 
the use of biotechnology-derived seeds by the 
farmer, or the use of enzymes in food processing.
In Chapter 3 the prerequisites for the 
development of modern biotechnology 
applications in the EU compared to other regions 
are analysed, based on scientific publication 
and patent application data and on data on the 
biotechnology sector.
Chapter 4 discusses the implications of 
modern biotechnology in terms of contributions 
to major EU policy objectives such as the Lisbon 
Agenda and the Sustainable Development 
Strategy.
Additional information on modern 
biotechnologies and methodology can be found 
in the Annex.
13 A list of members of the Advisory Committee can be found with the Preface.
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Biotechnology is ‘the application of science 
and technology to living organisms, as well as 
parts, products and models thereof, to alter living 
or non-living materials for the production of 
knowledge, goods and services’14.
Biotechnology had its beginnings in the 
use of micro-organisms for making bread or 
brewing beer millennia ago. Since then the 
knowledge about biological processes has 
increased considerably, resulting in many more 
applications (Figure 2-1). With the development 
of recombinant DNA technology in the 1970s, 
which enables the targeted modification of 
genetic material in organisms, the possibilities 
for biotechnology applications have enlarged 
further. This breakthrough marked the beginning 
of so-called modern biotechnology, albeit 
encompassing a broader range of technologies 
used not only in research and development, but 
also in production. These include technologies for 
the analysis and modification of DNA and proteins, 
technologies for the transformation of organic 
compounds using enzymes, and technologies 
using cells for repairing biological tissue. Modern 
biotechnology has contributed significantly to 
enhancing our knowledge of biological systems, 
thanks partly to the development of tools for the 
large-scale analysis of DNA. These tools, also 
known as micro-arrays or chips, were invaluable 
for producing the human genome map in 2003, 
and are now emerging for the analysis of proteins 
as well.
The biotechnologies considered in this study 
as modern biotechnology, further refining the 
above definition of biotechnology, are described 
briefly in Annex 1. Traditional biotechnology 
processes, e.g. used in end-of-pipe treatment of 
contaminated soil or sewage (bioremediation), 
are not included. However, combinations of well 
established fermentation processes with modern 
biotechnology, e.g. cheese-making using the 
recombinant enzyme chymosin, are considered.
Figure 2‑1 Biotechnology milestones
14 OECD (2006). OECD Biotechnology Statistics 2006, Paris.
2 Modern biotechnology applications and their 
economic, social and environmental implications
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2.1 Modern biotechnology in medicine 
and health care
Modern biotechnology is applied in 
medicine and health care in therapeutics, mainly 
for the discovery, development and production 
of novel drugs (biopharmaceuticals, but also 
small molecule drugs), in preventives for the 
development of recombinant vaccines, and in 
diagnostics, for protein- and nucleic acids based 
tests (i.e. mainly immunoassays and genetic 
tests).
Modern biotechnology has a direct impact 
on the pharmaceutical sector (NACE DG 24.4)15, 
which in 2002 created EUR 58 billion of added 
value16, or about 4% of the total value added 
of the manufacturing sector (NACE D). In 2003, 
the pharmaceutical industry comprised 4111 
companies in total, with 75% of these located in 
six EU countries (Germany, France, Spain, Italy, 
UK, and Poland). The 2006 EU Industrial R&D 
Investment Scoreboard demonstrates a similar 
geographic concentration: the majority of the total 
64 pharmaceutical companies included in the top 
1000 EU companies, ranked by R&D investment, 
were located in Germany (11), the UK (22) and 
France (9). According to Eurostat, these countries 
are also the largest producers of pharmaceuticals 
in terms of value-added. The production value 
of the EU pharmaceutical industry has grown 
steadily since 1993, at a higher growth rate than 
the average of the chemicals sector,17 and its trade 
surplus in 2004 was more than EUR 32 billion, 
having increased almost five times since 199018 
(USA, Switzerland and Japan being the top three 
trading partners).
2.1.1	 Biopharmaceuticals
Biomedical research has increased our 
understanding of molecular mechanisms of the 
human body, revealing many proteins and peptides 
produced by the human body in small quantities 
but with important functions, which makes them 
interesting for therapeutic applications. Examples 
are growth factors such as erythropoietin, 
stimulating red blood cell production, the 
human growth hormone, or immune system 
stimulating interferons. Modern biotechnology, 
in particular recombinant DNA technology, 
made it possible to produce these substances 
in larger quantities using microorganisms or 
cell cultures as “cell factories”, facilitating their 
therapeutic use. These products are subsumed 
under the term “biopharmaceuticals”. The first 
biopharmaceutical to reach the market was 
recombinant human insulin in 1982. Since 
then about 142 biopharmaceutical products 
have been launched worldwide (not including 
vaccines, see Chapter 2.1.2). The main product 
classes of marketed biopharmaceutical products 
are recombinant hormones such as human 
insulin, monoclonal antibodies used to treat e.g. 
cancer but also used for diagnostic purposes, and 
recombinant interferons and interleukins.
Economic significance of biopharmaceuticals
Over the last ten years (1996-2005) in the EU, 
an average of six new biopharmaceutical products 
have been launched per year,19 accounting for 
about 9% of pharmaceuticals launched in this 
period (Figure 2-2). Overall, in 2005, about 85 
biopharmaceutical products were available in the 
EU, more than twice as many as in 1996.
15 It includes the manufacture of basic pharmaceutical products and pharmaceutical preparations, such as medicaments, vaccines, 
homeopathic preparations, dental fillings, bandages and dressings. 
16 Eurostat.
17 Eurostat, European Business: Facts and Figures 1995-2004, 2005 Edition.
18 EFPIA (2006), The pharmaceutical industry in figures and Eurostat.
19 Data on pharmaceutical and biopharmaceutical products were retrieved by ETEPS from the PJB database pharmaprojects (http://
www.pjbpubs.com/pharmaprojects/index.htm). The EU is covered as a group with the exception of Estonia, Latvia, Lithuania, 
Malta, Slovenia and Cyprus; for these countries no data are available in the pharmaprojects database.
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The combined pharmaceutical market in 2005 
of the USA, the EU and Japan was about EUR 372 
billion (about 80% of the worldwide market), the 
EU having a share of 33%. Biopharmaceuticals 
in the USA, EU and Japan represented a market 
of EUR 38.5 billion in 2005,21 about 10% of the 
corresponding pharmaceutical market. The EU 
has a market share of 30%, similar to the market 
share for pharmaceuticals.
The biopharmaceutical market in the 
EU seems to be more dynamic than the 
pharmaceutical market, with average annual 
growth rates (23%) twice as high as for 
pharmaceuticals (11%). Accordingly, overall, the 
shares of biopharmaceuticals in the turnover of 
pharmaceuticals are increasing, indicating the 
growing importance of biopharmaceuticals from 
an economic perspective (Figure 2-3). The average 
turn-over per marketed biopharmaceutical in the 
EU has tripled over the last 10 years and, in 2005, 
reached a value of EUR 133 million per year.
Figure 2‑3 Share of turnover of 
biopharmaceuticals out of all pharmaceuticals, 
by region
Source: ETEPS22.
International comparison
The share of biopharmaceuticals in the 
pharmaceutical markets in the USA and 
Japan is similar to the EU, at 11% and 9% 
20 ETEPS (2006). Bio4EU Task 2 Main report.
21 (Bio)pharmaceutical revenues were analysed on the basis of the manufacturer ex-factory prices by ETEPS in the database 
IMS MIDAS, owned by IMS Health. All biopharmaceuticals (not including recombinant vaccines) approved by FDA or 
EMEA as listed by Walsh (Nature Biotechnology (2006), 24, (7), p. 769) were used by their generic name(s) as the basis 
for biopharmaceuticals. Of this list 16 products (among them six monoclonal antibodies, one insulin analogue, two growth 
hormones and three morphogenic proteins) could not be found in the database.
22 ETEPS (2006). Bio4EU Task 2 Main report.
Figure 2‑2 Accumulated numbers of biopharmaceuticals launched (left panel) and the share by 
numbers of biopharmaceuticals out of all pharmaceuticals launched between 1996 and 2005 (right 
panel), by region
Source: ETEPS20, IPTS calculations.
EU
USA
Japan
0
10
20
30
40
50
60
70
80
90
100
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
0% 3% 6% 9% 12%
Japan
USA
EU
EU
USA
0%
2%
4%
6%
8%
10%
12%
14%
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
2.
  M
od
er
n 
bi
ot
ec
hn
ol
og
y 
ap
pl
ic
at
io
ns
 a
nd
 t
he
ir
 e
co
no
m
ic
, s
oc
ia
l a
nd
 e
nv
ir
on
m
en
ta
l i
m
pl
ic
at
io
ns

JR
C
  R
EF
ER
EN
C
E 
R
EP
O
RT
respectively (Figure 2-2). Japan represents a 
much smaller biopharmaceutical market, with 
two biopharmaceutical products launched per 
year, whereas in the USA a similar number of 
biopharmaceuticals to the EU reached the market 
in the period 1996-2005. However, the USA 
clearly dominates the combined pharmaceutical 
and biopharmaceutical markets of the USA, 
EU, Japan, with market shares of 54% and 65% 
respectively. Japan, in contrast, plays a lesser role, 
with market shares of 10% and 5% respectively. 
The higher market shares of the USA coincide with 
a slightly higher average growth than in the EU 
(14% compared to 11% for pharmaceuticals and 
28% compared to 23% for biopharmaceuticals), 
as well as a higher average turnover per 
biopharmaceutical (in 2005: EUR 275 million 
in the USA compared to EUR 133 million in 
the EU). This could indicate higher sales in the 
USA or a higher price level, or a combination 
of both. It might also reflect the different health 
care policies in the USA and the EU Member 
States, the first relying more on competition and 
a less regulated market approach, whereas within 
the EU a broader mix of policies can be found, 
ranging from free pricing of pharmaceuticals to 
fixed prices.23
The EU seems to have a comparatively weak 
position in the development and marketing of 
biopharmaceuticals. Only 15% of all available 
products were developed by EU companies, 
whereas Swiss companies alone developed 10% 
and US companies 54%. This trend is also evident 
when we look at the top ten biopharmaceuticals 
according to sales, which make up more than half 
of the overall market. These products (see Table 
2.1) are largely produced by US companies (7 
Table 2.1 Top ten biopharmaceuticals ranked according to sales in 2005
Source: IMS Health, MIDAS, MAT Dec 2005, taken from EuroBio 2006 Press Kit.24
23 US (2004). “Pharmaceutical price controls in OECD countries: implications for U.S. consumers, pricing, research and 
development, and innovation.” International Trade Administration, US Department of Commerce, Washington, DC; http://
www.ita.doc.gov/drugpricingstudy. 
 Mrazek, M.F. (2002). Croatian Medical Journal 43: 453-461. 
24 http://www.eurobio2006.com/DocBD/press/pdf/18.pdf (conversion: 1 U.S. Dollar = 0.7765 Euro). 
Top 10 products Country
Sales
(M e, 2005)
Change over 
2004 (%)
Market 
share 
2005 (%)
Global biotech market 41 175 17.1 100.0
Erypo/Procrit (Johnson &Johnson) USA 2897 -8.8 7.0
Enbrel (Amgen/Wyeth) USA 2887 40.7 7.0
Aranesp (Amgen) USA 2800 38.0 7.0
Remicade (Johnson&Johnson/Schering-Plough) USA 2331 17.3 5.7
Epogen (Amgen) USA 2240 -0.8 5.4
Mabthera/Rituxan (Roche) Switzerland 2112 23.6 5.1
Neulasta (Amgen) USA 1925 31.7 4.7
Avonex (Biogen Idec) USA 1188 9.6 2.9
Lantus (Sanofi-Aventis) France 1174 47.5 2.9
Herceptin (Roche) Switzerland 1106 48.2 2.7
Total (top ten) 20 661 19.4 50.2
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out of 10), two are produced by a Swiss company 
and only one is produced by an EU company. It 
should be noted that half of these products are 
produced by biotechnology companies, and the 
other half by pharmaceutical companies. The 
most successful product class is erythropoietin, 
with three products in the top ten list (Erypro/
Procrit, Aranesp, Epogen; 19% market share). 
Furthermore, monoclonal antibodies (Mabthera/
Rituxan, Remicade, Herceptin; 14% market 
share), hormones (insulin product Lantus; 3%) 
and interferon (Avonex; 3%) seem to be successful 
product classes. The second best-selling product 
(Enbrel) is a growth factor inhibitor used for 
the treatment of inflammatory diseases such as 
rheumatoid arthritis.
Biosimilars
The emergence of biogeneric drugs 
or biosimilars will be an important factor 
in the future economic performance of 
biopharmaceuticals, especially as the patents 
of several biopharmaceuticals expire.25 The 
introduction of biosimilars in the market is 
expected to increase competition, which could 
not only help reduce health care costs, but also 
lead to improved products.26 At the same time, 
biosimilars (just like generics) are linked to the 
emergence of new national players in the global 
pharmaceutical market, such as India,27 China or 
South Korea. However, several issues complicate 
the development and regulatory approval of 
biosimilars. The manufacturing of a recombinant 
protein drug is very complex and may involve 
many steps, which could influence its biological 
properties. In this context, some experts argue 
that two biopharmaceuticals based on the 
same protein can never be completely identical 
and therapeutically equivalent. Hence, the 
question of whether it is possible to demonstrate 
bioequivalence is under debate, and the European 
Medicines Agency (EMEA) has issued the 
recommendation that a full preclinical and clinical 
data package is required for approval where such 
equivalence cannot be demonstrated.28,29 In spite 
of these uncertainties, the first biogeneric drug, 
Omnitrope (a recombinant growth hormone) was 
recently approved in the EU, following a positive 
evaluation by EMEA, and it is also approved in 
Australia and – even in the absence of a specific 
regulatory pathway for approval of biogenerics 
– in the USA.
Social implications of biopharmaceuticals
Biopharmaceuticals are the most visible 
result of modern biotechnology applications in 
medicine, both in terms of available products 
and economic significance. The ability to use 
natural proteins has opened up new possibilities 
for disease treatment, and potentially safer, more 
reliable product sources. Major therapeutic 
fields for which biopharmaceuticals have been 
developed are cancer, metabolic disorders and 
musculoskeletal and immunologic disorders.
The performance of biopharmaceuticals 
regarding disease treatment and effects on health 
care systems were analysed on the basis of four 
case studies:
− Recombinant human insulin for the treatment 
of diabetes
− Interferon-beta for the treatment of multiple 
sclerosis
25 Schellekens, H. (2005). Nephrology Dialysis Transplantation 20, suppl. 4: 31-36.
26 Schellekens, H. (2004). Trends in Biotechnology 22: 406-410. 
27 Jayaraman, K.S. (2003). Nature Biotechnology 21: 1115-1116. 
28 Committee for Proprietary Medicinal Products (2003). Guideline on Comparability of Medicinal Products Containing 
Biotechnology derived Proteins as Active Substance. Quality Issues. Evaluation of Medicines for Human Use, The European 
Agency for the Evaluation of Medicinal Products, London. 
29 EMEA (2005). Guideline on Similar Biological Medicinal Products, European Medicines Agency, London; http://www.emea.
eu.int/pdfs/human/biosimilar/043704en.pdf. 
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− CD20 antibodies against non-Hodgkin's 
lymphoma
− Enzyme replacement therapy for Gaucher's 
disease
The case studies present different 
biopharmaceutical product classes and target 
different diseases, partly being the only currently 
available treatment, as in the case of Gaucher's 
disease, or replacing animal insulin, as in the case 
of recombinant human insulin. The assessment 
focused on improved treatment, thus helping 
patients to live healthier and more productive 
lives, increasing social welfare and individual well-
being, and on the cost-effectiveness of treatments 
with a view to efficiency of health care systems.
Recombinant human insulin
Recombinant human insulin was the first 
biopharmaceutical product to reach the market, 
launched in 1982. Since then, it has largely 
replaced animal insulin; today only 30% of the 
worldwide available insulin is isolated from 
the porcine or bovine pancreas of slaughtered 
animals.30 At least 15 recombinant human insulin 
products are currently on the market, representing 
about 15% of the biopharmaceutical market 
by value. In developed countries animal-based 
insulin is hardly available any more.
Insulin is primarily targeted at Type 1 
diabetes patients, mainly children and 
adolescents (about 5-10% of all diabetes 
patients) who have lost their ability to 
produce insulin and need regular injections 
of insulin. About 30% of Type 2 diabetes 
patients require additional insulin to regulate 
their blood glucose levels. The underlying 
cause of Type 2 diabetes is an acquired loss 
of sensitivity to the hormone insulin, which 
affects adults usually over the age of 40 and 
is linked to diet and body weight. In 2003, 
there were about 194 million diabetes 
patients worldwide; this figure is expected to 
increase to more than 330 million by 2025 
due to an increase of obesity worldwide.31 
Complications from diabetes, such as stroke, 
renal failure, blindness, coronary artery and 
peripheral vascular disease, often reduce 
quality of life and life expectancy and entail 
considerable health care costs.
Although recombinant human insulin 
does not appear to have significant therapeutic 
differences compared to animal insulin, clinical 
adoption of recombinant insulin is high: about 
95% of Type 1 diabetes patients in the EU use 
recombinant insulin. Recombinant human insulin 
seems to be more expensive than animal insulin 
in most countries where both are available, e.g. in 
European countries (including non-EU countries) 
the average price of recombinant human insulin 
was twice as high as for animal insulin.32 One 
explanation for the widespread adoption could 
be the potentially improved safety of recombinant 
insulin regarding the risk of immune reaction 
and contamination of animal insulin. It is also 
important to realise that, according to a study 
carried out in the USA, the actual cost of insulin, 
including delivery, amounts to only 7.6% of 
diabetes-related health care expenditures.33
Recombinant human insulin is the starting 
point for the development of human insulin 
analogues, which reached the market several 
years ago. The analogues are developed by using 
genetic engineering to produce fast acting and 
slow acting human insulin. They are designed to 
improve the control of insulin requirements over 
30 IDF (2003). Diabetes Atlas, 2nd ed. International Diabetes Federation, Brussels. 
31 IDF (2003). Diabetes Atlas, 2nd ed. International Diabetes Federation, Brussels.
32 IDF (2003). Diabetes Atlas, 2nd ed. International Diabetes Federation, Brussels. 
33 American Diabetes Association (2003) Diabetes Care 26: 917-932. 
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the day, with obvious advantages for the patients. 
However, the generally higher prices may reduce 
their cost-effectiveness, especially in the case of 
diabetes type 2 patients.34
Recombinant human insulin and insulin 
analogues are effective in the treatment of 
diabetes; however, for these products there is 
currently limited experimental evidence showing 
additional efficacy compared with conventional 
animal insulin. Hence, the contribution of 
biotechnology-derived insulin products to 
reducing the burden of diabetes per se compared 
to animal insulin may need to be considered 
marginal. However, insulin analogues may 
improve the quality of life of diabetes patients, 
which could be seen as the major contribution 
of recombinant insulin. Judging such qualitative 
improvements would require more specific cost-
utility analyses and more fundamental ethical 
decisions.
Interferon-beta for multiple sclerosis
Until 1993, when interferon-beta reached 
the market, multiple sclerosis (MS) was treated 
with corticoids to accelerate recovery from 
relapses. Corticoids do not cure MS, and neither 
do any of the treatments currently available. Also, 
interferon-beta belongs to the group of disease 
modifying drugs: it does not cure MS, but it may 
slow down the development of some disabling 
effects and decrease the number of relapses. As 
such, it has developed into the first line treatment 
for MS. Currently, four interferon-beta products 
are available, representing about 8% of the 
biopharmaceutical market by value.
Multiple sclerosis (MS) is an autoimmune 
disease that affects the central nervous 
system. Its onset occurs primarily in young 
adults and it affects women more often 
than men. The exact cause of the disease 
is unknown, but a genetic predisposition 
is suspected. The disorder can manifest in 
a remitting or progressive development, 
and it is characterised by lesions that 
occur throughout the brain and spinal 
cord, which have severe consequences 
such as loss of memory or loss of balance 
and muscle coordination; other symptoms 
include slurred speech, tremors, and 
stiffness or bladder problems. Estimates 
of the prevalence of MS in the EU differ 
between about 257 000 in Western Europe35 
to over 563 000 cases in the EU.36 Given 
the number of people who suffer from MS 
and the fact that it primarily affects young 
adults, the individual consequences of this 
disease are severe and the economic and 
social costs are substantial.37,38 This is also 
reflected in the high share of “indirect” 
costs – i.e. of costs that occur outside the 
health care system, like productivity losses, 
costs for informal health care or estimates 
of intangible costs – that usually make up 
more than half of total costs.39
Regarding cost-effectiveness, no conclusive 
studies have been identified. The use of interferon-
beta for the treatment of MS is not without 
controversy. In 2002, the UK’s National Institute 
for Health and Clinical Excellence (NICE) issued 
a guidance not recommending interferon-beta 
34  IQWiG (2006). “Rapid-acting insulin analogues for the treatment of diabetes mellitus type 2.” Institute for Quality and Efficiency in 
Health Care, Cologne. Warren, E., E. Weatherley-Jones, J. Chilcott and C. Beverley (2004). Health Technology Assessment 8(45). 
35 WHO (2006). “Point prevalence for selected causes: by sex, age and WHO subregion: 2002.” Health statistics and health 
information systems. World Health Organization, Geneva. 
36  MSIF (2006). “European Map of MS database.” Multiple Sclerosis International Federation, London. (The figure reported for the 
EU does not include data on Cyprus, Lithuania and Malta.) 
37 Phillips, C.J. (2004). CNS Drugs 18: 561-574.
38 APF (2006). Le Livre Blanc de la sclérose en plaques. Etats Généraux de la SEP, Association des Paralysés de France, Paris. 
39 Kobelt, G. and M. Pugliatti (2005). European Journal of Neurology 12: S63-S67. 
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or the current alternative treatment glatiramer 
acetate (available since 2000 in some EU 
Member States) for the treatment of MS based 
on clinical performance and cost-effectiveness 
considerations.40 More recent evaluations 
show modest benefits of interferon-beta for the 
progression of MS in the short to medium term.41 
Data on long-term effects are not yet available.
CD20 antibodies against non-Hodgkin’s 
lymphoma
Non-Hodgkin’s lymphoma (NHL) is a type of 
cancer in which malignant cells form in the 
lymph system. Because the lymph tissue is 
found throughout the body, NHL can begin 
in almost any part of the body and spread to 
the liver and many other organs and tissues. 
NHL is more common in men and older 
age groups. Over the last three decades the 
incidence of NHL in western industrialised 
countries has been consistently on the rise, 
and it now ranks amongst the most frequent 
malignant diseases.42,43 In 2001 there were 
over 30 000 deaths within the EU due to 
NHL.44
Lymphomas were classically treated with 
radiotherapy and systemic chemotherapy (like 
“CHOP”, a specific combination of anti-cancer 
drugs). Over recent years these treatments have 
been supplemented by autologous (i.e. derived 
from the recipient) and allogeneic (derived 
from a donor other than the recipient) stem cell 
transplantation and by immunotherapy with 
monoclonal antibodies.45 In immunotherapy, 
the immune system is put on a higher level of 
alertness with respect to cancer cells; in the 
treatment of NHL, genetically engineered CD20 
antibodies have proven to be effective. The 
success of these antibodies relies on the fact that 
approximately 90% of the malignant B-cells in 
NHL express a CD20 antigen at their surface. This 
antigen is recognised by the corresponding CD20 
antibody, which triggers the immune system to 
mount a targeted attack on the malignant cells 
– while sparing most normal tissue. The need to 
engineer these antibodies is because patients do 
not generally produce effective antibodies against 
the relevant antigens.46 The first CD20 antibodies 
received authorisation in the EU in 1998. Currently 
two products are authorised in the EU, marketed 
by a Swiss and an EU company. Worldwide, three 
CD20 antibody products are available; none has 
been developed by EU companies.
To date, studies on the effectiveness and 
cost-effectiveness of CD20 antibodies are scarce. 
A systematic review that was carried out in the 
UK identified only one randomised controlled 
trial, which however confirmed the effectiveness 
of one CD20 antibody product (rituximab) in the 
treatment of aggressive NHL (in combination 
with CHOP) in certain patient groups. In the 
same review a cost-effectiveness analysis showed 
that the addition of rituximab to the CHOP 
treatment regime might extend the patients’ lives 
by about one “quality-adjusted life year” (QALY; 
the weighted equivalent of one healthy life year) 
at a cost of about EUR 15 000, which qualifies 
as a cost-effective intervention. These results also 
confirm the data provided by industry.47 Given 
40 NICE (2002). Technology Appraisal Guidance No. 32, National Institute for Clinical Excellence, London. 
41 Prosser, L.A., K.M. Kuntz, A. Bar-Or and M.C. Weinstein (2004). Value in Health 7: 554-568. Phillips, C.J. (2004). CNS Drugs 
18: 561-574. Amato, M.P. (2004). Expert Opinion on Pharmacotherapy 5: 2115-2126. Hoch, J.S. (2004). Expert Review of 
Pharmacoeconomics & Outcomes Research 4: 537-547. McCormack, P.L. and L.J. Scott (2004). CNS Drugs 18: 521-546. 
42 Trümper, L., P. Möller and A. Neubauer (2004). “Maligne Lymphome.” In: Hiddemann, W., H. Huber and C. Bartram (eds.) 
(2004). Die Onkologie (Teil 2). Springer Verlag, Berlin, pp. 1709-1774. 
43 Morgan, G., M. Vornanen, J. Puitinen, A. et al. (1997). Annals of Oncology 8: S49-S54.
44 IARC (2006). “CANCERMondial,” update of July 2006. Descriptive Epidemiology Production Group, International Agency for 
Research on Cancer, Lyon. (Does not include Cyprus; data for Belgium from 1997.) 
45 Trümper, Möller and Neubauer (2004), cf. footnote 42. 
46 ETEPS (2006). Bio4EU Task 2 Case studies report – Human Health Applications. 
47 Knight, C., D. Hind, N. Brewer and V. Abbott (2004). Health Technology Assessment 8(37).
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this scarcity of information, NICE for instance 
has recommended the (general) use of rituximab 
only in some cases of NHL.48,49 Another recent 
literature review of economic studies of currently 
available NHL treatment options also found 
(preliminary) evidence for the cost-effectiveness 
of rituximab in the treatment of various forms 
of NHL. However, this study also concluded 
that more and better economic evaluations are 
needed for a more comprehensive assessment 
of the various effective treatments for NHL – not 
only CD20 antibodies.50
Enzyme replacement therapy for Gaucher’s 
disease
Gaucher’s disease is an inherited metabolic 
disorder caused by one or more genetic 
defects that result in functional deficiency 
of an enzyme called glucocerebrosidase (or 
glucosylceramidase). This deficiency causes 
a lipid (glucocerebroside) to accumulate in 
the spleen, liver, lungs, bone marrow and 
sometimes in the brain, causing functional 
abnormalities. The resulting course of the 
disease can be quite variable, ranging from 
no outward symptoms to severe disability 
and death. Gaucher’s disease belongs to the 
rare diseases with a prevalence of fewer than 
5 individuals in 10 000. For instance, the 
prevalence of all types of Gaucher’s disease 
combined is one in 57 000 in Australia and 
only one in 86 000 in the Netherlands.51 
Given these prevalence rates, for an EU 
population of 458 973 024 in 2004,52 there 
could be around 5 000 to 18 000 individuals 
who suffer from Gaucher’s disease in the EU.
The treatment of choice for Gaucher’s 
disease, a rare inherited lipid-storage disorder, is 
an enzyme replacement therapy. Other options, 
such as bone marrow transplantation or removal 
of part of the spleen, are less used due to higher 
risks and the need for matching bone marrow 
donors.53,54 The enzyme, glucocerebrosidase, can 
be sourced from human placentas; however, the 
amount of enzyme needed to treat one patient 
required about 22 000 placentas per year. Since 
1997 (1994 in the USA) a recombinant enzyme 
has been commercially available (Cerezyme), 
and has proved as effective in treating Gaucher’s 
disease as the natural enzyme, but was 
more readily available and free of potential 
contamination.55 A more recent alternative, a 
small molecule drug approved in 2002 in the 
EU, makes use of an enzyme inhibitor, reducing 
the creation of the lipid.56 It is currently being 
marketed for patients who do not respond well to 
the enzyme drug.57
Enzyme replacement therapy in Gaucher’s 
disease has proven to be effective from a clinical 
point of view, with only a few mild adverse 
reactions, and it also improves the quality of life 
from the patients’ perspective.58,59,60 Estimates of 
48 NICE (2003). Technology Appraisal No. 65, National Institute for Clinical Excellence, London. 
49 NICE (2002). Technology Appraisal No. 37, National Institute for Clinical Excellence, London.
50 van Agthoven, M., C.A. Uyl-de Groot, P. Sonneveld and A. Hagenbeek (2004). Expert Opinion on Pharmacotherapy 5: 2529-2548. 
51 GOLD (2006). “Gaucher disease,” Disease Information Search. Global Organisation for Lysosomal Diseases, Buckinghamshire. 
52 Eurostat (2006). “Population by sex and age on 1 January of each year.” Theme: Population and Social Conditions. European 
Commission, Eurostat, Luxembourg. 
53 ETEPS (2006). Bio4EU Task 2 Case studies report – Human Health Applications. 
54 NINDS (2006). “Gaucher’s Disease.” Disorder Index. National Institute of Neurological Disorders and Stroke, Bethesda, MD. 
55 ETEPS (2006). Bio4EU Task 2 Case studies report – Human Health Applications.
56 Actelion (2006). “All milestones,” company information. Actelion Pharmaceuticals, Allschwil.
57 Actelion (2006). “Zavesca: balance by substrate reduction,” homepage. Actelion Pharmaceuticals, Allschwil. 
58 Whittington, R. and K.L. Goa (1992). Drugs 44: 72-93. 
59 Whittington, R. and K.L. Goa (1995). Pharmacoeconomics 7: 63-90.  
60 Damiano1, A.M., G.M. Pastores and J.E. Ware Jr. (1998). Quality of Life Research 7: 373-386. 
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the costs of procuring the quantities of the drug 
for one patient per year range from about EUR 100 000 
to several times that amount.61,62,63 Gaining one 
“quality-adjusted life year” (QALY64) with the 
enzyme replacement therapy may cost EUR 150 000 
to EUR 2 million, beyond any usually applied 
cost-effectiveness thresholds.65,66 This highlights 
the specific ethical questions linked to “orphan 
drugs”,67 namely whether scarce public money in 
the health care sector should be spent according 
to equity (all individuals are entitled to the same 
minimum quality of health care) or efficiency 
considerations (limited resources should be used 
to treat a large number of people who suffer from 
a disease that can be treated at a relatively low 
cost). 68
Biopharmaceuticals in clinical trials
Clinical trials provide an indication of what 
is in the pipeline of pharmaceutical products and 
the significance of biopharmaceuticals for the 
coming years. Cancer seems to be the dominant 
therapeutic field at which biopharmaceuticals in 
the pipeline are targeted.69 The absolute numbers 
of pharmaceuticals and biopharmaceuticals in 
clinical trials by EU companies increased between 
1996 and 2005 by about 40%. In 2005, EU 
companies had 109 biopharmaceutical products 
in clinical trials. The share of biopharmaceuticals 
in clinical trials is stable at about 11% (Figure 
2-4).
Figure 2‑4 Share of biopharmaceuticals out 
of all pharmaceuticals in clinical trials, by 
region
Source: ETEPS70.
US companies had about twice as many 
biopharmaceuticals in clinical trials than EU 
companies (190 candidates in 2005). Absolute 
numbers increased between 1996 and 2005 by 
28%, which is much less than the number of 
phar-ma-ceuticals, which increased by about 
80%. This results in an overall decrease of the 
share of biophar-maceuticals in clinical trials 
from 18% to about 12%, reaching the EU level 
in 2005. These shares indicate that a pronounced 
change in the significance of biopharmaceuticals 
within the pharmaceutical sector is not probable 
in the near future.
61 Whittington, R. and K.L. Goa (1995). Pharmacoeconomics 7: 63-90.  
62 Clarke, J.T.R. et al. (2001). Canadian Medical Association Journal 165: 595-596. 
63 Connock, M. et al (2006). Health Technology Assessment 10(24).
64 A QALY represents the weighted equivalent of one healthy life year.
65 Whittington, R. and K.L. Goa (1995). Pharmacoeconomics 7: 63-90.  
66 Connock, M. et al. (2006). Health Technology Assessment 10(24).
67 Orphan drugs are medicinal products for diagnosing, preventing or treating a life-threatening, seriously debilitating or serious 
and chronic condition affecting fewer than five in 10 000 persons (in the EU). Because these conditions occur so infrequently 
that the cost of developing an appropriate drug and bringing it to the market would not be recovered by the expected sales 
of the product, the pharmaceutical industry would be unwilling to develop the medicinal product under normal market 
conditions. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan 
medicinal products.” OJ L 018: 1-5. 
68 ETEPS (2006). Bio4EU Task 2 Case studies report – Human Health Applications.
69 Walsh, G. (2006). Nature Biotechnology 24(7): 769-776.
70 ETEPS (2006). Bio4EU Task 2 Main report.
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Intellectual Property
Modern biotechnology advances have led 
to the development of new drugs and enabling 
tools for the diagnosis of diseases. Additionally, 
completion of the human genome project has 
made it easier to associate specific genes (or 
gene combinations) to a disease, and thus to 
identify novel putative drug targets. Because of 
their potentially significant economic (and public 
health) implications, modern biotechnology 
applications are increasingly being patented.
Patenting is considered to have a stimulating 
effect on innovation, by allowing the inventor 
“freedom to operate”, which may in turn drive 
investment.71 However, there is also a suggestion 
that patenting may limit patients’ access to novel 
treatments (e.g. as a result of high licensing fees 
which would influence the cost of the treatment) 
and inhibit research, especially as a result of 
the proliferation of DNA patents.72 The most 
pertinent issues relate to the breadth of claims 
and the potential development of a patent 
thicket (a situation where different owners have 
overlapping patent rights, requiring multiple 
licences). Such broad claims could inhibit 
research, although a recent study indicates that 
presently there is not enough evidence to support 
this notion.73 However, the future development 
of patent thickets cannot be ignored. For 
diagnostics too (see Chapter 2.1.4) this may be 
a critical issue. For example, multiple patents 
might affect the development of microarray tests, 
where a specific combination of genes is used to 
diagnose (or predict) disease. In such a case, and 
if each gene to be used on the array has already 
been patented, then multiple licenses would be 
required prior to the development of the test to 
ensure no infringement takes place. This would 
probably affect the cost of the test, and perhaps 
its accessibility to services and patients.
2.1.2	 Vaccines
Vaccines are an important prophylactic 
medical approach in which modern biotechnology 
plays an increasing role. The “traditional” vaccine 
consists of live attenuated bacteria or viruses, 
of dead or inactivated bacteria, or of specific 
surface proteins of pathogens, e.g. harvested 
from the plasma of infected patients. Modern 
biotechnology makes it possible to specifically 
produce on a large scale only those proteins of 
pathogens which trigger the immune reaction. 
These recombinant vaccines have the advantage 
that they are produced in a non-pathogen host, 
ensuring that no pathogen will be present in the 
vaccine product, and making it clinically safe in 
that respect. The supply can easily be controlled 
and the approach allows the production of a 
defined, consistent product. Currently, there is 
growing interest in DNA vaccines which provoke 
an immune response utilising “naked” DNA 
instead of proteins (several are in phase I clinical 
trials for AIDS, malaria and influenza).
Economic significance of recombinant vaccines
Vaccines play a minor role in the 
pharmaceutical market, representing about 1% 
(EUR 563 million) of the worldwide market. 
The number of available vaccines has increased 
considerably: in the USA and the EU, over the last 
ten years the number has doubled. Overall the EU 
is the main producer of vaccines (52%) (Figure 
2-5). Recombinant vaccines represent about 20% 
of all available vaccines, most products targeting 
hepatitis B. EU companies developed 26% of all 
recombinant vaccines, US companies about 17%.
71 Nunnally, A.C. et al. (2005). Community Genetics 8: 209-216. 
72 Jensen, K. and Murray, F. (2005). Science 310: 239-240. 
73 National Research Council (2005). Reaping the benefits of genomic and proteomic research: intellectual property rights,
 innovation, and public health. The National Academies Press, Washington DC. 
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Figure 2‑5 Share of global vaccine 
production in 2005, by location of company 
headquarters
In the EU, the number of recombinant 
vaccines on the market has been stable since 
2001, while the number of conventional vaccines 
has continued to increase, leading to a drop in the 
share of recombinant vaccines from 25% to about 
14%. Still, in absolute terms, the market value 
for recombinant vaccines in the EU has nearly 
quadrupled over the last ten years, with revenues 
growing from EUR 65 million in 1996 to EUR 
259 million in 2005. This corresponds to 46 % of 
the total vaccines market, compared to 54% for 
the USA. It seems that recombinant vaccines are 
more successful in economic terms, generating 
on average higher turnover (EUR 23.5 million 
compared to EUR 17 million for conventional 
vaccines; 2005) and showing a more positive 
growth path (Figure 2-6). This could indicate that 
recombinant vaccines sell at higher quantities 
and/or prices than conventional vaccines.
Figure 2‑6 Average turnover per vaccine in 
the EU (e million)
Social implications of recombinant vaccines
Most recombinant vaccines are targeted at 
Hepatitis B. Walsh76 lists 15 recombinant hepatitis 
B vaccine products (also combination products 
including other vaccines) available in the EU 
and the USA. Two other recombinant vaccines 
are currently on the market, targeting cholera 
(including the recombinant cholera toxin B subunit 
of the pathogen Vibrio cholerae), and human 
papilloma virus (HPV). The latter reached the 
market only recently, with expectations of helping 
to reduce the cervical cancer rate in women, the 
main cause of which is an infection with HPV. 
Since it was impossible to propagate the virus in 
culture, recombinant DNA technology provided a 
critical tool for developing a vaccine77.
74 ETEPS (2006). Bio4EU Task 2 Main report. 
75 ETEPS (2006). Bio4EU Task 2 Main report.
76 Walsh, G. (2006). Nature Biotechnology 24(7): 769-776.
77 Crum, C. et al. (2006). Nature Reviews Drug Discovery 5(8): 629-630.
Source: ETEPS75, IPTS calculations.
Source: ETEPS74, IPTS calculations.
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Hepatitis B is a widespread virus. According 
to WHO, about 6% of the world population 
are infected. For the EU it can be assumed 
that about 100 000 new infections occurred 
in 2004, although the rate decreased since 
1996 from 6.55 per 100 000 inhabitants to 
3.49.78,79 Hepatitis B can cause acute and 
chronic infections; the latter might develop 
into liver cirrhosis and liver cancer, leading 
to about 1 million deaths each year.
According to Ulmer et al.80 the main driver 
for recombinant vaccine development in the 
case of hepatitis B was the need to develop a 
safer, better characterised vaccine. An additional 
benefit was the unrestricted availability of 
the vaccine compared to the conventional 
alternative, a vaccine derived from the plasma of 
infected individuals. Since the available literature 
gives no indication of adverse reactions to the 
plasma-derived vaccine, it can be assumed that 
the experience with AIDS/HIV contamination 
of blood products in the 1980s pushed the 
development and use of a potentially less risky 
vaccine. The recombinant vaccine was launched 
in 1986 and in industrialised countries replaced 
conventional vaccines within a few years.
Studies indicate that vaccination is 95% 
effective in preventing chronic infections in 
uninfected individuals,81 not distinguishing 
between the conventional or the recombinant 
vaccine. There seems to be consensus regarding 
the effectiveness of available hepatitis B vaccines, 
with different vaccination strategies being analysed 
and from a cost-effectiveness perspective. No 
studies were identified comparing the different 
vaccines in terms of cost-effectiveness impacts. 
It can be assumed that the confidence in the 
recombinant vaccine and its ready availability 
might have contributed positively to the decline 
in hepatitis B incidence rates in the EU over the 
last 15 years.
Recombinant vaccines in clinical trials
A look at the share of recombinant vaccines 
in clinical trials of vaccines reveals the growing 
importance of recombinant biotechnology in 
vaccines development over the last ten years. In 
2005 the share of recombinant vaccines out of all 
vaccines in clinical trials reached 75%, up from 
about 40%-50% in 1996,82 and indicating an 
increasing number of recombinant vaccines on 
the market in the future. Examples for recombinant 
vaccines in development are a recombinant 
anthrax vaccine and a vaccine against several 
serogroups of Neisseria meningitides, the cause 
of meningitis.83
2.1.3	 Modern	biotechnology	in	drug	development	
and	production
Drug development is a lengthy process (it 
takes up to 10-12 years before a drug reaches the 
market) consisting of the following main steps:
i) drug discovery and preclinical development 
(includes target identification and validation, 
lead screening and optimisation, preclinical 
studies),
ii) clinical trials (phases I, II, and III).84
With respect to drug discovery, biotechnology 
provides a combination of enabling techniques 
utilised in identifying putative targets and 
drug candidates. Recent advances in “omics” 
technologies (genomics, proteomics etc.), in 
78 In 2004 approx. 3.49 new hepatitis B infections per 100 000 individuals were reported for the EU. This amounts to some 16 
000 new cases. Considering that 50% of hepatitis B infections go unreported and that two thirds are asymptomatic, a 6-times 
higher figure can be assumed to be more realistic, i.e. about 100 000 infections per year.
79 WHO (2006). “European Health for All Database (HFA-DB),” June 2006. World Health Organization Regional Office for 
Europe, Copenhagen. 
80 Ulmer, J.B. et al. (2006). Nature Biotechnology 24(11): 1377-1383.
81 WHO (2006). “Hepatitis B.” Fact sheet No. 204. World Health Organization, Geneva. 
82 ETEPS (2006). Bio4EU Task 2 Main report.
83 Ulmer, J.B. et al. (2006). Nature Biotechnology 24(11): 1377-1383.
84 DiMasi, J.A., et al. (2003). Journal of Health Economics 22: 151-185.
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combination with bioinformatics, have improved 
our understanding of the molecular genetic 
contribution to diseases, leading to identification 
and selection of multiple potential drug targets 
at the same time (high-throughput/microarray 
approach). Modern biotechnology has also 
impacted on target validation, e.g. through the 
development of genetically modified (transgenic 
or knockout) animals (mostly mice) as disease 
models or antibody-based assays. Finally, 
biotechnology is contributing to drug safety by 
way of improved delivery methods (e.g. for gene 
therapy and vaccines).
At the clinical trial level, where the safety and 
efficacy of a drug candidate is tested, the use of 
pharmacogenetic approaches, i.e. identification 
of the underlying genetic differences in patients’ 
drug response in order to modulate therapy, is 
increasing (see Chapter 2.1.5). In the design 
of clinical trials, such information may help 
determine the appropriate drug dosage for a 
specific subset of patients, minimising adverse 
drug reactions.85 This approach can also be 
applied in validating predictive biomarkers, for 
example in cancer treatment.86 As a result, the 
use of pharmacogenetic data is considered to 
have a potentially positive impact, at least on 
the cost of clinical trials, both by helping select 
the most appropriate patient populations and by 
minimising toxicity effects.87 In this context, the 
European Medicines Agency (EMEA) and the 
US Food and Drug Administration (FDA) have 
recently published guidelines for the submission 
of pharmacogenetic data.88
In spite of the rapid development in science 
and the use of modern biotechnology techniques, 
the attrition rate remains high (only about one 
drug candidate out of every ten subjected to 
clinical trials is actually licensed),89 and the 
costs associated with drug development have 
increased (average cost to develop a new 
biopharmaceutical has recently been estimated 
at about EUR 920 million, slightly higher than 
the development costs of conventional drugs),90 
indicating a potentially widening gap between 
scientific advancement and bedside application. 
However, certain experts argue that the high 
attrition rates may stem from the complexity of the 
targeted diseases and the somewhat fragmented 
scientific knowledge related to them, whereas 
the high costs may be at least partly attributed to 
the long development times and design of large 
clinical trials to meet regulatory requirements 
(particularly regarding safety). At the same time, 
some analysts have suggested that the application 
of new technologies may further increase costs (at 
least in the short run), as these might lead to the 
identification of numerous potential drug targets 
which are not presently well understood.91
Thus, it is unclear whether modern 
biotechnology has significantly improved the 
R&D process, but it is suggested that its potential 
could be harvested through better co-ordinated 
interdisciplinary and translational research to 
foster the development of therapeutic products.92 
The EU is taking steps to this end, e.g. by setting 
up the Innovative Medicines Initiative, a platform 
that brings together stakeholders from industry, 
academia, SMEs, regulatory authorities, health 
care providers, and patient organisations.93
85 Hopkins, M.H. et al. (2006). Nature Biotechnology 24: 403-410.
86 Sargent, D., Conley, B., Allegra, C. and Collette, L. (2005). J. Clin. Oncol. 23: 2020-2027.
87 Lesko, L.J. and J. Woodcock (2002). The Pharmacogenomics Journal 2: 20-24. 
88 EMEA (2006). Draft guideline on briefing meetings. EMEA/81167/2006.  FDA (2005). Guidance for industry: pharmacogenomic 
data submissions. U.S. Food and Drug Administration, Rockville, M.D.  EMEA (2006). Guiding principles processing Joint 
FDA-EMEA Voluntary Genomic Data Submissions (VGDSs) within the framework of the confidentiality agreement. European 
Medicines Agency, London. 
89 “Climbing the helical staircase. A survey of biotechnology.” The Economist (London), 29 March 2003, pp. 3-18.
90 Tufts Center for the Study of Drug Development Impact report 2006 Nov/Dec. 8(6). 
91 DiMasi, J.A., et al. (2003). Journal of Health Economics 22: 151-185.
92 Pisano, G.P. (2006). Harvard Business Review 84(10): 114-125. 
93 The Innovative Medicines Initiative (IMI) Strategic Research Agenda (2005), http://ec.europa.eu/research/fp6/pdf/innovative_
medicines_sra_final_draft_en.pdf
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Modern biotechnology currently plays only 
a limited role in the production process of small 
molecule drugs. Expert interviews94 indicate that 
the share of biotechnological related to chemical 
production processes is between 10% and 15%. 
The share is expected to increase in the future.
The use of animal models in research
Animals are employed in scientific research 
and drug development for purposes ranging from 
gene function studies to drug target validation 
and toxicity testing. Recent estimates indicate that 
worldwide 75-100 million vertebrates are used 
each year in research for various purposes ranging 
from drug or cancer research to toxicity tests.95 
Most commonly, animals are used as research 
models for the study of a specific biological 
or molecular process that is associated with a 
disease or a genetic condition in humans.96 This 
use has increased, particularly since researchers 
uncovered the similarity of important molecular 
pathways between human and non-human 
species (e.g. mice and rats) by sequencing and 
comparing their genomes.
There are many instances of the contribution 
of animal models to medical advances, e.g. the 
development of the polio vaccine or therapies 
for genetic conditions such as cystic fibrosis.97 
Nevertheless, it has been suggested that 
experimental animals may be compromised 
immunologically, which might in turn lead to 
unreliable conclusions.98 The suitability of animal 
models as such has been questioned, because it is 
argued that the differences that do exist between 
humans and animals compromise their validity. 
In either case it is recognised, though, that careful 
research design is paramount.
Apart from these concerns about the 
suitability of animal models, concerns also relate 
to the welfare of the animals themselves: some 
reports indicate that experimental animals may 
experience distress ranging from minor discomfort 
to moderate and severe effects.99 Specific animal 
models are most typically developed through 
genetic modification (e.g. gene insertion or 
deletion, introduction of targeted mutations), 
which might, have a potential negative impact 
on the animals, either because of the procedures 
employed (e.g. microinjection of transgenes) or 
the modification itself.100 With the production 
of genetically modified animals for research 
on the increase, these welfare concerns gain in 
importance.101
In this context, the 3-R-principle102 
(replacement, reduction and refinement) has 
been proposed to guide research using animals 
in a way that minimises their use and potential 
discomfort: replacement refers to the substitution 
of animals by non-animal alternatives, reduction 
to minimising the number of animals used, and 
refinement aims at minimising animal discomfort. 
The 3-R-principle has been acknowledged by the 
existing legislation on animal protection (Directive 
86/609/EEC103) but is also a key component of 
the recently adopted Community Action Plan on 
the Protection and Welfare of Animals, which 
94  Interviews were carried out by ETEPS. In total 28 companies were approached. These included enzyme, fine chemicals and 
pharmaceutical companies. Companies whose main field of activities are enzymatic applications or chemistry in general were 
also included. 
95 Baumans, V. (2005). Rev. sci. tech. Off. Int. Epiz. 24: 503-514. 
96 “The use of non-human animals in research: a guide for scientists.” The Royal Society, UK, February 2004, http://www.
royalsociety.org/displaypagedoc.asp?id=11514.
97 “The use of non-human animals in research: a guide for scientists.” The Royal Society, UK, February 2004, http://www.
royalsociety.org/displaypagedoc.asp?id=11514.
98 Poole, T. (1997). Lab Anim. 31: 116-124.
99 Baumans, V. (2005). Rev. sci. tech. Off. Int. Epiz. 24: 503-514.
100 EuroGroup for Animal Welfare submission to the Biotechnology for Europe Study (http://bio4eu.jrc.es/submissions.html) and 
Baumans, V. (2005). Rev. sci. tech. Off. Int. Epiz. 24: 503-514.
101 Baumans, V. (2005). Rev. sci. tech. Off. Int. Epiz. 24: 503-514.
102 Russell, W.M.S. and S.L. Burch (1959). The principles of humane experimental technique. Methuen, London. 
103 Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the 
Member States regarding the protection of animals used for experimental and other scientific purposes. OJ L 358, 18.12.1986.
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outlines specific measures for the promotion of 
animal welfare in the EU until 2010.104 Modern 
biotechnology applications can contribute to 
these objectives. For instance, the increasing 
use of in vitro methods for toxicity testing or as 
screening tools helps reduce animal use. At the 
same time, knowledge gained through genomics 
improves experimental design, which could in 
turn reduce the number of animals needed per 
experiment.
2.1.4	 In	vitro	diagnostics
In vitro diagnostics105 (IVDs) are tools (e.g. 
reagents, chips etc.) for testing specimens taken 
from the body and intended for use in a broad 
spectrum of health care applications, including 
evaluation of an individual’s likelihood of 
developing specific diseases or conditions, their 
early detection and/or diagnosis, identification 
or quantification of treatment, monitoring of 
treatment effectiveness etc.
Modern biotechnology diagnostics are a 
subgroup of in vitro diagnostic tests which are 
either protein-based or DNA-based. The first 
category refers to tests that can be used to identify 
changes in the levels of proteins during disease 
(e.g. hepatitis, prostate cancer specific enzymes). 
In addition, protein-based assays have been 
developed to identify foreign proteins during an 
infection (e.g. HIV tests). In general, this involves 
detecting a protein by a specific antibody (e.g. 
immunoassays). DNA-based tests (also often 
referred to as molecular diagnostics) identify 
alterations in the DNA sequence correlating with 
a disease or a heightened risk of developing a 
disease.
Diagnostics based on modern biotechnology 
are mainly found in the area of immunochemistry 
testing and molecular testing. Immunochemistry 
tests are utilised to detect immune reactions by 
measuring the body’s antigen/antibody reaction 
to foreign agents. The main components of such 
tests are recombinant antibodies, and they can 
be used to test for a broad range of conditions 
including cancer, allergies, and infectious 
diseases. Molecular testing involves the 
investigation of disease association with a specific 
genotype. The most established application of 
this group of diagnostics is genetic testing for 
various monogenic disorders (e.g. muscular 
dystrophy) or other diseases such as cancer (e.g. 
BRCA1 and two tests used for the identification 
of predisposition to breast cancer), and infectious 
diseases (e.g. HIV testing). Genetic testing might 
be used to support diagnosis, and to identify 
individuals with increased risk of developing 
a certain disease (predictive). Genetic testing 
may also be utilised in reproductive decision-
making and is usually pertinent when parents 
are at high risk or have previously experienced 
a serious genetic disorder in the family. This 
application includes carrier testing, prenatal 
testing and preimplantation genetic diagnosis 
(done in conjunction with in vitro fertilisation). 
It is estimated that DNA testing is currently 
available for over 1000 genetic disorders. The 
number of genetic tests performed for diagnostic, 
confirmatory or predictive purposes was recently 
estimated to be likely above 700 000 per year 
with an economic dimension of around EUR 500 
million.106
Economic significance of modern biotechnology 
diagnostics
The lack of relevant statistical data and 
databases means that only a superficial analysis 
of the economic significance of modern 
104 European Commission COM (2006) 13: Communication from the Commission to the European Parliament and the Council on 
a Community Action Plan on the Protection and Welfare of Animals 2006-2010. 
105 The US FDA defines in vitro diagnostics as: reagents, instruments and systems intended for use in diagnosis of disease or other 
conditions, including a determination of the state of health, in order to cure, mitigate, treat or prevent disease or its sequelae. 
Such products are intended for use in the collection, preparation and examination of specimens taken from the human body. 
106 Ibarreta, D., A.K. Bock, C. Klein and E. Rodríguez-Cerezo (2003). Towards quality assurance and harmonisation of genetic 
testing services in the EU. European Commission, DG JRC/IPTS, EUR 20977. 
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biotechnology in diagnostics can be made for 
the sector and for the EU. The global IVD market 
was estimated at more than EUR 22 billion in 
2004,107 which equals about 6% of the combined 
pharmaceutical markets of the USA, EU and 
Japan. Immunochemistry and molecular testing 
represented about 30% of the market, or EUR 
6.6 billion (EUR 5.4 billion for immunochemical 
tests, EUR 1.2 billion for molecular diagnostic 
tests) (Figure 2-7).
Figure 2‑7 Share of modern biotechnology 
diagnostics out of the global IVD diagnostics 
market in 2004
Five EU countries (UK, France, Italy, Germany, 
and Spain) account for about 26% of the modern 
biotechnology related diagnostics market in 
2004 (EUR 1.7 billion), a similar share as for the 
overall IVD market. The US market share for IVD 
diagnostics represents about 42%, while the share 
of modern biotechnology diagnostics is even 
higher at 51% (EUR 3.4 billion). Considering that 
the population in the five EU countries and the 
USA are roughly similar, the USA seems to spend 
about twice as much on modern biotechnology 
diagnostics than the EU countries. This is also 
reflected in the higher share that these types of 
diagnostics have in the regional IVD market 
(37%; Table 2.2).
No information is available on the 
positioning of EU companies regarding modern 
biotechnology diagnostics. An indication can 
be derived from the list of the top 15 companies 
according to IVD sales,111 which, based on the 
sales figures, might represent more than 80% of 
the IVD market. Only two EU companies are listed 
in the top 15 IVD companies (Bayer Diagnostics, 
Germany; bioMerieux, France), with sales of 
about EUR 2 billion or 9% of the world market. 
The share attributable to modern biotechnology 
diagnostics is not known. The majority of the top 
15 companies are based in the USA.
107 ETEPS (2006). Bio4EU Task 2 Main report.
108 ETEPS (2006). Bio4EU Task 2 Main report.
109 Immunochemistry and molecular diagnostics.
110 ETEPS (2006). Bio4EU Task 2 Main report.
111 ETEPS (2006). Bio4EU Task 2 Main report.
Table 2.2 Estimate of biotechnology‑based109 diagnostics and IVDs revenues in 2004
Source: ETEPS110, IPTS calculations, *Includes: UK, France, Spain, Italy, and Germany.
Source: ETEPS108, IPTS calculations.
 
Biotechnology-based 
diagnostics
(billion e)
Share of total
IVDs
(billion e) Share of total Share of biotech in IVDs
Europe* 1.7 26% 5.8 26% 29%
USA 3.4 51% 9.3 42% 37%
Others 1.5 23% 7.04 32% 21%
Total 6.6 100% 22.14 100% 30%
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Social implications of modern biotechnology 
diagnostics
Diagnostics are gaining importance for 
health care, constituting an invaluable set of tools 
for diagnosis, but in recent years this has been 
even more true for prognosis and prevention. As 
they are often a central part of first-line clinical 
decisions, diagnostics have become a crucial 
component of health care, with growing social 
implications in terms of their impact on health 
outcomes and health care delivery and costs.112
In an era of increasing health care 
expenditure, the use of sophisticated diagnostics 
based on biotechnology is costly and may 
therefore pose a further economic strain on 
health care systems in spite of their potential 
positive role in improving public health through 
earlier diagnosis and prevention. In this context, 
assessing their impact on both quality of life and 
health care delivery and costs is essential. This is 
being done by way of three case studies, covering 
a broad spectrum of important communicable 
and non-communicable conditions. These include 
HIV/AIDS testing, cardiac diagnostic assays and 
genetic testing (phenylketonuria).
Modern biotechnology-based HIV/AIDS testing
The main types of HIV tests used currently for 
diagnosis, evaluation, monitoring and treatment of 
disease are based on modern biotechnology. These 
tests fall largely into two categories: i) protein-
based (immunoassays) and ii) nucleic acid-based 
tests (NATs). The first category detects the presence 
of HIV (antibody or antigen) in a patient’s blood 
sample and is typically used for diagnosing an 
infection or screening blood donations. Some 
immunoassays have been designed to give rapid 
results in a non-laboratory setting.
Nucleic acid tests detect DNA (or RNA) 
sequences, which are highly specific to the virus. 
These tests can detect HIV genetic material in 
very small amounts and with a quick turnaround, 
which makes them a vital tool for the early 
detection of an infection and for identifying 
mutated strains (genotyping). This application 
is crucial for monitoring drug resistance and 
disease management (e.g. applying appropriate 
therapy, monitoring transmissions etc.) and is 
widely applied. Their ability to identify emerging 
mutations before the phenotypic onset of drug 
resistance is another crucial advantage in terms of 
making a timely change in therapeutic strategy.
Acquired immunodeficiency syndrome 
(AIDS) is caused by the human 
immunodeficiency virus (HIV). HIV belongs 
to the group of retroviruses typically 
characterised by the long interval between 
infection and symptom development. 
Infected individuals suffer gradual but severe 
deterioration of their immune system. The 
first case of HIV/AIDS was reported more 
than 20 years go; by the end of 2005 an 
estimated 38.6 million people were infected 
worldwide.113 Antiretroviral therapy became 
available a decade ago and increased patient 
survival considerably, converting HIV/AIDS 
into a chronic disease. However, the high 
mutability of the virus and the resulting drug 
resistance remains a challenge for therapy. 
Currently, sub-Saharan countries are most 
affected. According to UNAIDS, about 1.2 
million people in the USA were living with 
HIV at the end of 2005, and approximately 
40 000 new infections occur each year. 
In 52 countries of the WHO’s European 
region, it has been estimated that 2.2 
million people were living with the virus114 
in 2005. The majority of these are in Eastern 
Europe and central Asia, where the overall 
rates of newly diagnosed HIV infections 
112 The Lewin Group (2005). The value of diagnostics, innovation, adoption and diffusion into health care. AdvaMed, Washington, DC. 
113 UNAIDS (2006). Report on the global AIDS epidemic. UNAIDS, Geneva. 
114 WHO Europe (2005). “HIV/AIDS in Europe: Overview.” Fact sheet EURO/14/05.
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have increased significantly since 1998. In 
the same report, it is predicted that by 2010 
100 000-580 000 people will need antiretroviral 
therapy, indicating the growing importance of 
HIV/AIDS for health care.
A recent study indicates that in Europe drug-
resistant virus variants are frequently present 
in patients who have been recently infected or 
patients suffering from a chronic infection.115 
The early identification of such variants is critical 
for monitoring the progression of the disease 
but more importantly for adjusting the therapy 
accordingly.116 Thus, resistance testing is now 
recommended117 for treatment-naïve patients, 
persons newly infected within two years and 
patients who are not responding to therapy or 
during pregnancy. However, as these tests are 
relatively expensive, their widespread application 
is a matter for debate.
Several studies118 have investigated the 
cost-effectiveness of routinely using genotyping 
for drug resistance in different scenarios (e.g. 
treatment failure or treatment-naïve patients, 
prevalence etc.). In the studies reviewed, 
genotyping was shown to be cost-effective 
although at different ratios and depending on 
the prevalence of the disease. Although most of 
the studies investigate the situation in the USA 
(there testing is already reimbursed in all but 
two states) one European study reports a similar 
result i.e. that routine testing after each treatment 
failure increases both life expectancy and health 
care costs per patient.119 The cost-effectiveness of 
immunoassays is not clear.
The uptake of HIV genotyping in routine 
clinical practice is predicted to be driven by 
the high costs of new drugs. As monitoring 
drug resistance is essential for the effective 
management of HIV-infected patients, these 
biotech tests may have a significant impact on the 
epidemic by minimising its spread.
Modern biotechnology in cardiac diagnostic 
assays
The term cardiovascular disease (CVD) 
collectively refers to a class of diseases affecting 
the heart or the blood vessels. Individuals 
suffering from cardiovascular disease, particularly 
arteriosclerosis, are at high risk of an Acute 
Myocardial Infarction (AMI, heart attack),120 
which is currently the leading cause of death in 
the adult population in the USA (one out of every 
five deaths121). The rapid diagnosis of an AMI 
episode (and its distinction from other non-critical 
conditions with similar symptoms) is crucial for 
the effective management of the disease.122
Cardiovascular disease (CVD) was estimated 
to have contributed to a third of global 
deaths in 1999 (WHO) and it is predicted 
to become the leading cause of death in 
developing countries by 2010.123 In the EU, 
cardiovascular disease causes more than 
1.9 million deaths per year and is the main 
cause of years of life lost due to premature 
deaths.124 The overall cost of CVD in the EU 
was recently estimated at EUR 169 billion 
annually.125
115 Wensing, A.M.J. et al. (2005). The Journal of Infectious Diseases 192: 958-966. 
116 Blum, R.A., N. Wylie, T. England and C. French (2005). Pharmacogenomics 2: 169-179. 
117 Guidelines have been published by the US Department of Health and Human Services Panel on Clinical Practices for treatment 
of HIV infection, the EuroGuidelines Group, and the British HIV Association. 
118 Weinstein, M.C. et al. (2001). Annals of Internal Medicine 134: 440-450. Sanders, G.D. et al. (2005). The New England Journal 
of Medicine 352: 570-585. Paltiel, A.D. et al. (2006). Annals of Internal Medicine 145: 797-806. 
119 Corzillius, M. et al. (2004). Antiviral Therapy 9: 27-36.
120 A heart attack is caused when the supply of blood and oxygen to the heart is blocked. This is typically a result of a clot in the 
coronary artery. 
121 American Heart Association (http://www.americanheart.org/presenter.jhtml?identifier=4591).
122 American Heart Association, “Heart and Stroke Facts”,
 http://www.americanheart.org/downloadable/heart/1056719919740HSFacts2003text.pdf.
123 http://www.who.int/cardiovascular_diseases/priorities/en/.
124 Petersen, S. et al. (2005). “European cardiovascular disease statistics.” British Heart Foundation, London. 
125 Leal, J. et al. (2006). European Heart Journal 27: 1610-1619. 
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Tests for the diagnosis of AMI are based 
primarily on detecting a defined set of biomarkers 
associated with this condition. These assays 
are based on the use of monoclonal antibodies 
to detect AMI-associated proteins. Their use 
in the clinic has made it possible to rapidly 
identify patients suffering an AMI episode, and 
to distinguish them from patients who display 
similar symptoms but are not actually in danger of 
an AMI. Additionally, these assays can be applied 
in monitoring disease progression in response to 
specific therapies.
The economic benefit for health care 
systems resulting from the clinical application 
of cardiac diagnostics is not entirely clear, 
although it is estimated that a positive impact 
may be made by saving, for example, the costs 
of treating patients who are not in danger (it is 
estimated that only 15% admitted to hospitals 
for chest pains are actually experiencing a heart 
attack).126 Certain studies support this estimation. 
For instance, one investigation explored the cost-
effectiveness of various diagnostic strategies for 
patients suffering chest pain (one of the main 
symptoms of AMI but also of other non-life-
threatening conditions). The study showed that 
immediate cardiac immunoassay testing alone 
had incremental cost-effectiveness as compared 
to immunoassay testing combined with overnight 
hospital admission for further observation.127 
Some hospitals have reported savings from using 
cardiac immunoassays (mainly as a result of 
minimising the number of days a patient might 
spent in hospital just for observation), in spite of 
the high cost of the test.128,129
Genetic testing
Modern biotechnology techniques have led 
to a wealth of genetic information, especially 
in correlation to specific diseases. This has in 
turn facilitated the rapid development of tests 
that can diagnose or identify the risk of disease 
by analysing an individual’s genetic makeup. 
Genetic testing mainly refers to DNA testing130. 
It is estimated that DNA testing is currently 
available for over 1000 genetic disorders, and 
the methods rely mainly on detecting specific 
mutations through PCR and DNA sequencing.131
The most common diseases for which 
genetic testing is performed are those with a 
higher frequency in a population. These include 
cystic fibrosis, Duchenne muscular dystrophy, 
haemophilia A and B, familial breast cancer, 
fragile-X syndrome, myotonic dystrophy, 
heamochromatosis, and hereditary non-polyposis 
coli. The association of specific mutations with 
these diseases is well established; this may be one 
reason for the increased use of the respective tests. 
In certain cases, genetic testing has replaced other 
diagnostic methods. For instance, the genetic test 
for myotonic dystrophy is widely used in clinical 
practice as it is less invasive and more accurate 
than the previously applied electromyography, 
which failed to distinguish between this condition 
and other less severe types of myotonia.132
In addition to disease testing, other quite 
common, but perhaps less visible, non-medical 
applications of genetic testing include paternity 
testing and forensics. Other applications, which 
are only indirectly related to human health, 
include testing for animal diseases and food 
126 ETEPS (2006). Bio4EU Task 2 Case studies report – Human Health Applications.
127 Goodacre, S. and N. Calvert (2003). Emergency Medicine Journal 20: 429-433. 
128 Gwynedd Hospital Bangor, Wales. 
129 Polanczyk, C.A. et al. (1999). Annals of Internal Medicine 131: 909-918. 
130 Genetic testing is defined in this report as DNA-based testing used to identify variations in the DNA sequence that correlate 
with a disease or higher risk to develop a disease. 
131 McPherson, E. (2006). Clinical Medicine and Research 2: 123-129. 
132 McPherson, E. (2006). Clinical Medicine and Research 2: 123-129. 
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testing (discussed in more detail in Chapter 
2.2.2.3)
However, one broader clinical 
implementation of genetic testing is largely 
missing. For instance, testing for phenylketonuria, 
a genetically inherited metabolic disease, uses 
primarily biochemical methods, rather than DNA 
testing per se, partly because the biochemical 
tests are very efficient and not as costly, but also 
because the association of specific mutations with 
the disease phenotype is not yet entirely clear.133
The frequent lack of a clear association 
between a particular genetic composition and 
a pathology stems primarily from the complex 
nature of the human genome but also from the 
fact that several genetic-based diseases may be 
influenced by the environment, which makes it 
difficult to design highly specific and sensitive 
DNA tests (this is less likely to affect monogenic 
disorders where one specific gene is linked 
to a certain condition). However, the limited 
application of genetic testing in the clinic may 
be a result of several other factors, including 
the lack of proven utility in clinical, social and 
ethical terms, and associated costs (both direct 
and indirect, e.g. for genetic counselling).134 For 
instance, BRCA1 and 2 testing and counselling 
for breast cancer was estimated to cost more than 
EUR 1500 per test in 2001.135
The cost-effectiveness of genetic testing 
depends on many factors,136 and it is an essential 
tool for decision-makers and stakeholders when 
considering genetic testing (e.g. government, 
insurers etc.). However, only few economic 
analyses of genetic testing exist, and those that 
are available have covered a limited number of 
diseases. The overall scarcity of cost-effectiveness 
studies for genetic testing makes it difficult to 
evaluate their potential impact on the efficiency 
of health care systems. This is further complicated 
by the unclear reimbursement situation and the 
limited information on patients’ views on these 
diagnostic technologies (e.g. are they willing 
to pay for these tests even if their benefit is not 
clear). More research would be needed on these 
aspects, which will affect the wider clinical use 
of genetic testing in the future.
One important implication of genetic 
testing relates to the development of systematic 
collections of human biological samples and 
associated data, known as biobanks. These have 
become an important research tool, particularly 
in the context of genetic association studies.137 
While the importance of biobanks in improving 
the understanding of disease is accepted, ethical 
concerns may be raised with regard to the use and 
protection of the collected data and/or samples. 
At the EU level, the regulatory framework for 
protecting personal data is provided by Directive 
95/46/EC.138
2.1.5	 Emerging	 biotechnology	 applications	 in	
medicine	and	health	care
Cell-based therapies
Cell-based therapies are a new therapeutic 
approach which is in development. Tissue 
engineering (TE), aimed at regenerating diseased 
tissues and organs through the use of cells and the 
aid of supporting structures and/or biomolecules, 
is currently the most advanced cell-based therapy. 
About 40 products are available on the market, 
mainly autologous skin replacements, cartilage 
and bone products, generating sales of about 
EUR 60 million/year. The field is considered to 
133 ETEPS (2006). Bio4EU Task 2 Case studies report – Human Health Applications.
134 Higashi, M.K. and D.L. Veenstra (2003). The American Journal of Managed Care 9: 493-500. 
135 Lawrence, W.F. et al. (2001). Cancer Epidemiol. Biomarkers Prev. 10: 475-481. 
136 Phillips, K.A. et al. (2004). The American Journal of Managed Care 10: 425-431. 
137 Smith, G.D. et al. (2005). The Lancet 366: 1484-1498. 
138 Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with 
regard to the processing of personal data and on the free movement of such data. OJ L281/31 23.11.1995. 
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be in an early development phase; R&D activities 
are targeting diabetes (targeting insulin producing 
cells) and cardiovascular diseases (engineering 
e.g. heart valves and blood vessels), but also 
full organ replacement as a long-term objective. 
Besides a number of technical challenges (e.g. 
suitable biomaterial for scaffolds, understanding 
and controlling cell differentiation, off-the-shelf 
products, prevention of immunogenic rejection, 
scaling up manufacturing processes, quality 
control tools), the lack of a harmonised EU 
regulatory framework and the fact that current 
TE products do not provide unique life-saving 
treatments and face substantial competition with 
(less expensive) conventional products presents 
challenges for the development of TE. A proposal 
for a new regulation covering TE is currently 
being discussed by the EU institutions139.
Other cell-based therapies such as those for 
the treatment of Parkinson with foetal cells are 
still in early clinical development. The emerging 
character of cell-based therapies is also reflected 
in the increasing, albeit low, numbers of clinical 
trials carried out by US and EU companies. EU 
companies show increasing activity since 1999, 
with about 15 clinical trials in 2006. US companies 
account for about twice as many clinical trials (30 
in 2006), with no significant growth since 2002. 
However, many cell-based therapies are probably 
tested on an individual patient’s basis with 
autologous cells, and have not yet reached the 
stage of a defined product to be developed. Thus 
the number of clinical trials might underestimate 
the applications in the clinic.
Stem cells
Stem cells are non-specialized cells that 
have the capacity for self-renewal and the 
ability to differentiate under certain physiologic 
or experimental conditions, into various types 
of specialized cells140. This unique ability to 
generate any type of cell has brought stem cells 
to the forefront of medical research particularly 
with respect to treatment of diseases (e.g. cancer, 
cardiovascular and neurodegenerative disorders) 
but also including tissue engineering141,142. At the 
same time, the use of stem cells in drug discovery 
is recognized as important and is gaining 
ground143,144.
There are two main categories of stem cells: 
embryonic stem cells (ESCs), which are derived 
from the inner cell mass of embryos at the 
blastocyst stage, and somatic (adult) stem cells, 
which are derived from various fetal and post-
natal organs145. The main difference between the 
two types is that ESCs are pluripotent, i.e. have the 
capacity to differentiate into any one of the more 
than 200 cell types found in the body, whereas 
adult stem cells can differentiate only into the 
cell types found in the tissue in which they reside. 
However, adult stem cells are difficult to access 
and isolate in some cases, and, unlike ESCs, they 
do not replicate indefinitely in culture.
One application of stem cells in the clinic, 
namely bone marrow transplantation, has been a 
reality for over 40 years. This process is mainly 
used with the aim of replenishing haematopoietic 
stem cells in leukaemia patients. Currently, 
clinical trials are being carried out testing the use 
139 http://ec.europa.eu/enterprise/pharmaceuticals/advtherapies/.
140 http://stemcells.nih.gov/info/basics/basics1.asp.
141 Vats, A. et al. (2005) J. R. Soc. Med 98: 346-350. 
142 NIH (2001). “Stem cells: Scientific progress and future research directions”. U.S. Department of Health and Human Services, 
National Institutes of Health, Bethesda, MD. 
143 Tutter, A.V., G.A. Baltus, and S. Kadam (2006). Curr. Opin. Drug Discov. Devel. 2: 169-175.
144 McNeish, J. (2004). Nat. Rev. Drug Discov. 3: 70-80.
145 O’Connor, T.P. and R.G. Crystal (2006). Nat. Rev. Genetics 7: 261-276.
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of adult stem cells in the treatment of inherited 
diseases such as lysosomal storage disorders and 
immunodeficiencies146. Another application is 
in delivering gene therapy for the treatment of 
cancers (e.g. ovarian, lymphoma) but also for 
monogenic disorders (e.g. Gaucher’s disease, 
Fanconi anaemia)147. Research involving ESCs 
for the treatment of diabetes, Alzheimer’s, and 
Parkinson’s disease, is still in the preclinical stage. 
Stem-cell-based therapies for spinal cord related 
disease or injuries have also attracted scientific 
attention. In spite of this, technical challenges 
(e.g. immunorejection, potential uncontrolled 
cell proliferation which may lead to cancer) 
and the limited understanding of the stem-cell 
differentiation process still hinder the wider 
clinical application of stem cells.
Research on human embryonic stem 
cells is controversial in many countries, due 
to the fact that extracting stem cells kills the 
embryo.148. Some ethicists argue that embryonic 
stem cell research is an instrumentalisation of 
human beings and should thus be completely 
prohibited, regardless of the potential benefits 
for treating disease149. Many research efforts aim 
at finding solutions to facilitate the generation of 
ESCs without damaging or killing the embryo. 
Several concerns have also been raised regarding 
privacy of the donors of cells and embryos and 
the use of ESCs to create human embryos (for 
non-research purposes) or human/nonhuman 
chimeras150. Although stem cell therapies are 
still far from approval, a proliferation of related 
patents is already a reality, raising concerns about 
its potential impact on research. A recent survey 
shows that nearly 18 000 stem cell patents have 
been filed since 1994, with the majority coming 
from the USA151. Similar figures were retrieved 
only considering patent applications at EPO. The 
results indicate that stem cell patents have share 
of about 6% of all biotechnology patents in the 
period 1995-2004, equivalent to about 5000 
patents152.
Gene therapy
The concept of gene therapy is to introduce 
a gene into a cell, resulting in a product which 
achieves a specific therapeutic goal. For 
instance, a defective gene may be replaced by a 
functional one – this approach has been applied 
in the treatment of one type of severe combined 
immunodeficiency (SCID). Worldwide, about 
26 children suffering from SCID have been 
treated with gene therapy with some success. 
Gene therapy is also being tested in clinical 
trials for the treatment of cancer, replacing the 
defective tumour suppressor gene p53, one of 
the most common defects linked to cancer. Other 
gene therapy products in clinical trials target 
cardiovascular diseases, monogenic hereditary 
disorders such as cystic fibrosis and respiratory 
diseases such as asthma153.
Gene therapy, while considered a promising 
approach, has had several setbacks. In addition 
to difficulties in achieving the required efficacy 
of treatment, safety turned out to be an issue. 
In 1999, a patient in the USA died after having 
participated in a gene therapy clinical trial, and 
in France children developed leukaemia after 
having been treated with gene therapy against 
SCID. These difficulties may be reflected in the 
development of new gene therapy approaches. 
Since 2000 in the USA and 2001 in the EU, the 
number of clinical trials has not increased and 
is stable at about 50 and 30, respectively154. For 
146 Fischbach, G. D. and R.L. Fischbach (2004). J. Clin. Invest. 114: 1364-1370.
147 Thomson, J.A. et al. (1998). Science 282: 1145-1147.
148 Nuffield Council (2000) “Stem cell therapy: the ethical issues.” Discussion Paper. Nuffield Council on Bioethics, London.
149 Eurobarometer 64.3. http://www.ec.europa.eu/research/press/2006/pdf/pr1906_eb_64_3_final_report-may2006_en.pdf.
150 Greely, H.T. (2006). PLoS Medicine 3: 571-575.
151 UK Stem Cell Initiative (2005). Report and Recommendations. UK Department of Health, London, http://www.advisorybodies.
doh.gov.uk/uksci/uksci-reportnov05.pdf.
152 ETEPS (2006). Bio4EU Task 2 Main report.
153 O’Connor, T.P. and R.G. Crystal (2006). Nat. Rev. Genetics 7: 261-276. Branca, M.A. (2005). Nature Biotechnology 23(5): 519-
521. Seymour, L.W. (2006). Trends in Biotechnology 24(8): 347-349. 
154 ETEPS (2006). Bio4EU Task 2 Main report.
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comparison, for pharmaceuticals, the number of 
clinical trials was in the range of 1500 and 1000 
for the USA and EU in 2005. Gene therapy patent 
applications increased from zero in the period 
1995–1997 to about 14% of all biotechnology 
patents worldwide in the period 2002–2004155. 
Only one product has currently been marketed, in 
China, since 2003 (p53-based Gendicine against 
head and neck squamous cell carcinoma).
Antisense and RNA interference (RNAi)-based 
therapies
The underlying causes of several diseases 
are pathogenic proteins that are produced by 
the human body’s cells. The selective inhibition 
of gene expression and thus protein production 
is potentially a powerful tool in therapy. Two 
recently emerging approaches use nucleic acid to 
achieve this goal: antisense technology and RNA 
interference.
Antisense technology uses synthesised 
short, single stranded sequences of nucleic 
acids (oligonucleotides) which bind sequence-
specifically to mRNA (i.e. the molecule from which 
a protein is generated) and initiate degradation of 
the target mRNA inhibiting expression and protein 
production. Antisense approaches are targeted 
at cancer and viral diseases. So far only one 
antisense product has been made commercially 
available, for the treatment of cytomegalovirus 
retinitis in HIV/AIDS patients156.
RNA interference (RNAi) approaches make 
use of a cellular mechanism for silencing gene 
expression. Specific mRNAs can be targeted to 
be enzymatically cleaved leading to a highly 
specific decrease in production of the respective 
protein. The discovery of RNAi gene silencing by 
two USA-based researchers in 1998 was awarded 
the 2006 Nobel Prize in Medicine157. Since 
1998, research activities have taken off, leading 
to the first therapeutic products in pre-clinical 
and clinical development by US companies in 
2003 and by EU companies two years later. In 
2006, about 49 products were in development 
by US companies, while EU companies were 
developing 9 products. Worldwide, in 2005, only 
5 products were in clinical trials, all developed 
by US companies.
Therapeutic vaccines
Vaccines are typically prophylactic, i.e. they 
are administered to healthy individuals to prevent 
infectious diseases. However, currently there is 
growing interest in developing and using vaccines 
for the treatment of various diseases as well, 
including infectious diseases. These therapeutic 
vaccines use disease-specific proteins as antigens 
to boost or induce a specific immune response 
in the patient with the aim of treating an already 
existing condition. Although the majority of the 
work is geared to developing vaccines against 
tumours, several infectious and autoimmune 
diseases such as AIDS, hepatitis B, tuberculosis, 
and substance dependence are also targeted. 
At the same time, current studies focus on the 
development of therapeutic vaccines against 
neurodegenerative diseases (e.g. Alzheimer’s), 
and prion diseases such as Bovine Spongiform 
Encephalopathy (BSE) and Creutzfeldt–Jakob 
disease.158. Therapeutic vaccines often include 
cell-based approaches, using the patient’s own 
cells, e.g. cancer cells, to stimulate an immune 
response.
Currently, three therapeutic cancer vaccines 
are on the market in some countries. Additionally, 
four vaccines against infectious diseases are 
marketed as both prophylactic and therapeutic 
vaccines. In 2005, EU companies had about 
30 products in clinical trials, with the numbers 
155 ETEPS (2006). Bio4EU Task 2 Main report.
156 http://ott.od.nih.gov/pdfs/VitraveneCS.pdf.
157 http://nobelprize.org/nobel_prizes/medicine/laureates/2006/.
158 Sela, M. and R.M. Hilleman (2004). PNAS 101: 14559.
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steadily rising since 1995; US companies’ 
products were increasing slightly faster with 
about 45 products in clinical trials in 2005.
Pharmacogenetics
Pharmacogenetics is the study of the influence 
of genetic variation on inter-individual differences 
in drug response with the aim of tailoring therapy 
to individual genetic make-up. Although it is not a 
new discipline159, it has recently been invigorated 
by advances in genomics which allow the study 
of not just single genes but entire molecular 
pathways. These biotechnology tools have 
significantly improved not only the identification 
of the underlying causes of disease and adverse 
drug reactions, but also the search for new drug 
targets (the term pharmacogenomics has been 
coined to describe this approach)160.
Pharmacogenetics may play an important 
role in reducing the cost of disease management 
(e.g. the high cost of treating adverse drug 
reactions) by making treatments as safe and 
effective as possible for every individual or 
for specific populations (e.g. BiDil – the first 
“race-specific” therapy approved by FDA in 
2005)161,162. Additionally, it might help improve 
drug discovery and development (e.g. design of 
better/more focused clinical trials by identifying 
at-risk patients163, identification of drug targets 
etc.), which would in turn potentially reduce the 
costs of drug development as well.
Nevertheless, only a few products have 
reached the market and clinical practice. 
Examples include: i) the DNA chip AmpliChip 
which is testing for variants of two key enzymes 
in drug metabolism (reached the market in 
2003)164, ii) the HER-2 test which is used prior 
to prescribing Herceptin® to breast cancer 
patients (only 20-30% of women with breast 
cancer overexpress HER-2 and the drug affects 
only cancers overexpressing this molecule)165, 
and iii) a test for variants of the enzyme 
thiopurine methyltransferease before prescribing 
6-mercaptopurine for the treatment of acute 
lymphocytic leukaemia in children. A different 
example, not directly related to drug response 
though, is Bayer’s Trugene® HIV genotyping test 
which may be used to monitor drug resistance (as 
a result of the virus’ mutability) in HIV-infected 
patients, and modify therapy accordingly166.
Several diagnostic products with a 
pharmacogenetic component are currently 
being developed. In a recent study167, 21 tests 
were identified as being under development 
by companies for applications such as drug 
metabolism, anti-viral drug resistance, and cancer 
(14 in the US, 7 in the EU). Most companies 
see pharmacogenetics as an integral part of the 
drug development process, rather than just as 
an approach to diagnostic test development 
for personalised medicine. Nevertheless, co-
development of a drug with its respective 
diagnostic is increasingly receiving attention and it 
is seen as an important opportunity for identifying 
drug responders or individuals at potential 
risk for adverse events. The FDA published a 
concept paper on this topic in 2005 with the 
aim of initiating discussions between industry 
and government and ultimately developing draft 
guidance168.
159 Motulsky, A.G. (1957). J. Am. Med. Assoc. 165: 835-837.
160 Goldstein, D.B., S.K. Tate and S.M. Sisodiya (2003). Nat. Rev. Genetics 4: 937-947. 
161 Henig, R.M. (2004). “The genome in black and white (and gray)” New York Times (New York) 47, 10 October.
162 Daar, A. S. and P.A. Singer (2005). Nat. Rev. Genetics 6: 241-246.
163 MORST (2005). Futurewatch: Biotechnologies to 2025. Ministry of Research, Science and Technology, Wellington. 
164 Nuffield Council (2003) “Pharmacogenetics: ethical issues.” Discussion Paper. Nuffield Council on Bioethics, London. 
165 Herper, M. (2005). Genentech’s wall of data. Forbes.com (New York), April 26. 
166 http://www.fda.gov/cber/seltr/K000038L.htm.
167 Zika, E., D. Gurwitz and D. Ibarreta (2006). Pharmacogenetics and pharmacogenomics: state-of-the-art and potential
 socio-economic impact in the EU. European Commission DG JRC/IPTS, EUR 22214.
168 http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf.
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Nanomedicine
The term nanomedicine may be defined as 
the use of nanoscale or nanostructured materials 
in medicine, which, according to their structure, 
have unique medical effects (e.g. the ability to 
cross biological barriers or the passive targeting 
of tissues)169. The potential of nanomedicine for 
delivering more specific and effective therapies 
with minimal side-effects is well recognised, as 
is its contribution to the development of more 
elaborate and sensitive diagnostics. Nevertheless, 
several challenges must be overcome before 
nanomedicine is widely applied in the clinic.
Nanomedicine applications include drug 
(and gene) delivery, in vitro diagnostics, in 
vivo imaging and biomaterials (e.g. implants). 
Currently, the field is dominated by nano drug 
delivery systems (NDDS), which account for 
more than 75% of the market170. The aim of 
NDDS is to improve the bioavailability and the 
pharmacokinetics of therapeutics, thus improving 
efficacy and specificity while minimising side 
effects. Another important goal is to improve 
delivery (e.g. render it more specific to the site of 
disease).
Nanomedicine is a rapidly growing research 
field with significant potential to deliver improved 
diagnostics and innovative therapeutics. In recent 
years, the number of research publications on 
nanomedicine has greatly increased (more than 
1200 in 2004)171, with 76% of these focusing on 
drug delivery. The EU leads in scientific output 
(36% of worldwide publications are European, 
compared with 32% from the USA). Commercial 
interest in nanomedicine applications has also 
increased in the last 5 years, a clear indication 
of this trend being the rise in the number of 
patent filings. However, in patenting (25%), the 
EU lags behind the USA, which holds 54% of 
patents in nanomedicine, indicating the difficulty 
of translating the EU’s strength in research into 
products. 38 nanomedicine products were found 
to be on the market, generating estimated sales of 
EUR 5.4 billion in 2004172.
2.1.6	 Summary
Economic significance
Modern biotechnology in medicine and 
health care considering market values is strongest 
in biopharmaceuticals, followed by in vitro 
diagnostics and vaccines (Figure 2-8).
Figure 2‑8 Share of biopharmaceuticals, 
recombinant vaccines and modern 
biotechnology diagnostics in the EU in 2005, 
by turnover (e billion)
Biopharmaceuticals, vaccines and part 
of the diagnostics sector are covered by the 
pharmaceutical sector in NACE173. In 2002, the 
EU pharmaceutical sector (NACE DG 24.4174) 
contributed about 4% to the gross value added 
(GVA) of the manufacturing sector (NACE D), and 
0.7% to overall EU GVA.
169 Wagner, V., A. Dullaart, A.K. Bock and A. Zweck (2006). Nature Biotechnology 24: 1211-1217.
170 Wagner, V., A. Dullaart, A.K. Bock and A. Zweck (2006). Nature Biotechnology 24: 1211-1217.
171 Wagner, V., A. Dullaart, A.K. Bock and A. Zweck (2006). Nature Biotechnology 24: 1211-1217.
172 Wagner, V., A. Dullaart, A.K. Bock and A. Zweck (2006). Nature Biotechnology 24: 1211-1217.
173 NACE is the Nomenclature of economic activities (French: Nomenclature générale des activités économiques) applied by Eurostat. 
174 NACE DG 24.4 includes Manufacture of pharmaceuticals, medicinal chemicals and botanical products. 
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The share of GVA in the turnover of the 
pharmaceutical sector is about 34%. Given 
the EU market value of biopharmaceuticals 
and recombinant vaccines (EUR 7.3 billion 
in 2002), and assuming a similar GVA share 
for these products as for pharmaceuticals 
(although biotechnology as a new technology 
might improve process efficiency), modern 
biotechnology accounted for 5.3% of the value-
added of the pharmaceutical sector in 2002, and 
for 0.25% of that of the manufacturing sector. 
This puts it on a par with agro-chemicals (NACE 
DG 24.2) or man-made fibres (NACE DG 24.7) 
(see Table 2.3). Biotechnology-based diagnostics, 
assuming the same turnover/GVA ratio as for 
pharmaceuticals, play a minor role compared to 
biopharmaceuticals.
This calculation only considered the direct 
economic contribution of biopharmaceuticals, 
recombinant vaccines and diagnostics. Indirect 
contributions stemming from the use of these 
products and potentially resulting in cost savings 
and improved health status have not been 
included. A recent study investigating the link 
between health and the economy in the European 
Union finds that better health contributes to 
economic growth in four ways: higher productivity, 
higher labour supply, higher skills, and more 
savings available for more capital formation (e.g. 
in anticipation of a longer life expectancy after 
retirement)175. The indirect contribution of modern 
biotechnology to economic growth by enabling a 
healthier population could not be discerned from 
the available literature.
EU companies seem to be less competitive 
in product development, probably also because 
the biotechnology sector is less developed and 
less mature. In terms of products in clinical trials, 
US companies in 2005 had 75% more products 
in the pipeline than EU companies, which is also 
indicative of a stronger position on the market in 
future. In vaccines, the EU has a strong position; 
however, clinical trials, i.e. future products, 
are dominated by US companies. In modern 
biotechnology-based diagnostics, the situation is 
Table 2.3 Contribution of biotechnology‑based applications to the economy of the EU
*EU-19;** Includes: UK, France, Spain, Italy, and Germany, 2004, figures in italics are estimates.
175 Suhrcke, M. et al. (2005). The contribution of health to the economy in the European Union. European Commission, DG 
Health and Consumer Protection. 
EU-25 (2002)
Turnover
(e billion)
GVA
(e billion)
Share of 
chemicals GVA 
(%)
Share of 
manufacturing GVA 
(%)
Share of
EU-25 GVA 
(%)
EU-25 (all economic activity) 8783 100
Manufacturing (NACE D) 5799 1529 100 17.4
Chemicals (NACE DG 24) 601 171 100 11 2
Agro-chemicals (NACE DG 
24.2) 12 2.5 0.03 0.2 0.03
Pharmaceuticals (NACE DG 
24.4)
171 58 34 4 0.7
Man-made fibres (NACE DG 
24.7) 12 3 0.03 0.2 0.03
Biotechnology-based products
Biopharmaceuticals* 7 2.4 1.4 0.2 0.03
Diagnostics** 1.7 0.6 0.06 0.04 0.01
Recombinant vaccines 0.3 0.1 0.4 0.007 0.001
Total biotech 9 3.1 1.86 0.25 0.04
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not clear. The small proportion of EU companies 
in the top 15 diagnostics companies could also 
indicate a relatively weak position in the relevant 
subsectors.
Contribution to employment
Modern biotechnology’s contribution to 
employment is mainly seen in the creation of 
higher qualified jobs. The quantitative impact is 
difficult to measure, mainly due to limited data 
availability and the difficulties of including indirect 
employment effects. However, employment effects 
are likely to correspond to the overall diffusion of 
modern biotechnology applications. As with the 
diffusion of biotechnology applications, it can be 
assumed that some of the newly generated jobs 
take the place of existing ones.
Social implications
A general conclusion regarding health 
biotechnology’s contribution to public health in 
terms of better disease prevention and treatment, 
cost-effective interventions, and better quality of 
life for patients is difficult to draw, as this strongly 
depends on the individual product and the 
condition treated. The case studies analysed in this 
study seem to indicate that biopharmaceuticals 
and recombinant vaccines are effective 
approaches to disease treatment and prevention. 
Modern biotechnology has enabled a safe and 
in principle unlimited supply of well defined 
products, in contrast to isolation from animal 
or human sources (insulin, glucocerebrosidase, 
hepatitis B vaccine). It has also opened up the 
prospect of further advances in treatment for the 
benefit of patients (insulin analogues). However, 
all these advantages come at a price, and 
biopharmaceuticals, partly due to their complex 
manufacturing and handling, are comparatively 
costly in general. The cost-effectiveness of the 
biopharmaceuticals studied often could not be 
determined due to a lack of appropriate studies. In 
some cases there are no conventional alternatives 
for comparison, which, for example in the case of 
orphan drugs such as glucocerebrosidase, raises 
difficult questions concerning the affordability for 
health care systems of very expensive treatment 
for a limited group of patients. However, it 
seems that for example the recombinant hepatitis 
B vaccine is cost-effective, partly due to its 
preventive character.
Diagnostics based on modern biotechnology 
appear to be gaining importance in all aspects 
of clinical practice, including disease diagnosis, 
monitoring and prevention. However, their 
actual implementation in the clinic varies 
widely, ranging from routine (e.g. HIV testing for 
monitoring drug resistance) to limited use (e.g. 
genetic testing for phenylketonuria). Moreover, 
although these diagnostic tools may offer clinical 
benefits they potentially represent an economic 
strain on health care systems mainly because 
of their direct and indirect costs. Further cost-
effectiveness studies would help elucidate their 
actual overall benefit. Some experts, in fact, 
highlight the use of these tools to complement, 
rather than to replace, clinical medicine176.
Cost-effectiveness analyses are still generally 
rather scarce, and may present diverging results 
depending on the methodologies applied. 
Thus, some of the results should be regarded as 
preliminary and may be difficult to extrapolate 
in reaching a general conclusion on the 
social implications of modern biotechnology 
applications as a whole in medicine and health 
care.
Environmental implications
The use and/or manufacturing of 
biotechnology-based products for the treatment 
176 McPherson, E. (2006). Clinical Medicine and Research 2: 123-129.
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(or diagnosis) of humans or animals may have a 
potential impact on the environment. However, 
direct evidence for this is scarce; it is often 
thought that the production of medicinal products 
using biotechnological approaches might have 
less negative effects on the environment than 
previous methods.
The potential environmental impact 
of biotechnology-based products has been 
recognised by regulatory authorities. In the EU, 
Directive 2001/83/EC177 relating to medicinal 
products for human use first introduced 
a requirement for the assessment of the 
environmental impact of such products on a case-
by-case basis, prior to marketing authorisation. 
In this context, the European Medicines Agency 
(EMEA) has recently published guidelines on 
the environmental risk assessment of medicinal 
products for human use178 which is focusing on the 
potential risks arising from the use of the products 
rather than their manufacturing. Another EMEA 
guideline also addresses the environmental risk 
assessment of products containing or consisting 
of genetically modified organisms179, based on 
the requirement under pharmaceutical legislation 
(Regulation EC/726/2004180) that human 
medicinal products respect the environmental 
safety requirements laid down in Directive 
2001/18/EC181 on the deliberate release into the 
environment of genetically modified organisms. 
At the same time, ERAPharm, an FP6-funded 
programme aiming at improving the scientific 
basis and methods for evaluating potential risks 
that pharmaceuticals pose to the environment, 
is expected to finalise its results and provide 
relevant recommendations in 2007182.
In addition to biopharmaceuticals, 
biotechnology is applied in the production 
process of pharmaceutical compounds. The ratio 
of biotechnological to chemical processes is 
estimated to range between 10% and 15%183 and 
their application in the manufacturing of health-
related products such as antibiotics might have a 
positive impact on the environment by improving 
resource and energy use, emissions of other 
pollutants to water, air and soil, and generation of 
waste. One example of this is the production of 
cephalosporin (see Chapter 2.3.1.6).
2.2 Modern biotechnology in primary 
production and agro-food
Primary production and agro-food 
encompasses the primary sectors producing raw 
materials, i.e. agriculture, forestry, horticulture, 
animal husbandry, and fisheries, as well as the 
food processing and retailing sector beyond 
the “farm gate”, supplying the consumer with 
food products. The food chain (Figure 2-9) that 
connects primary production and consumers (in 
the “farm to fork” approach) includes complex 
linkages. Changes in one part of the chain (e.g. 
improvements in pig meat quality due to breeding 
efforts) impact on the other parts, e.g. providing 
advantages for farmers, retailers, and consumers.
Modern biotechnology is mainly applied 
in the sectors providing inputs to primary 
production, such as breeding and propagation 
of plants and animals, the production of feed 
additives, veterinary pharmaceuticals and 
diagnostics. Furthermore, via the use of the 
177 Directive 2001/83/EC of the European Parliament and the Council of 6 November 2001 on the Community Code relating to 
medicinal products for human use. OJ L 358, 18.12.1986.
178 http://www.emea.eu.int/pdfs/human/swp/444700en.pdf.
179 http://www.emea.eu.int/pdfs/human/bwp/13514804en.pdf.
180 Regulation (EC) No 726/2004 of the European Parliament and the Council of 31 March 2004 laying down Community 
procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a 
European Medicines Agency, OJ L 136, 30.4.2004, p.1.
181 Directive 2001/18/EC of the European Parliament and the Council of 12 March 2001 on the deliberate release into the 
environment of genetically modified organisms and repealing Council Directive 90/220/EEC, OJ L 106, 17.04.2001, p.1.
182 http://www.erapharm.org/.
183 ETEPS (2006). Bio4EU Task 2 Main report.
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above modern biotechnology-derived products 
downstream, modern biotechnology has an 
indirect impact on the actual production of crops, 
livestock and fish. Further down the food chain, 
modern biotechnology is used in the production 
of enzymes, which are used as inputs for food 
processing (see Chapter 2.3.1.3 biocatalysis in 
food production), and in the traceability of food 
ingredients (e.g. of GM food and feed, of end 
products such as meat) and assurance of food 
safety (testing for pathogens such as salmonella).
Very often the use of modern biotechnology 
is not visible in the product, i.e. modern 
biotechnology tends to be involved in product 
development and production processes, where 
it may be used as a core, key or supportive 
technology. Apart from genetic modification of 
plants and animals, the applications of modern 
biotechnology in primary production and agro-
food receive little public attention.
The following analysis will mainly focus 
on the sectors to which modern biotechnology 
is most relevant, namely the input sectors, in 
which it is directly applied, and the primary 
production and food processing sectors, which 
are the main users of modern biotechnology-
derived products. The food chain further down 
to retailers and consumers will only be discussed 
where appropriate, e.g. considering modern 
biotechnology applications in food-related 
diagnostics. For the sake of simplicity, the term 
agro-food sector will be used throughout, 
including the input sectors, primary production 
and food processing.
The primary sector in the EU produced a 
turnover of EUR 363 billion in 2003, equivalent 
to gross value added (GVA) of EUR 181 billion 
(50%). Compared to overall EU economic activity, 
this represents 2.06% of EU GVA. In rural areas, 
the economic significance of the primary sector 
can be significantly higher. The primary sector 
represents about 5% of EU employment.
The sub-sectors of primary production have 
different shares in GVA (Figure 2-10). Agriculture 
and hunting (NACE sector A01) is the largest 
activity with 87% (1.79% of GVA), followed by 
Figure 2‑9 Diagram of the food chain184
184  Adapted from: Tait, J., J. Chataway and D. Wield (2001). PITA project: Policy influences on technology for agriculture: chemicals, 
biotechnology and seeds. Final report. Scottish Universities Policy Research and Advice Network (SUPRA), Edinburgh. 
Inputs:
manufacturing and
primary sector
Primary sector
Food processing
Retail
Consumers
Tr
an
sp
or
ta
tio
n 
an
d 
Di
st
rib
ut
io
n
Chemical manufacturing
(plant protection products,
fertilisers, veterinary products,
feed and food additives, diagnostics, etc.)
Breeding and propagation
(seeds, eggs, embryos,  etc.)
Crop, forestry, animal and fisheries production
Food processing and related activities (e.g. animal feed)
Retail
Consumers
C
on
se
qu
en
ce
s,
 O
pp
or
tu
ni
tie
s 
an
d 
C
ha
lle
ng
es
 o
f 
M
od
er
n 
Bi
ot
ec
hn
ol
og
y 
fo
r 
Eu
ro
pe
1
JR
C
  R
EF
ER
EN
C
E 
R
EP
O
RT
forestry with 11%. Crop production accounts for 
about half of primary production value; livestock 
production represents about 40%. Fishing 
and aquaculture (NACE B) are comparatively 
small activities with 0.027% and 0.016% of 
EU GVA, respectively. In terms of employment, 
agriculture and forestry together represent 97% 
of the primary production workforce, or 9.8 
million employees185. Regionally, fisheries may 
be highly important, but it accounts for only 
0.13% of EU employment. The food-processing 
sector (NACE DA 15), including feed production, 
represents 2.06% of the EU GVA, and 2.2% 
of EU employment. Primary production and 
food processing are the main users of modern 
biotechnology products (e.g. seeds, diagnostics, 
enzymes) in the agro-food sector and represent 
overall 4.1% of EU GVA.
Figure 2‑10 Contribution of the agro‑food 
sub‑sectors to EU GVA
Modern biotechnology-derived products 
are provided by the sectors that supply inputs to 
primary production and food and feed processing, 
in the form of seeds, veterinary pharmaceuticals 
and diagnostics, feed ingredients, and enzymes 
for food processing186 (see also Chapter 2.3.1.1). 
These sectors account for about 2% of the agro-
food sector or 0.1% of the EU economy, with 
plant-related activities accounting for more than 
half of the total (Figure 2-11). Overall, the agro-
food sector as defined here represents about 
4.22% of EU GVA. As a comparison, food-related 
wholesale retail and catering together represent 
about 3.4% of EU GVA.
Figure 2‑11 Input sectors applying modern 
biotechnology, share in overall turnover
The current state of EU agriculture in the 
global context has been reviewed elsewhere187. 
The economic importance of EU agricultural 
production has been declining, while the trends 
in terms of agricultural output vary by sub-sector. 
Similarly, the number of people working in 
185 2002 data for the primary sector (NACE branch A) from: ‘Rural Development in the European Union – Statistical and Economic 
Information – Report 2006, DG Agriculture and Rural Development.
186 The input sectors using modern biotechnology include the following: seeds and planting stock; nursery flowers and plants; 
animal breeding; fish breeding; manufacture of fine chemicals; veterinary products and services; diagnostics in the agro-food 
sector. 
187 Scenar 2020 – Scenario study on agriculture and the rural world. European Commission, DG Agriculture and Rural 
Development,   http://ec.europa.eu/agriculture/publi/reports/scenar2020/indextech_en.htm.
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agriculture is declining, both in absolute terms and 
as a proportion of the total workforce. However, 
productivity has generally been increasing, 
mainly as a result of technical advances. EU 
shares in the global agricultural market vary by 
sub-sector and are influenced by a large number 
of factors including environmental variability, 
globalisation and EU Common Agricultural 
Policy measures. Current trends, such as further 
trade liberalisation and increased worldwide 
agricultural production (especially in developing 
countries where both improved productivity 
and area expansion are driving factors) place 
additional strains on the competitiveness of EU 
agriculture. While the economic importance of 
the primary sector has been decreasing in the EU, 
the added value generated by it is increasingly 
captured elsewhere in the supply chain, e.g. in 
the manufacturing sector involved in raw material 
processing. As competitiveness is correlated 
to comparatively lower production costs and 
improved productivity, technical innovations are 
likely to continue to be influential in the future. 
Moreover, the environmental pressure from 
agriculture has been decreasing, mainly as a result 
of technical innovations in production and better 
use of inputs, in turn driven by environmental 
regulations and cost savings.
Based on the available data, the direct 
and indirect adoption and socio-economic 
implications of modern biotechnology were 
assessed and are presented below. If data were not 
available, expert opinion was sought to provide 
estimates of adoption. The same procedure for 
calculating adop-tion was used for all modern 
biotechnology applications, although modern 
bio-technology may have different roles in the 
production process. The relative contribution 
of modern biotechnology to the measures used 
(GVA and turnover) may differ depending on its 
use: it will be highest where biotechnology is a 
core technology, where the value generated may 
be allocated 100% to modern biotechnology; 
and lowest where it is a supportive technology, 
where its main role is in improving the efficiency 
of production processes and therefore overall 
competitiveness.
The indirect adoption and socio-economic 
contributions of modern biotechnology are 
also assessed. While analysis of the social and 
environmental implications is more qualitative, 
a common method of quantifying economic 
significance was used throughout. The relative 
importance of inputs to the overall production 
activity of users may vary, but is not quantifiable, 
therefore the same procedure was used in all 
cases: the indirect contribution was measured in 
terms of the GVA generated (or turnover if GVA 
data were not available) by production processes 
that used modern biotechnology-derived inputs, 
e.g. the farm-gate turnover from the share of crop 
output derived from seeds produced through 
the use of molecular markers, or the turnover 
generated by the sale of processed foods that use 
modern biotechnology-based enzymes.
2.2.1	 Modern	biotechnology	in	the	breeding	and	
propagation	of	crops,	livestock	and	fish
Crops and livestock used today in agriculture 
are the result of a long selection process. Since 
the early days, breeding methods have become 
more sophisticated and the latest innovations have 
come from modern biotechnology. The objective 
of selective breeding is to optimise plants or 
animals for specific purposes or conditions, and 
to stabilise the new characteristics throughout 
the subsequent generations. Selective breeding 
is based on differences in the genetic material of 
the organisms188.
The use of molecular markers and genetic 
modification are the most important modern 
biotechnology techniques applied to support 
breeding efforts. Molecular markers (certain DNA 
regions linked directly or indirectly to specific 
188 Selective breeding of plants and animals is more complex than presented; for example, plant breeding makes use of a variety of 
techniques, such as planned hybridisation, mutation breeding, and somaclonal variation.
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traits) are used in several ways: Marker Assisted 
Selection (MAS) and related techniques make use 
of them to identify and help incorporate desirable 
traits into selection schemes189. Molecular markers 
are also used indirectly to improve the breeding 
process, e.g. in the verification of pedigrees 
(through the use of microsatellites for lineage 
traceability in fish, for example). Overall, the 
use of molecular markers may simplify breeding 
procedures, improves the accuracy of selection 
and increases the rate of genetic progress 
(reducing the development time) by identifying 
organisms carrying desirable genetic variants for 
a given trait at an earlier age.
Genetic modification (GM), also known 
as genetic engineering or recombinant DNA 
technology, is one of the newest methods to 
introduce novel traits to plants and animals. 
Currently, the technique is more advanced for 
crops. GM animals are not yet used commercially 
for food production; recent commercial 
applications can be found in the production of 
pet fish and the production of pharmaceuticals in 
goats’ milk. The adoption of GM crops worldwide 
has been faster than that of other innovations in 
plant varieties, such as the introduction of hybrid 
maize decades ago. In the first year of introduction 
(1996) about 1.7 to 2.6 million hectares of GM 
crops were grown, almost exclusively in the USA. 
Eleven years later (2006) the area under GM 
crops had expanded to 102 million hectares in 22 
countries, of which 11 are high-income economies 
and 11 developing countries. During this period 
(1996-2006), two agronomic traits introduced by 
genetic engineering into a few major crops have 
dominated the market. These traits are herbicide 
tolerance and insect resistance (referred to as Bt 
crops since the gene conferring resistance comes 
from the soil bacterium Bacillus thuringiensis). 
Today, GM varieties have a significant world share 
of the four major agricultural crops for which they 
are commercially available (17% of maize global 
area, 18% of canola, 64% of soybean and 38% 
of cotton)190.
Propagation techniques are used to increase 
the number of individuals with favourable 
genetic characteristics at a faster pace and in 
a cost-effective manner, and as such support 
breeding efforts. In the case of plants, cells and 
tissues are used for propagation in vitro, also 
referred to as micropropagation. This technique 
allows quick, space-saving multiplication of a 
plant with desirable characteristics, providing 
sufficient uniform and high quality material. It 
also facilitates the production of disease-free 
plants. It has been adopted where it promised 
to be cost-effective compared with conventional 
plant propagation methods based on plant seeds 
or cuttings; it is mainly used to provide young 
and mother plants but also for the large scale 
production of some cut flowers and pot plants.
In livestock breeding, modern biotechnology-
based propagation refers to assisted reproduction 
techniques, which are mainly used in embryo 
transfer (ET). ET covers a number of techniques 
such as transfer from donor to recipient, sexing 
(through microsurgery on the embryo), freezing, 
and splitting (split embryos develop into 
genetically identical siblings). Related techniques 
that may be concomitantly applied are hormone 
stimulation of ovulation, semen sexing and in-
vitro fertilisation. ET can be understood as a 
further development of artificial insemination, 
which has been used for about 60 years and still 
is the main method of livestock propagation in 
some species (e.g. cattle).
Currently, the main applications of modern 
biotechnology for fish are ploidy induction 
and sex reversal, and, to a lesser but increasing 
189 MAS includes the use of genotyping in the identification and selection for Single Nucleotide Polymorphisms (SNPs) of single-
gene determined traits and the use of genotyping coupled with mapping and other techniques in identification and selection 
for complex, multi-gene-determined traits through Quantitative Loci (QTL) manipulation; the latter includes most of the 
economically relevant traits, such as birth weight, weaning weight, growth, reproduction, milk production and carcass quality, 
for animal breeding.
190 James, C. (2006). Global Status of Commercialized Biotech/GM Crops in 2006. ISAAA Brief No. 35 (Ithaca, N.Y.).
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extent, the use of molecular (genetic) markers 
to optimise breeding strategies. Ploidy induction 
results in an increase in sets of chromosomes from 
two to three by giving embryos a heat-, cold- or 
pressure shock shortly after fertilization. While 
polyploidy is lethal in mammals and birds, it has 
led to the development of many improved plant 
varieties, and triploid fish are viable and usually 
sterile. Triploidy can be advantageous for several 
reasons, including increased growth, increased 
carcass yield, increased survival and increased 
flesh quality. Sex manipulation is used to create 
monosex populations by hormonal treatment and 
appropriate breeding techniques. The resulting 
increased productivity is based on faster growth, 
reduced aggression and delayed maturation. 
Molecular markers in fisheries management 
(harvest fisheries) is still at a rather experimental/
pilot phase.
The application of modern biotechnology 
in breeding/propagation is relevant mostly at the 
top of the breeding pyramid191, the aim being to 
facilitate and accelerate genetic improvements 
in the plant or animal population. For example, 
modern biotechnology can be used to select for or 
introduce desirable traits into already “elite” lines 
of crop plants, i.e. cultivars that are already well 
developed for commercialisation. Additionally, 
modern biotechnology may also be used 
throughout the breeding schemes further down the 
pyramid, for example in parentage identification 
and lineage traceability. However, impacts at the 
top of the breeding pyramid are felt at the bottom 
of the breeding and production scheme and since 
genetic improvements are in general cumulative 
over generations, the impacts are long term192. The 
direct impacts of modern biotechnology in this 
area are felt by breeding companies/departments 
and other specialised biotechnology companies 
supporting the breeding/propagation of plants/
animals, while the indirect impacts are felt by 
producers/farmers. The indirect impacts may also 
be felt further down the chain, especially through 
the processing stage, and perhaps also all the way 
through to retail and consumption. However, 
because of the complex structure of the agro-
food sector, our assessment will mainly focus on 
the input and first user stage, i.e. the farm gate; 
qualitative descriptions of indirect impacts further 
down the chain will be made in cases where such 
information is available.
2.2.1.1 Breeding and propagation of plants
Crop production accounts for about half of 
the value of primary production activities. Crops 
and plants also account for a significant share 
(61%, see Figure 2-11) of the input sectors of 
the agro-food sector. The modern biotechnology 
techniques currently used in plant breeding and 
propagation mainly relate to molecular markers, 
genetic modification, and micropropagation193. 
These technologies are used and applied either 
by breeding/seed companies, or by specialised 
laboratories involved in the supply of horticultural 
products and/or young plants.
Economic significance of molecular markers and 
genetic modification in crop breeding
The use of molecular markers in breeding
Molecular markers are applied in research 
in almost all plant-related sectors, namely 
crops (including vegetables), fruits, and forestry. 
However, they appear to be used commercially 
191 A breeding pyramid consists of three main components: at the top of the pyramid (apex) are the highest-merit breeders (males 
and females in animals); below these are the multipliers, used to disseminate the desirable genetic makeup; at the bottom of 
the pyramid (and therefore largest in number) are the production plants/animals. For example, one great-grandparent boar may 
be responsible for the genetics of 10 800 parent females or 570 000 slaughter pigs (ETEPS (2006). Bio4EU Task 2 Case studies 
report – Primary Production and Agro-food Applications.).
192 Breeding schemes are more complex than this; while, in general, genetic improvements are cumulative over generations, this 
may not always be the case for all individual traits.
193 There is a large variety of techniques used in plant breeding, such as hybridisation, mutation breeding, somaclonal variation, 
which fall outside the scope of the study unless they are used in combination with one of the three techniques discussed.
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mainly in the crop sector, most commonly in 
maize and vegetable194 breeding. Although data 
on the uptake for other crops is not available, a 
recent publication195 suggests that maize breeding 
is more amenable to the application of MAS as 
compared to wheat, barley and rice, for biological 
as well as agronomic reasons. Maize is one of the 
most important crops in the EU, grown on about 6 
million ha with a yield of about 55 million tonnes/
year (4% of all crop production by value). Selective 
breeding targets agronomic traits such as cold and 
drought tolerance and pest resistance, but also 
quality traits such as protein content196.
The EU seed sector comprises more than 
400 seed companies, of which approximately 
10% generate 40% of the turnover, indicating 
that a large part of seed production is provided 
by a small number of medium-sized and large 
companies. The European Seed Association 
(ESA) estimated the turnover from seed sales of 
EU seed companies at EUR 6.1 billion for 2003197 
while employment is estimated at more than 30 000 
employees. The share of maize in total EU seed 
production is estimated at EUR 405 million 
(6.6%), based on the maize area cultivated and 
seed cost information198.
The adoption of molecular markers in maize 
breeding seems to depend on company size. 
Experts indicated that medium-sized and large 
companies apply molecular markers 100% to 
maize breeding, whereas smaller companies 
show a lower adoption rate (as low as 33%)199. 
Also ESA states that molecular markers are 
commonly used as a tool in the seed industry200.
Given the adoption of molecular markers in 
maize breeding and the turnover of commercial 
maize seed, it is estimated that EUR 133 405 
million or 2.2%-6.6% of total seed turnover at 
EU level is related to the use molecular marker-
related technologies (for 2003), equivalent to 
0.01%-0.03% of the turnover of the agro-food 
sector. As market shares of medium-sized to large 
companies are likely to be higher, the upper 
value might be more accurate. Indirectly, the 
adoption of molecular marker technologies may 
also contribute to the turnover generated by using 
the seeds for crop production. While exact data 
for the share of maize produced in the EU from 
molecular marker-derived seeds is not available, 
applying the breeders’ adoption rate to crop 
production and assuming that the alternative 
main seed providers (mainly the USA) have also 
adopted the technology at similar or higher rates, 
results in a turnover value of EUR 2.4-7.4 billion. 
This accounts for 0.2%-0.6% of agro-food sector 
turnover. While this estimate may not be allocated 
completely to the use of molecular markers, it 
provides an indication of the indirect economic 
significance of the adoption of this technology.
The adoption of molecular marker-based 
technologies in the breeding of other crops is 
not known. For illustrative purposes, assuming 
an overall adoption rate of 33%, similar to the 
low adoption rate for maize, would result in EUR 
2 billion seed turnover, representing 0.17% of the 
agro-food sector turnover. Assuming that about 
a third of all seeds planted are derived from the 
application of molecular markers in breeding, the 
194 See for example http://www.keygene.com.
195 Koebner, R (2004). “MAS in cereals: green for maize, amber for rice, still red for wheat and barley.” Paper for the workshop on: 
Marker assisted selection: a fast track to increase genetic gain in plant and animal breeding? 17-18 October, Turin, http://www.
fao.org/Biotech/docs/Koebner.pdf. 
196 Interviews with experts from industry and academia (ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production 
and Agro-food Applications).
197 Eurostat data for intermediate consumption of seeds and planting stock (first generation and certified seed) and the value of 
multiplied seed result in a slightly higher turnover of EUR 8.3 billion for the seed sector, but this includes propagating material 
other than seeds. Therefore, the ESA data will be used in the following calculations.
198 The estimate is based on the maize area cultivated (6 195 000 ha) and the cost of maize seed (EUR 65.39 per ha), resulting in 
EUR 405 million maize seed turnover.
199 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
200 http://bio4eu.jrc.es/submissions.html ESA submission excerpt: “All seed companies make use of modern technologies (including 
biotechnological methods and applications) in their work. e.g., DNA-markers assisted breeding and selection is a common tool 
in today’s modern seed industry to speed up variety development and target breeding efforts”.  
2.
  M
od
er
n 
bi
ot
ec
hn
ol
og
y 
ap
pl
ic
at
io
ns
 a
nd
 t
he
ir
 e
co
no
m
ic
, s
oc
ia
l a
nd
 e
nv
ir
on
m
en
ta
l i
m
pl
ic
at
io
ns

JR
C
  R
EF
ER
EN
C
E 
R
EP
O
RT
indirect relevance of this modern biotechnology 
increases to EUR 55.5 billion, or 4.7% of the 
agro-food sector turnover.
According to ESA statistics, the EU seed 
sector employs about 30 000 staff. No data is 
available for employment in molecular marker-
supported breeding, although, theoretically, direct 
employment (not just R&D related) would most 
likely correspond to the general diffusion rate.
Genetic modification of crops
The number of GM crops authorized for 
cultivation in the EU is small compared to other 
world regions. In practice, the only GM crop 
currently available to EU farmers for cultivation 
is a GM maize resistant to insects, commonly 
known as Bt maize201. Within the EU, Spain is 
the only country growing significant quantities 
of Bt maize. Spain cultivated 53 667 hectares of 
Bt maize varieties in 2006. France cultivated the 
second largest area with about 5000 hectares in 
2006. Germany, Portugal, the Czech Republic 
and Slovakia also grew Bt maize in 2006 but 
reported comparatively small areas of about one 
thousand hectares or less202. Table 2.4 shows GM 
maize adoption rates in the EU and worldwide in 
2005, for which figures are more definitive.
In Spain, GM seed turnover increased from 
EUR 4.1 million in 2002 to EUR 11.9 million in 
2004208, illustrating the annual increase of GM 
maize area. These figures can be taken to represent 
total EU GM seed turnover since the GM area in 
other EU Member States was negligible for the 
three-year period analysed (2002-2004).
On this basis, GM maize seed accounts for 
about 2.9% of EU maize seed turnover, reflecting 
Table 2.4 GM maize adoption rates in the EU and worldwide in 2005
201 In the EU two Bt maize events are authorised for cultivation. These are Syngenta’s transgenic event Bt-176, authorised in 1997, 
and Monsanto’s  transgenic event MON-810, authorised in 2003.
202 James, C. (2006). Global Status of Commercialized Biotech/GM Crops in 2006. ISAAA Brief No. 35 (Ithaca, N.Y.).
203 Spanish Ministry of Agriculture (2006), Superficie en hectáreas de variedades de maíz GM, http://mapa.es/agricultura/pags/
semillas/estadisticas/serie_maizgm98_06.pdf. 
204 EUROSTAT (2006) Agriculture and fisheries statistics http://epp.eurostat.ec.europa.eu/. 
205 James, C. (2005). Global Status of Commercialized Biotech/GM Crops in 2005. ISAAA Brief No. 34 (Ithaca, N.Y.).
206 USDA (2005). Acreage in 2005, http://usda.mannlib.cornell.edu/reports/nassr/field/pcp-bba.
207 USDA (2006). Adoption of genetically engineered crops in the U.S. in 2005: corn varieties. http://www.ers.usda.gov/Data/
BiotechCrops/ExtentofAdoptionTable1.htm.
208 GM maize seed prices per hectare and the annual GM maize area are obtained from the GM crops case study for the BIO4EU project. 
Adoption rates (share of GM maize area out of total grain maize area) Source of data
Spain 53 225 ha/421 724 ha 12.62% Spanish Ministry of Agriculture203
France 500 ha /1 654 000 ha 0.03%
EUROSTAT204
Clive James205
Germany 300-500 ha/443 000 ha 0.07%
Czech Republic 150 ha/ 98 000 ha 0.15%
Portugal 750 ha/110 000 ha 0.68%
EU 54 925ha/6 059 000 ha 0.90%
USA 15 649 920 ha/30 096 000 ha 52% USDA 2005206, USDA 2006207 
South Africa 289 000ha/1 700 000 ha 17% Clive James205
World-wide 21 200 000 ha/147 000 000 ha 14% Clive James205
Note: In the USA GM maize can be either Bt maize, Herbicide Tolerant (HT) maize or HT/Bt maize while in the EU only Bt maize is grown. 
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the generally low adoption rate of GM maize 
in the EU (0.9% of the total grain maize area 
in 2005, see Table 2.4). GM seed accounts for 
about 0.2% (EUR 11.9 million) of overall EU 
seed turnover. GM maize accounted for EUR 85 
million209 or 1.2% of EU maize crop production.
A recent study210 analysed the agronomic 
and economic performance of Bt maize cultivated 
in Spain, compared to conventional maize. In 
2002-2004, farmers using Bt maize obtained 
an average increase in their gross margin of 
EUR 85 per hectare and growing season compared 
with farmers growing conventional maize. This 
represents an increase of 12% over the average 
gross margin obtained by maize farmers in Spain. 
These benefits, however, vary widely in the 
three regions studied, ranging from EUR 125 per 
hectare to just EUR 7 per hectare. GM seed prices 
paid by farmers are higher than for conventional 
maize seeds. On average this price difference 
in seeds accounts for EUR 30 per hectare. The 
economic welfare resulting from the adoption of 
Bt maize in Spain is basically shared by farmers 
and seed companies. Bt maize belongs to the so-
called first generation of GM crops which aim to 
provide higher production efficiency at farm level. 
Therefore, direct benefit for consumers could 
only come from a reduction of the market price. 
No differences in the price received by Spanish 
farmers for Bt maize or conventional maize crop 
were found in the study. In Spain, the Bt maize 
grain produced is used entirely for animal feed 
production. These findings match with Spanish 
feed industry claims that the introduction of 
Bt maize in Spain has not reduced the cost of 
their raw material. The largest share of welfare 
created by the introduction of Bt maize (74.4 % 
on average) went to Bt maize farmers and the rest 
went to the seed companies (25.6% on average), 
taken to include seed developers, seed producers 
and seed distributors.
The same study looked at factors which 
might have affected the adoption of Bt maize in 
Spain. One of the most relevant factors is farm 
size because it is frequently a surrogate for other 
factors such as farmers’ wealth. In contrast to 
other technologies such as machinery which 
require extensive capital investments and many 
hectares over which the farmer can spread the 
costs of acquisition, the adoption of Bt maize 
in Spain has been farm size-neutral because 
the technology is linked to the seeds, which are 
completely divisible and can be used in any 
amounts.
Some experts consider the potential 
economic impacts of GM crops not yet approved 
for commercial cultivation by EU farmers, but 
cultivated elsewhere in the world, to be an 
opportunity cost for the EU, in terms of forgone 
benefits. There is a small but growing number 
of ex ante studies addressing this potential 
economic impact211. Positive on-farm and 
aggregate economic benefits are predicted by 
these studies, derived from increased yields 
and reduced production costs for farmers. 
However, these analyses should also consider 
the novel regulatory framework on labelling 
and traceability of GMOs and derived products 
that became operative in 2004212. It introduces 
issues such as possible market segmentation, 
price differentials, and novel costs for identity 
preservation and labelling/traceability. Analyses 
of the economic impacts of introducing GM crops 
in agriculture in the EU should also now consider 
the novel concept of coexistence between GM 
and non-GM agriculture developed by the 
209 Average GM maize yields in Spain were 11 430 kg per hectare during the three-year period 2002-2004. These yields, multiplied 
by the €0.128 per kilogram received by farmers in 2004, result in revenue of €85 million.
210 Gómez-Barbero, M., J. Berbel and E. Rodríguez-Cerezo (2007). Adoption and socioeconomic impacts of the first genetically 
modified crop introduced in EU agriculture: Bt maize in Spain. European Commission, Seville. (Publication in preparation.)
211 Gómez-Barbero, M. and E. Rodríguez-Cerezo (2006). Economic impact of dominant GM crops worldwide: a review. European 
Commission. DG JRC/IPTS, EUR 22547. 
212 Regulation (EC) No 1830/2003 of the European Parliament and of the Council of 22 September 2003 concerning the traceability 
and labelling of genetically modified organisms and the traceability of food and feed products produced from genetically 
modified organisms and amending Directive 2001/18/EC; OJ L268, 18.10.2003, p.24.
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EU213. Member States have begun drafting rules 
requiring farmers cultivating GM crops to take 
measures (if necessary) to ensure coexistence and 
consequently to bear the resulting costs. A similar 
framework does not exist in other areas of the 
world where GM crops are cultivated; this raises 
new questions regarding the GM crop adoption 
process by EU farmers and its economic balance.
As with molecular marker-supported 
breeding, no employment data are available 
for developing and marketing GM seed. As GM 
seeds are mainly produced in the USA and Chile, 
the employment impact in the EU might be low. 
At farm level, it seems that the adoption of Bt 
maize in comparison to conventional maize had 
no effect on the number of farm labourers214.
Environmental implications of molecular markers 
and genetic modification in crop breeding
The environmental effects of modern 
biotechnology applications in plant breeding are 
relevant almost entirely at the crop production 
stage and further down the chain for any uses that 
may be affected by new or improved crop traits. 
Breeding itself is on a much smaller scale than 
the grow-out phases.
Molecular markers support selective 
breeding. Genetic selection has been considered 
an important driver of productivity improvements, 
but is not the sole factor. Nevertheless, a 
substantial proportion of the improvements 
in resource productivity is ascribed to genetic 
selection. Therefore, qualitatively, the impacts to 
be expected are similar to those of conventional 
selection. The environmental implications of 
the use of molecular marker-based technologies 
will depend on the trait that is targeted, and 
quantitatively, depend on the difference obtained 
in the targeted trait and the level of adoption of 
the technology. While targeted traits in maize 
breeding differ, it can be assumed that the 
adoption of molecular markers in breeding is 
mainly neutral or beneficial to the eco-efficiency 
of the primary sector because of the general aim 
to increase productivity and/or efficiency. While 
a negative effect cannot be ruled out, such as in 
situations where the selection for an important trait 
indirectly affects agricultural resource efficiency, 
it is highly unlikely, as resource efficiency also 
has substantial economic implications.
For GM crops, studies have been carried 
out to analyse (potential) environmental impacts. 
Any innovation that results in changes in the way 
a crop is managed may have an impact on the 
environment. There is scientific consensus that 
the impact of the introduction of GM varieties 
has to be analysed case by case depending on 
the nature of the genetic modification and the 
changes in field management prompted by the 
new characteristics of the variety (e.g. herbicide 
tolerance, insect resistance)215. In particular, Bt 
crops can potentially reduce the environmental 
pressure of intensive agriculture (through less 
spraying of insecticides) but could also have an 
impact on non-target insect species (since the 
GM plant produces its own insecticide) that 
must be evaluated. Data on changes in the use 
of pesticides due to Bt maize cultivation in Spain 
(from empirical evidence gathered in the survey 
described in the economic section) show that 
42% of conventional maize growers surveyed 
do not use insecticides at all for controlling 
corn borers, and this figure increases to 70% for 
Bt maize growers. 21% of conventional maize 
farmers give two or more treatments per year, and 
this figure is reduced to 2% for Bt maize growers. 
On average, conventional maize growers 
applied 0.86 treatments/year compared with 
0.32 treatments/year for Bt maize growers. This 
213 Commission Recommendation of 23 July 2003 on guidelines for the development of national strategies and best practices to 
ensure the coexistence of genetically modified crops with conventional and organic farming. 
214 Gómez-Barbero, M., J. Berbel and E. Rodríguez-Cerezo (2007). Adoption and socioeconomic impacts of the first genetically modified 
crop introduced in EU agriculture: Bt maize in Spain. European Commission, DG JRC/IPTS. (Publication in preparation.) 
215 FAO (2004). The State of Food and Agriculture, 2003-04. Food and Agriculture Organization, Rome. 
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reduction is modest in absolute terms because 
insecticide control of corn borers is very difficult. 
The lack of effectiveness and additional cost 
is the reason why many maize farmers do not 
spray insecticides specifically for controlling corn 
borers, but accept the yield losses. Regarding the 
environmental impacts on non-target organisms 
and development of resistant pest populations, 
no detrimental effect of farm scale Bt maize 
cultivation in Spain has been observed on non-
target arthropod activity or abundance, according 
to research commissioned by the Spanish 
Ministry for the Environment and performed by 
public institutions. Data collected for 5 years 
on commercial Bt maize plantings (1998-2003) 
did not show an increase in resistance for corn 
borer populations sampled in Spain216. However, 
the researchers argue for the need to maintain 
systematic monitoring for longer periods.
Economic significance of micropropagation of 
plants217
Micropropagation has been applied with 
variable success to the different agricultural 
and horticultural fields. The commercial 
uptake of micropropagation has been highest 
in ornamental plants (e.g. flowers, foliage 
plants, woody ornamentals, etc.), followed 
by vegetable plants and fruit plants. Certain 
plants can only be propagated profitably by 
means of micropropagation; for example in 
the case of orchids this technique allows the 
production of large and uniform plant stocks 
in a short time, allowing the price of orchids 
to fall. The huge demand for some ornamental 
plants such as orchids can only be fulfilled by 
applying micropropagation. Consumer demand 
is a strong driver in selecting the types of plants 
produced. Current production techniques for 
micropropagation have enabled strong and 
continued growth in the micropropagation 
industry.
The main actors in micropropagation 
are specialised commercial laboratories and 
laboratory units of young plant producing 
companies. The activity of a company may be 
limited to the production and sale of young/
mother plants, or may also involve the grow-out 
phases (open land or in greenhouses) up to final 
retail sale. Some companies are simultaneously 
involved in the micropropagation of several 
different plant types (e.g. ornamentals, vegetables) 
and in plant breeding. As a result, the economic 
activity of micropropagation is spread over 
several different sectors, which results in a lack of 
relevant statistical information.
The annual value of “nursery flowers and 
plants” and “adult ornamental plants and flowers” 
(end products) in the EU has been estimated 
at EUR 6.4 and 8.3 billion, respectively (2003 
data)218. EU production is characterised by the 
highest production intensity, achieved mainly 
through the use of modern technologies. The value 
of production is stable for adult ornamental flowers 
and plants but is increasing for nursery flowers and 
plants. The EU is a net exporter of nursery flowers 
and plants and a net importer of adult ornamental 
flowers and plants, but the overall balance is 
positive because EU domestic production is 
the main source of internal consumption. The 
Netherlands, Germany and Italy are the top 
producers of nursery and adult plants and flowers. 
Overall, nursery and adult flower and plant 
production is a very competitive sector, the main 
advantages of EU producers compared to their 
competitors (mainly in developing countries) being 
capital availability linked to modern technology 
use, logistics and a large home market. To this 
end, micropropagation seems to be one tool that 
enables some EU producers to remain competitive. 
216 De la Poza, M. et al (2005). Crop Protection 24(7): 677-684. 
217 Non-referenced information is based on expert opinion (ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production 
and Agro-food Applications). 
218 All sector information based on: Working Document of the Commission staff on the situation of the flowers and ornamental 
plants sector (DG AGRI, 2006).
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Interviews with different horticulture/breeding 
companies (for which micropropagation plays a 
role) producing orchids, pot plants, strawberries 
and ornamental woods revealed that most 
companies use micropropagation for at least 80% 
of their activities, indicating a high adoption rate of 
this technique in these companies. A conservative 
estimate puts micropropagation-related turnover 
at about EUR 39-313 million, or 0.6%-5% of the 
total value of the annual production of nursery 
plants219. In the production of adult ornamental 
plants and flowers derived from micropropagated 
young plants and mother stock, micropropagation 
is indirectly related to a turnover of EUR 50-390 
million, or 0.004%-0.033% of the agro-food sector 
turnover.
Micropropagation is a labour intensive 
technique, with labour costs representing 
65%-85% of production costs, more than for 
conventional propagation techniques. This is one 
reason for moving micropropagation activities 
to lower wage countries. Micropropagation 
companies have a comparatively high proportion 
of skilled staff (11%) due to the large proportion of 
laboratory work (academics, engineers, technical 
assistants, gardeners). However, at the same 
time, a large number are unskilled and seasonal 
workers. From the companies interviewed it 
was estimated that about 75% of employees are 
involved in micropropagation.
Environmental implications of micropropagation 
in plants
Micropropagation has rather marginal 
environmental implications compared to 
molecular marker technologies and genetic 
modification as it does not affect the breeding 
value of the crop in question; it is merely 
involved in the multiplication step of the 
breeding process. Nevertheless, the following 
environmental implications may be considered, 
even if in absolute terms the impacts are likely 
to be small220: i) micropropagation will indirectly 
improve the efficiency of the breeding process 
through the multiplication of desirable genotypes, 
and therefore it will have some share in the change 
that the related breeding scheme induces; ii) the 
field growing periods are shortened compared 
to conventional seed-based propagation which 
implies a reduction of the water, fertiliser and 
pesticides used; iii) micropropagation techniques 
can ensure propagating material is disease-free, 
reducing pathogen transfer.
Summary of modern biotechnology applied to 
plants
Out of the three main modern biotechnology 
techniques applied to plants, the use of molecular 
marker-based technologies221 seems to have the 
highest economic significance due to the high 
adoption rate in breeding of at least one of the 
major crops in the EU. GM crops, because of 
low adoption rates, have comparatively little 
significance on an EU level; however, impacts 
might be considerable on the farm scale for 
specific applications. The maize seed companies 
interviewed suggested that the sector would not 
remain competitive without the use of molecular 
markers in the breeding process. Molecular 
marker-based breeding was reported to increase 
the costs for the breeding companies in the short 
term, due to high initial investment costs and the 
need for qualified employees, but to be profitable 
in the long term. The high costs might prove to be 
a challenge for smaller companies which might 
not be able to remain competitive. However, 
maize breeding is dominated by large companies 
in the USA and EU, the main competitors.
219 These estimates are based on the figure of 193 micropropagation laboratories reached in a survey in 1996-97 (http://www.
uwe.ac.uk/fas/cost822), and the range of turnover of the companies interviewed in this study (EUR 250 000 to EUR 2 000 000) 
applying the adoption rate of 80%.
220 Expert opinion (ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications). 
221 Note, however, that there is some interdependence of the various breeding tools, as modern biotechnology techniques may be 
applied simultaneously, as well as in combination with “conventional” breeding practices.  
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The turnover generated from economic 
activities using modern biotechnologies in the 
production process has been estimated at EUR 184-
730 million, and may rise to EUR 2.38 billion under 
the assumption that all plant breeding has adopted 
molecular marker techniques in the breeding 
process. The use of modern biotechnology-derived 
products by the user sectors, i.e. the crops and 
plants produced from seeds and young plants 
(indirect significance) is relevant to a turnover of 
about one order of magnitude higher than the 
direct contributions, amounting to 0.2%-0.7% of 
the turnover of the agro-food sector. These figures 
provide an indication for the importance of modern 
biotechnology to these sectors, and should be used 
with caution since they are based on a number of 
assumptions and since modern biotechnologies 
are not the sole factor responsible for output. 
Overall, modern biotechnology is being applied 
to plant breeding and propagation to a significant 
extent in the EU for specific applications, while 
the respective sectors are important players in the 
world market.
The environmental implications of the 
application of modern biotechnologies to 
the breeding and propagation of plants are 
mainly indirect (i.e. through resource efficiency 
improvements), but may also be direct (trait-
specific) as in the case of some GM crops. While, 
overall, the environmental implications seem to 
be positive, modern biotechnologies may present 
novel and sometimes indirect environmental 
risks, necessitating robust case-by-case evaluation 
and monitoring.
2.2.1.2 Breeding and propagation of livestock
The value of livestock production at farm 
level represents about 40% of overall agricultural 
primary production in 2004 (EUR 127 billion222). 
Additionally, some crop production is used for 
animal feed; the EU feed industry has a turnover 
of about EUR 35 billion. Cattle, mainly dairy 
cattle, and pigs are major livestock segments (56% 
and 20% of agricultural output, respectively), and 
globally important. For example, after China, the 
EU is the largest producer of pig meat worldwide 
with production of about 22 million tonnes/year. 
According to a preliminary estimate by FABRE223, 
breeding efforts are responsible for an economic 
gain from improved production of EUR 1.83 
billion annually. Cattle account for 27% (EUR 
500 million), pigs for about the same, poultry for 
33%, and fish for 4%.
Information from livestock breeding 
companies indicates that about 20%-30% of 
their turnover is related to the use of modern 
biotechnology224. This includes mainly molecular 
marker-supported breeding and embryo transfer 
techniques (ET). Genetic modification of livestock 
for food production has not yet reached the 
commercial scale.
Economic significance of molecular markers used 
in livestock breeding225
Molecular markers are applied in animal 
breeding in the same way as in plants. However, 
no definitive data are available on the extent to 
which molecular markers are used in livestock 
breeding. Breeding companies/organisations do 
not usually distinguish nor record their molecular 
markers-related activities separately from 
conventional breeding practices. Moreover, there 
is an intellectual property rights issue specific to 
animal breeding in that, while genetic markers 
may be patented, there is no animal equivalent 
to the plant breeder’s rights, which may hamper 
both development and documentation of the use 
of molecular markers in livestock breeding226.
222 All statistical information from Eurostat, 2003 data.
223 FABRE (2006). Sustainable farm animal breeding and reproduction: a vision for 2025. 
 FABRE Technology Platform, Oosterbeek. 
224 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
225 Non-referenced information is based on expert opinion (ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production 
and Agro-food Applications).
226 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. Working Group ‘FABRE Technology 
Platform’ (2006). Sustainable farm animal breeding and reproduction: a vision for 2025. http://www.fabretp.org/content/view/21/43/.
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Examples for the use of molecular marker-
based technologies in livestock breeding can 
be found in pig breeding. Since the 1990s, pig 
breeding has made use of genetic information. 
A targeted trait for molecular marker-based 
pig breeding is for example, the absence of the 
halothane gene227, which is responsible for pale, 
soft and exudative (PSE) pig meat and stress 
sensitivity228,229. Other targeted traits include 
increased litter size230 and disease resistance231. 
One publicly reported example is the use of 
seven meat quality genetic markers to identify 
pigs with improved meat quality. Based on an 
agreement between a breeding company and a 
German retailer a pig meat quality programme 
to supply branded meat was set up232. Under this 
scheme, pig producers were offered around EUR 0.02 
per kg premium if they used boars selected for the 
programme.
The livestock breeding sector is heterogeneous 
in structure, comprising cooperatives or companies 
organised nationally that have relatively high 
domestic market shares. For example, no single 
organisation among pig breeders has an EU market 
share of more than 25%. There seems to be one 
big pig breeding company (PIC/Sygen/Genus, UK/
USA), and about 3 to 6 medium-sized breeding 
organisations (in Denmark, Netherlands, France, 
Belgium and the UK), and numerous smaller 
organisations and national schemes. Conditions 
are similar in the cattle breeding sector, although 
cooperatives tend to be more important and private 
companies less so.
Data gathered from a survey of major 
EU livestock breeders233 (mainly cattle and 
pig breeders) indicate that molecular marker-
related turnover accounts for about 14%-28%234 
of the breeding sector’s turnover or EUR 207-
411 million. This translates into 0.02%-0.03% 
of the overall agro-food sector turnover. Sales 
outside the EU accounted for more than half, 
corroborating the strong competitive position of 
EU livestock breeders and the relative importance 
of the technology.
Extrapolating the estimated adoption rates 
to total EU livestock production (as EU breeders 
have major shares in EU farm-gate production), 
provides an indication of the indirect relevance 
of molecular marker based technologies in 
livestock; it is estimated that molecular marker-
assisted breeding indirectly affects the generation 
of turnover of EUR 17.8-35.7 billion (which is 
14%-28% of overall livestock production at EUR 
127 billion), or 1.5%-3% of agro-food sector 
turnover.
Environmental implications of molecular markers 
in livestock breeding
The implications of molecular markers in the 
livestock breeding sector are similar to those for 
227 The gene is called the halothane gene because pigs carrying two copies of the gene are prone to physiological stress and die 
when subject to halothane anaesthesia. Pigs with one copy of the gene produce leaner meat.
228 McLaren and Rohl, personal communication quoted in http://dbgenome.iastate.edu/|max/Reviews/1998_review/implic.html.
229 Otto, R. et al. quoted in Primetiva, L., R. Klont, O. Southwood and G. Plastow (2006). “The influence of ultimate pH on meat 
quality and the role of marker assisted selection.” In: Rehout, V. (ed.) Biotechnology 2006. Scientific Pedagogical Publishing, Cˇ. 
Budeˇjovice, p. 41-44. 
230 Unpublished results of Short, Wilson, McLaren and Plastow, quoted in: Rothschild, M.F. and G.S. Plastow (1998). Current 
advances in pig genomics and industry applications. Department of Animal Science, Iowa State University, Ames, I.A. http://
db.genome.iastate.edu/%7Emax/Reviews/1998_review/.
231 Van der Steen, H.A.M., G.F.W. Prall and G.S. Plastow (2005). J.Anim.Sci 83:E1-E8.
232 ThePigSite (2005). “EDEKA Südwest and PIC Deutschland sign technology contract for meat quality,” 28 June. 5M Enterprises 
Ltd., Sheffield. http://www.thepigsite.com/swinenews/9611/. And expert opinion (ETEPS (2006). Bio4EU Task 2 Case studies 
report – Primary Production and Agro-food Applications.
233 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
234 Breeding organisations answering the survey (in total 16 organisations) stated that a share of 28% of their turnover relates 
to MAS. This is assumed to be the maximum value for MAS contribution to overall breeding activity (if applied to the whole 
breeding sector), as companies active in MAS are more likely to answer the survey. The minimum contribution is assumed to be 
the share of the turnover  value declared by these organisations over the total breeding sector turnover, which comes to 14%.
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plants. In general235, there are no examples of use 
of molecular marker that provide direct benefits 
to the environment, but the indirect impact may 
be considerable, and similar to what is achieved 
through traditional genetics. For example, 
improving the growth rate and food conversion 
ratio reduces the amount of emissions and 
resource use per unit output. Similarly, molecular 
markers used to improve the reproductive rate 
may reduce the number of breeding animals that 
need to be kept in order to produce a slaughter 
generation animal, and hence the amount of 
pollution from keeping such breeding animals, 
although the implications at the breeding stage 
are far fewer compared to the grow-out phases.
Social implications of molecular markers in 
livestock breeding
The social implications of modern 
biotechnologies currently applied in animal 
breeding and propagation are mainly in animal 
health and welfare, and the discussion will 
therefore be limited to these aspects.236 A 
baseline animal welfare concern for some is that 
modern biotechnologies are artificial, compared 
with natural selection and reproduction, but this 
is a common feature with more conventional 
agricultural practices. The impact on animal 
welfare of assisted breeding using molecular 
markers has also been discussed, although to a 
lesser extent compared to other applications. 
Marker-assisted breeding is not considered to 
be different in qualitative terms from traditional 
quantitative genetics-based breeding, as the 
means and targets are similar. The major difference 
that molecular marker information makes is that it 
improves efficiency in driving genetic selection.
Direct impacts on animal welfare will depend 
on the trait targeted: conventional breeding 
through quantitative genetics has already been 
criticised for selecting for production traits 
without due concern for specific animal welfare 
issues237; the relevance of molecular markers to 
animal welfare therefore depends more on the 
trait targeted than on the technology itself. One 
advantage for animal welfare is that molecular 
marker-assisted breeding may also be geared 
more to disease resistance and product quality-
related attributes, which have positive public 
health implications, than to clearly productivity-
related ones. A look at the traits targeted in pig 
breeding238 indicates that molecular marker-
assisted breeding has already been directly 
applied to traits with positive animal welfare 
implications: an example, which experts say 
has already been extensively applied in pig 
production, is selection against the ‘Halothane’ 
gene, which has reduced pre-slaughter mortality 
in pigs from between 4-16 per 1 000 pigs to 
nearly zero239. Similarly, a survey of two Spanish 
commercial abattoirs suggested that pre-slaughter 
deaths (during transport and lairage) could be 
reduced from 0.22%-0.02% through selection 
against the “Halothane” gene240. However, some 
of the traits targeted, such as increased litter size, 
would also require the consideration of potential 
indirect negative animal welfare effects241.
Economic significance of embryo transfer in 
livestock242
Embryo transfer (ET) is a propagation 
technique aiming to increase the productivity of 
selected females, and to multiply animals with a 
favourable genetic make-up at a faster pace, and 
235 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
236 A number of emerging applications, however, are now aiming at other “social” objectives, such as targeting the development 
of zoonotic disease-resistant animals (e.g. BSE-resistant cattle developed via genetic modification) or selection for nutritional 
quality traits (e.g. through MAS).
237 See for example “The welfare of chickens kept for meat production (broilers),” SCAHAW report, European Commission, 2000. 
238 For references and expert opinion see ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food 
Applications.
239 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
240 Fàbrega, E. et al. (2002). Animal Welfare 11(4): 449-452. 
241 See for example Weary, D.M. et al. (1998). Applied Animal Behaviour Science 61: 103-111.
242 Non-referenced information is based on expert opinion (ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production 
and Agro-food Applications).
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as such supports breeding efforts. It is currently 
widely used only in cattle, where it is limited 
to the top of the breeding pyramid due to the 
high cost. ET is estimated to be about 15 times 
more expensive than artificial insemination (AI) 
in on-farm costs. Only approximately 0.5% of 
calf production results from ET. Expert opinion 
indicates that at least 75% of bulls used as donors 
for AI are derived from ET in those countries with 
the largest numbers of cattle. It has also been 
reported that the use of ET has increased the rate 
of genetic improvement by 30% (as measured by 
productivity) compared to conventional breeding 
schemes without ET243.
In cattle there is a large international trade 
in semen and embryos, meaning that livestock 
genetic evaluation can occur across borders. The 
EU is an important player in the international 
cattle breeding sector as five of the ten largest 
cattle breeding companies are based in the EU. 
There are a number of different companies/
organisations involved in cattle breeding, such as 
large privately owned companies and cooperatives 
operating on an international scale, significant 
national schemes (e.g. in Denmark, France and 
Italy) and numerous smaller organisations, such 
as individual breed societies or AI associations 
(e.g. in Germany several of the AI associations 
have their own breeding programmes).
In the top 12 EU countries for ET (Figure 
2-12) about 94 000 embryos were transferred in 
2004. The three most active countries, France, 
the Netherlands and Germany, account for about 
60% of all embryos transferred. From survey data, 
the value of ET trans-fer activities in the EU has 
been estimated at EUR 190 million244.
 Figure 2‑12 Total transfers of cattle embryos, 
by top EU countries
Given the pyramid struc-ture of cattle 
production and the estimate that 75% of bulls 
used for breeding, i.e. AI, are de-rived from 
ET, we can take it that the use of ET indirectly 
supports 75% of the total turnover of cattle farm-
gate output, which produces a figure of EUR 55.2 
billion, representing 4.6% of agro-food sector 
turnover.
Environmental implications of embryo transfer in 
livestock
As ET is not directly involved in altering 
breeding value but only in the propagation 
(and therefore faster dissemination) of desired 
genotypes, the main environmental impact is 
through assisting the rapid and cost-effective 
dissemination of improved resource productivity 
based on genetic improvements. For example, 
243 Villanueva, B, G. Simm and J.A Wooliams (1995). Animal Science 61: 231-239.
244 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
245 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
 Source: ETEPS245.
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the number of cattle in the EU is declining whilst 
output is steady or increasing. This is particularly 
obvious for milk production, which has been the 
focus of selection for the last fifty years. In the EU-
15, cattle numbers decreased from 1994 to 2001 
(with the exception of Sweden) by approximately 
11%. In the same period the average milk yield 
per head increased by 17%246.
Social implications of embryo transfer in 
livestock247
One technique used in ET, ovum pick-up 
(OPU), is an invasive method and therefore may 
have negative implications for the welfare of 
individual animals that need to be balanced by 
the benefits obtained from the technology. Kolar 
and Rusche reviewed the acceptance of these 
technologies (by animal welfare organisations)248. 
Two organisations (of the six surveyed) did not 
accept ET or in vitro production (IVP) (however, 
only two of the organisations generally accepted 
AI). These results suggest that there are consumer 
concerns (raised by welfare groups) about the 
impact of these procedures on animal welfare. 
Public perception of reproduction techniques 
was also considered for France and the UK in 
the SEFABAR project249. It was found that AI was 
unanimously accepted in these two countries, with 
the author interpreting this to be a consequence 
of both its usefulness amongst humans and its 
length of service. In both countries, IVF and ET 
were represented as displaying some of the same 
features but some of the participants viewed 
them negatively in terms of animal production. 
Education, labelling and minimum standards 
were suggested as means of addressing concerns.
On the other hand, ET is considered a very 
safe method of disseminating genetics in terms of 
infectious disease (under regulations laid down 
by IETS250 and OIE251). Thus, internationally it 
is thought of by some as contributing to animal 
welfare in terms of animal health.
Summary of modern biotechnology applied to 
livestock breeding and propagation
Molecular marker-based technologies and ET 
are the main modern biotechnology techniques 
applied to livestock breeding and propagation, and 
together they directly account for EUR 397-600 
million of the turnover of the breeding sector252. 
While it is clear that the application of molecular 
markers and ET are not the only factors in the 
success of breeding efforts, but rather supplement 
breeding efforts based on conventional 
quantitative genetics, their application and 
diffusion seems to be significant. Given the use 
of modern biotechnology-derived animals further 
down the chain, all the way to the farm gate, it 
is estimated that modern biotechnology indirectly 
affects 58-72% of animal production, which in 
turnover terms represents EUR 73.4-91.4 billion 
of the EU annual animal output, or 6.1%-7.6% of 
EU agro-food sector turnover.
In general, modern biotechnologies such 
as molecular marker technologies and ET lead 
to improvements in the eco-efficiency of the 
primary sector, which, in combination with 
the comparatively stable economic activity 
of EU livestock production in recent years, 
should result in a relative decrease in livestock-
related environmental pressure. However, 
246 Table 4.1 in: Liinamo, A.-E. and A.vM. Neeteson-van Nieuwenhoven (2003). Economic value of livestock production in the EU 
– 2003. Farm Animal Industrial Platform, Oosterbeek. 
247 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
248 Kolar, R. and B. Rusche (2003). “Animal welfare aspects of farm animal breeding and reproduction: chances for a sustainable 
future?” In: Liinamo, A.E. and A.M. Neeteson-van Nieuwenhoven (eds). Sustainable farm animal breeding and reproduction. 
Final Workshop Proceedings. SEFABAR, Oosterbeek, pp. 17-35.
249 Ouédraogo, A.P. (2003). “Symbolic goods in the market place: public perceptions of farm animal breeding and reproduction 
in France and UK” In: Liinamo, A.E. and A.M. Neeteson-van Nieuwenhoven (eds). Sustainable farm animal breeding and 
reproduction. Final Workshop Proceedings. SEFABAR, Oosterbeek, p36-46.
250 IETS: International Embryo Transfer Society.
251 OIE: World Organisation for Animal Health. 
252 Including turnover from embryo transfer activities and from molecular marker-related breeding activities.
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animals are sentient beings, and there are also 
potential risks in terms of animal health and 
welfare that need to be carefully accounted for 
in selection programmes in general and the use 
of biotechnologies in particular, along with the 
focus on enhanced productivity.
2.2.1.3 Breeding of fish
The main modern biotechnologies currently 
used in aquaculture are polyploidy induction 
and sex reversal. The use of molecular markers 
to optimise breeding strategies is increasing. 
Molecular markers in fisheries management 
(harvest fisheries) is still at a rather experimental/
pilot phase. Harvest fisheries and aquaculture are 
of less economic significance than agriculture. 
However, regionally they can be very important.
Economic significance of modern biotechnology 
in breeding fish
In 2004, the EU aquaculture sector 
produced a total of 1.4 million tonnes of fishery 
products with a value of some EUR 2.8 billion. 
Production has been relatively stable since 1999, 
after a considerable increase between 1993 and 
1999 (46%). The EU accounts for about 2.5% 
of worldwide production by volume and 4.6% 
by value, being the world production leader for 
some species such as trout and mussels. Within 
EU fisheries production, aquaculture represents 
19% by volume, but 30% by value. Spain (26%), 
France (18%) and the UK (15%) are the largest 
producers in the EU. The largest world producers 
are Asian countries, with China producing nearly 
30 times as much as the EU253.
In the EU, Atlantic salmon, rainbow trout, and 
oysters are among the five major species farmed. 
A survey of salmon, trout and oyster breeders and 
experts provided an indication of the adoption 
of modern biotechnologies in aquaculture254. It 
stated that molecular markers have been mainly 
used in salmon and trout breeding for parentage 
assignment supporting breeding efforts (e.g. via 
microsatellites) and accounted for 30% of the 
revenues of salmon and trout breeders (EUR 10 
and 11 million, respectively), and 10% (EUR 2 
million) for oyster breeders255. Sex reversal and 
ploidy induction techniques have mainly been 
applied to trout and oyster breeding, accounting 
for about 50% (EUR 18 million) and 20% (EUR 
4 million) of total turnover, respectively. Applying 
these adoption rates to farm-level production 
provides an indication of the indirect relevance 
of modern biotechnologies. It was estimated 
that approximately 15% of EU-wide fish farming 
turnover was produced through the use of seed fish 
produced with the aid of modern biotechnologies 
(EUR 432 million), representing 0.04% of overall 
agro-food turnover.
Overall, available information indicates 
that modern biotechnologies are important 
for particular sectors, namely sex-reversal and 
ploidy induction in trout and oyster production 
and molecular markers in assisting genetic 
selection (almost exclusively through pedigree 
identification and related technologies and not 
through markers for specific traits) for salmon and 
trout, as a relatively large share of seed fish are 
produced using these technologies. Expert opinion 
indicates that sex and ploidy–related technologies 
may have reached the limits of potential benefit 
where applied (i.e. trout and oysters) and that, 
therefore, adoption is not likely to increase in 
the future. Nevertheless, these techniques have 
not been adopted to the same extent by all EU 
Member States, and thus EU-wide adoption can 
be expected to increase in the future. The highest 
increase in adoption is, however, expected for 
the use of molecular markers in breeding of all 
relevant species. Overall, an increase in the use 
253 European Commission (2006) Fact and figures on the CFP; European Commission (2006), Statistics in focus 23/2006 
Aquaculture.
254 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
255 Referring to shares and absolute values of the companies that responded to the survey and not the whole sector.
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and importance of modern biotechnologies in fish 
farming can be expected. Currently, however, the 
economic significance of breeding activities and 
aquaculture production is marginal in relation to 
the agro-food sector as a whole.
Regarding employment, the survey indicates 
that about 5% of employees in breeding 
companies/hatcheries have biotechnology-related 
jobs. However, no employment statistics are 
available for this sector. For fish farming, based 
on modern biotechnology adoption rates, it is 
estimated that about 10 000 jobs (out of 65 000) 
are related to modern biotechnology products.
Environmental implications of modern 
biotechnology in fish breeding and propagation
The environmental implications of the use 
of molecular markers in fish breeding have not 
been recorded. Nevertheless, the basic principles 
behind the potential environmental relevance of 
this technology are the same in all applications 
(fish, plants, and livestock). In relative terms, 
the expected improvements may be larger as 
fish breeding is more recent compared to plant 
and livestock breeding and therefore the genetic 
improvements to be made are larger; in absolute 
terms, however, the impacts are likely to be 
smaller, as the technology is used to a smaller 
extent in fish farming than in plants and livestock, 
and as the overall aquaculture output is much 
smaller. As far as ploidy and sex manipulation 
are concerned, the producers’ survey256 revealed 
benefits associated with the adoption of the 
technology, related to improved production 
efficiency, and reduced need for chemical 
treatment following secondary infections due to 
aggressiveness and stress.
Social implications of modern biotechnology in 
the breeding and propagation of fish
As far as ploidy induction and sex reversal 
in fish are concerned, both favourable and 
unfavourable views on their impacts on animal 
welfare have been expressed257. All-female trout 
production has been associated with a general 
increase in animal welfare as it is claimed to 
help alleviate up to 50% of secondary infections 
caused by early maturation, and its associated 
characteristics, such as reducing the need for 
chemotherapeutics. The induction of triploidy has 
been associated with increased deformity and 
susceptibility to disease (low stress tolerance) but 
also with the beneficial avoidance of maturity-
related stressors.
2.2.2	 Modern	 biotechnology	 in	 feed	 and	 food	
production,	animal	health	and	agro-food	
diagnostics
2.2.2.1 Modern biotechnology in feed and food 
production
Economic significance of modern biotechnology 
in feed additives
Feed additives have been gaining in 
importance as the consumption of animal 
products is increasing globally. The role of feed 
additives is mainly to complement the nutritional 
profile258 of feeds in several ways. Feed enzymes 
mainly function as digestibility enhancers, 
whereas vitamins, amino acids and minerals 
directly complement the nutritional profile of 
feeds. Modern biotechnology has been applied 
in the production of a large number of feed 
additives, mainly feed enzymes (e.g. phytases), 
amino acids (e.g. lysine) and vitamins (e.g. 
riboflavin). The European Feed Manufacturers 
256 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
257 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
258 Feed additives also target physical performance, but this is not relevant for biotechnology-based feed additives. 
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Federation (FEFAC) estimates that approximately 
3% of feed material consumption comprises feed 
additives (out of the approximately 143 million 
tonnes of EU feed production in 2005)259, while it 
has been estimated that 65% of poultry and 10% 
of swine feed already contain enzymes such as 
carbohydrases or phytase260. Moreover, the EU 
and the USA are currently the global leaders in 
compound feed production, at 143 million tonnes 
(24% share) and 150 million tonnes (25% share), 
respectively, while the annual turnover of the EU 
compound feed industry in 2004 was estimated 
at approximately EUR 36 billion.
Feed enzymes are developed to function as 
digestibility enhancers for a variety of nutrients, 
such as phytases for plant phytate degradation 
and release of phosphorus content, carbohydrases 
for carbohydrate degradation, etc. The production 
of enzymes is described in greater detail in 
Chapter 2.3.1.1. The use of enzymes in feed may 
result in a variety of changes, mainly related to 
feed formulation and ingredient composition 
as well as to nutrient utilisation at the animal 
production stage. Feed formulation has been 
traditionally driven by least-cost objectives, but 
lately environmental and food quality aspects 
have been gaining importance. For example, 
the use of phytase may allow a higher share 
of plant ingredients or different types of plant 
ingredients in feed for monogastric animals (such 
as pigs, poultry and some fish) and a reduction 
in the use of inorganic mineral supplements. 
The use of enzymes affects the whole chain 
from feed ingredient producers, through the feed 
manufacturer, to the animal producer.
Phytate is an organic molecule containing 
high levels of phosphorus, which is a natural 
constituent of many plant ingredients 
used in animal feeds. 50%-80% of the 
total phosphorus in pig and poultry diets 
is bound in the largely unavailable form 
of phytate, as monogastric animals lack 
sufficient quantities of the enzyme phytase 
that naturally catalyses the degradation. 
Modern biotechnology has enabled the 
cost-effective production and use of phytase 
products for animal production, through the 
use of recombinant DNA techniques with 
selected microbial strains. The use of phytase 
in animal feeds leads to better phosphorus 
utilisation, and also improves the utilisation 
of protein and other minerals261. Besides the 
benefits in terms of animal performance, 
phytase addition also has important 
environmental implications, as it can 
reduce phosphorus emissions by animal 
facilities. Moreover, emerging modern 
biotechnology applications offer novel 
solutions here: new plant varieties of low 
phytate content have been developed using 
chemical mutagenesis techniques262,263, 
GM plant varieties expressing phytase 
have been developed264,265, and a GM pig 
(EnviropigTM266,267) developed by researchers 
in Canada expresses phytase that is secreted 
in the saliva, all of which provide promising 
alternatives for tackling the same problem.
259 http://www.fefac.org/statistics.
260 van Beilen, J.B. and Z. Li (2002). Current Opinion in Biotechnology 13: 338-344. 
261 Kornegay, E.T. (2001). Digestion of phosphorus and other nutrients. In: Bedford, M.R. and G.G. Partridge (eds). Enzymes in farm 
animal nutrition. CABI Publishing, Marlborough, pp. 237-271.
262 Raboy, V. et al. (2000). Plant Physiol. 124: 355-368.
263 Sands, J.S. et al. (2001). J. Anim. Sci. 79: 2134-2142.
264 Zhang, Z.B. et al. (2000). Journal of Animal Science 78(11): 2868-2878.
265 Koegel, R.G. et al. (1999). Alfalfa produced phytase for supplementation of poultry and swine rations. ASAE Paper 996127 (St. 
Joseph, M.I.).
266 Golovan, S.P. et al. (2001). Nat. Biotechnol 19: 741-745.
267 http://www.uoguelph.ca/enviropig/.
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Amino acids and vitamins are supplements 
that provide essential nutrients lacking in the 
macro ingredients used in feed. An illustrative 
example is the case of the amino acid lysine268 
(see also Chapter 2.3.1.6): modern biotechnology 
has facilitated the industrial-scale production 
of lysine, which is used in a large proportion of 
prepared animal feeds, mainly for monogastric 
animals (pigs, poultry and carnivorous farmed 
fish). This means for example that soy-derived 
ingredients can be partly substituted by wheat 
and corn-derived ingredients (which have a lower 
lysine content compared to soy) in pig feed, and 
fishmeal can be partly replaced with wheat and 
corn-derived ingredients for carnivorous farmed 
fish. This substitution may also have impacts 
on the EU crop-growing sector and trade flows, 
as soybean meal is largely imported by the 
EU269. Another example is the biotechnological 
production of the vitamin riboflavin: 70% 
of global production is used for animal feed 
(see also Chapter 2.3.1.6). The production of 
riboflavin using modern biotechnology has 
apparently resulted in cost reductions of 40%-
50% compared to the conventional chemical 
production process270, thus potentially facilitating 
its use as a feed additive.
In general, modern biotechnology enables 
the production of feed additives at lower costs, 
making their use by the feed industry (and livestock 
producers) more attractive. However, the share of 
feed containing modern biotechnology-derived 
amino acids and vitamins in their formulation is 
not known. The worldwide feed additives market 
is estimated at about EUR 4.8 billion271, including 
amino acids, vitamins, minerals, antibiotics, 
enzymes and acidifiers. Modern biotechnology 
plays a major role in the production of additives, 
whereby amino acids, all of which are produced 
using modern biotechnology, represent about 
36% of the feed additives market. Several vitamins 
and organic acids used in animal feed are also 
produced using modern biotechnology (see also 
Table 2.6). No data were available regarding the 
EU market for feed additives, but based on the 
data for lysine production, the EU share of feed 
additive production is estimated at about 20% or 
EUR 960 million. Of this, nearly 90% is estimated 
to be modern biotechnology-derived (EUR 860 
million), representing 0.067% of the turnover of 
the agro-food sector.
Environmental implications of modern 
biotechnology in feed additives
Feed additives (whether biotechnology-based 
or not) in general optimise nutrient utilisation, 
thereby improving the environmental performance 
of animal production. Some feed additives have a 
direct environmental impact, such as most of the 
feed enzymes. Phytase addition, for example, has 
been reported to significantly reduce phosphorus 
emissions in pig and poultry production. On the 
other hand, many feed additives result in indirect 
environmental benefits by optimising nutrient 
metabolism and utilisation, such as in the case 
of lysine, which may reduce nitrogen excretion 
in pig production272. Moreover, as the addition 
of lysine to pig feeds is accompanied by the 
replacement of soybean by wheat or maize, and 
as the area needed to grow soybeans is larger 
than the corresponding area for maize or wheat, 
the use of lysine may also considerably reduce 
the agricultural area needed per unit output273. 
In general, as low protein and low phosphorus 
diets are increasingly used in animal production, 
268 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
269 http://www.fefac.org/statistics.
270 EuropaBio (2003). White biotechnology: gateway to a more sustainable future. EuropaBio, Brussels. 
271 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
272 Gâtel F. and E. Porcheron (2003). “The role of cereals in the European protein supply.” In: FEFANA workshop proceedings, 
Protein supply for European pigs 2010, Brussels, 18 March, p. 23-27.
273 Toride, Y. (2002). “Lysine and other amino acids for feed: production and contribution to protein  utilization in animal feeding.” 
In: Protein sources for the animal feed industry: FAO Expert Consultation and Workshop, 29 April - 3 May, Bangkok. Food and 
Agriculture Organization, Rome, p. 161-166. 
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partially due to stricter environmental regulations, 
the importance of these two feed additives can 
also be expected to increase.
Economic significance of modern biotechnology 
in food processing
The use of enzymes in food processing is 
described in detail in Chapter 2.3.1. The direct 
economic significance mainly relates to the 
turnover realised by the enzyme producers relevant 
to food applications (EUR 390-585 million); the 
production of modern biotechnology-based food 
additives would add more to this estimate. The use 
of enzymes by the food and beverage processing 
sector provides an estimate of the indirect 
economic contributions (EUR 304 billion).
2.2.2.2 Modern biotechnology in animal health
Economic significance of modern biotechnology 
in animal health
The veterinary pharmaceutical market 
represents only a small share of the global 
pharmaceutical market274, accounting for about 
3% (EUR 13 billion). The market is further 
divided into products for companion animals and 
products for farm animals. The latter segment is 
mainly influenced by cost considerations and an 
emphasis on prevention rather than treatment of 
diseases. Products for farm animals account for 
about 60% of the sales of animal health products 
(including vaccines). Major product groups are 
vaccines and immunostimulants, antibiotics and 
anti-parasitics275. Modern biotechnology is used 
in the development and production of vaccines 
and antibiotics.
Antibiotics, partly produced using modern 
biotechnology, accounted for about 28% of the 
veterinary pharmaceutical market in 2004276. 
Their use for prophylactic, therapeutic and 
growth promotion reasons has been reduced due 
to food safety concerns and the development 
of bacterial resistance to antibiotics. The use of 
antibiotics in feed as growth promoters (apart 
from coccidiostats277) is banned in the EU278.
Bovine somatotropin (bST) is a hormone 
naturally produced by dairy cows which 
regulates milk production. A recombinant 
bST product (rbST) was commercialised by 
Monsanto in the USA in 1994, under the 
name POSILAC, as a treatment to enhance 
milk production. The use of rbST has been 
controversial, and while it has been approved 
in a number of countries, it was banned in 
the EU, as well as Canada, Australia, New 
Zealand and Japan, on the grounds of harm 
to animal health and welfare. While the EU 
has not approved the commercialisation of 
the product within its borders, it allows the 
import of dairy products derived from cows 
treated with rbST. The adoption of rbST by 
the US dairy cattle sector has been estimated 
at an average of 30% of the national dairy 
cow population, but with considerable 
variation (15-45%) depending on the 
region and the herd size279. Most ex-post 
economic assessments of rbST adoption in 
the USA have reported significant increases 
in milk output and numerically positive 
but non-statistically significant increases 
in profitability, mainly due to the large 
variability among farms. The numerical 
increase in profitability for adopters has been 
estimated at around US$100 (EUR 78) per 
274 ETEPS (2006). Bio4EU Task 2 Main report.
275 Based on the 64 veterinary products approved by the European Medicines Agency (EMEA) 1995-2006 (biotechnology derived 
products, performance enhancers and vaccines for EU-wide prophylactic programmes).
276 ETEPS (2006). Bio4EU Task 2 Main report.
277 Coccidiostats prevent and treat coccidiosis in poultry, a disease caused by protozoa and resulting in damage to the intestines of 
the infected animal. Infections can spread rapidly and often are fatal.
278 Regulation (EC) 1831/2003 of the European Parliament and of the Council on additives for use in animal nutrition. OJ L 268/29, 
18.10.2003.
279 Barham, B.L., J.D. Foltz, S. Moon and D. Jackson-Smith (2004). Review of Agricultural Economics 26: 32-44. 
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year per cow. A recent study has also reported 
a significant decrease in the production cost 
of milk following rbST adoption, with an 
estimated cost saving of US$46-104 (EUR 
36-81) per cow280.
Modern biotechnology is mainly applied in 
vaccine development and production. Vaccines 
represent about 20% of the global veterinary 
pharmaceutical market. About 50% of the 
products approved by the European Medicines 
Agency (EMEA) between 1995 and 2006 belonged 
to this group. Of these, about 75% were modern 
biotechnology-derived, mainly using genetic 
engineering (see also Chapter 2.1.2 on vaccines 
for human health). The global turnover on animal 
vaccines has been estimated at EUR 2.6 billion281. 
The EU share is assumed to be 50% (based on 
Table 2.5), or EUR 1260 million. About 75% are 
modern biotechnology-based, corresponding 
to EUR 920 million (0.016%-0.12% of turnover 
in the agro-food sector). The vaccine market for 
farm animals is highly dependent on official 
vaccination programmes and disease status in the 
individual EU Member States. Once eradication 
has been achieved, the vaccine is prohibited for 
further use.
The above turnover estimate for vaccines 
is a conservative estimation, since several 
major veterinary pharmaceutical companies are 
EU companies. Of the top sixteen veterinary 
pharmaceutical companies, eight are located 
in the EU (5 in France, 2 in Germany and 1 in 
the Netherlands). Three specialise in veterinary 
products, while the others are pharmaceutical 
companies that produce veterinary products 
alongside other health products (Table 2.5). The 
280 Tauer, L.W. (2006). AgBioForum 9: 79-83.
281 ETEPS (2006). Bio4EU Task 2 Main report.
282 ETEPS (2006). Bio4EU Task 2 Main report.
Table 2.5 Major veterinary pharmaceutical producers (source ETEPS282)
*Additional companies for which turnover or employment information was not available are:BASF (Germany), Dainippon/Sumitomo 
(Japan), Degussa (Germany), and DSM (Netherlands).
Company* Country
Turnover in veterinary 
products
(2005, e million)
Employees
Pfizer Animal Health USA 1600
Merial France 1500 5000
Intervet Netherlands 1094 4800
Bayer Germany 700
Fort Dodge USA 693
Elanco USA 680
Schering Plough AH USA 672
Novartis Switzerland 622 2300
Adisseo France 512 1200
Idexx USA 500 3000
Virbac France 372 2230
Boehringer Ingelheim Germany 361
CEVA France 271 1732
Alpharma USA 248
Phibro Animal Health USA 220 992
Vetoquinol France 196.6 1140
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share of modern biotechnology-based activities 
could not be determined for these companies. 
However, as with human pharmaceutical 
products, it can be assumed that most use 
modern biotechnology in product development 
and production.
Diagnostics using modern biotechnology are 
mainly applied for the detection and monitoring 
of notifiable diseases in the context of animal 
health. These applications will be described in 
the following chapter dealing with diagnostics in 
the food chain in general.
Social implications of modern biotechnology in 
animal health
Prevention of disease in farm animals plays 
an important role both in economic terms and 
as regards animal welfare and public health 
(zoonoses) issues. Vaccination is one approach to 
disease prevention and has proven to be effective 
in the eradication of diseases in the EU Member 
States. Vaccination potentially decreases animal 
suffering from diseases and avoids the need for 
pharmaceutical treatment. Modern biotechnology 
is increasingly used to develop vaccines, in 
particular ‘marker’ vaccines, which allow a 
distinction to be made between vaccinated and 
infected animals. This in turn allows disease 
monitoring and targeted animal culling before 
symptoms appear, limiting the spreading of the 
disease. The vaccine against pseudorabies or 
Aujeszky’s disease is one example283, and was 
also the first GMO authorised in the EU.
Aujeszky’s disease, also called pseudorabies, 
is a notifiable disease primarily affecting 
pigs, a major livestock in the EU. It is 
caused by a virus and results in nervous 
disorders in affected animals, increased 
mortality of piglets and reduced fertility. 
The disease had not existed widely outside 
Eastern Europe before the 1960s, but 
by 1989 it had a worldwide distribution 
affecting 43 countries284. Prior to vaccine 
development and administration, the only 
options were either to allow the disease to 
remain endemic in the population or to try 
and control it through animal culling. This 
resulted in substantial animal and economic 
losses, as Aujeszky’s disease is one of 
the most dangerous diseases in domestic 
pigs285. Currently, there are 10 EU Member 
States where the disease is still endemic, 
while 10 of the 13 EU Member States for 
which relevant information was available 
are disease-free with or without continuing 
vaccination and 3 are currently vaccinating 
the endemically affected population286.
The biotechnology vaccine against 
pseudorabies was developed at the beginning of 
the 1980s with two main objectives: to develop 
a live vaccine (known to be more effective than 
inactivated viruses) and to develop a vaccine 
to allow a distinction to be made between 
vaccinated and infected animals, thus facilitating 
the eradication of the disease. Genetic engineering 
was used to produce a modified virus, approved 
in 1989, which is not infectious and allows, 
due to the deletion of a specific surface protein, 
vaccinated pigs to be distinguished serologically 
from pigs infected with the natural virus. The 
vaccine (the only type authorised in the EU) 
provided the basis for the EU programme for the 
eradication of pseudorabies disease.
283 See ETEPS (2006) for more information. (ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food 
Applications.) 
284 http://www.defra.gov.uk/animalh/diseases/notifiable/aujeszkys/.
285 Müller, T., et al. (2003). Journal of Veterinary Medicine B 50: 207-213.
286 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications.
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Environmental implications of modern 
biotechnology in animal health
The environmental impacts of modern 
biotechnologies applied in the production of 
animal health products are in general positive: 
firstly, there is a general trend towards increasing 
prevention (vaccination and other immuno-
stimulation/disease-resistance methods based on 
pre- and pro-biotics, all of which are increasingly 
biotechnology-based), which leads to a decrease 
in the use of less desirable chemical treatments 
(e.g. antibiotics). The prevention of disease and 
subsequent disease eradication inherently bring 
about improvements in production efficiency 
associated with a healthy stock. Moreover, a 
decrease in the use of antibiotics will diminish 
the negative impacts of microbial resistance 
to antibiotics, while marker vaccines make 
eradication programmes more effective, therefore 
reducing the number of animals that need to be 
culled.
2.2.2.3 Modern biotechnology in diagnostics in  
 the food chain
Economic significance of modern biotechnology 
in diagnostics in the food chain
Diagnostics are applied throughout the 
food chain: in livestock production for animal 
health purposes (e.g. foot-and-mouth disease 
detection), in food safety and public health 
(e.g. salmonella testing or bovine spongiform 
encephalopathy (BSE) detection), and for 
traceability purposes (e.g. GM food and feed 
detection and quantification, end product and 
origin identification). Modern biotechnology 
is mainly used for DNA-based diagnostic tests 
and immunoassays (see also Chapter 2.1.4 on 
diagnostics in human health). Diagnostics are far 
less used for veterinary purposes in comparison 
to human medicine. This is also reflected in the 
comparatively marginal turnover on veterinary 
diagnostics, estimated at about EUR 400 million 
in 2003287, compared to EUR 22 billion for the 
overall in-vitro diagnostics (IVD) market. Half of 
the largest veterinary pharmaceutical companies 
are located in the EU, so the EU share is assumed, 
due to the lack of statistical data, to be 50%, or 
EUR 200 million. Additionally, diagnostics for 
food safety and traceability purposes are valued 
at EUR 500 million288, 20% (EUR 87 million) of 
the total for rapid, biotechnology-based methods. 
The economic value of modern biotechnology 
diagnostics can be roughly estimated at EUR 
300 million, which represents 0.03% of turnover 
in the EU’s agro-food sector. Laboratory-related 
turnover in modern biotechnology diagnostics 
for food safety and veterinary health may be 
conservatively estimated at EUR 1.5 billion289, 
accounting for 0.23% of agro-food turnover in 
the EU.
Farm animal disease outbreaks can have 
serious economic consequences, so fast and 
accurate diagnosis is an important tool in their 
prevention and/or monitoring. In the case of 
bovine spongiform encephalopathy (BSE), the 
UK lost beef export markets, sales of beef went 
down by 40% and the price of beef fell by 25%, 
resulting in an economic loss for the UK of about 
0.1%-0.2% of GDP290 in the year following the 
outbreak. Losses of the same order of magnitude 
were calculated for the more recent outbreak of 
foot-and-mouth disease in the UK.
287 ETEPS (2006). Bio4EU Task 2 Main report. 
288 No data are available at sector level, so a best estimate was taken from the data provided by: Blankenfeld-Enkvist, G., and M. 
Brännback (2002). Technological trends and needs in food diagnostics. Technology Review 132/2002, National Technology 
Agency, Helsinki. The report covers the food chain from raw material to end products (turnover of EUR 491 million). 
Furthermore, GMO diagnostics were included (estimated at EUR 3 million for 1999 with predicted annual growth rates of 
100%; a more conservative estimate was taken).
289 DNA-based tests and immunoassays for GMO detection cost EUR 6-150 per test while laboratory analysis costs €100-570). For 
BSE testing (immunoassay), laboratory analysis was estimated at EUR 40-50. (ETEPS (2006). Bio4EU Task 2 Case studies report 
– Primary Production and Agro-food Applications).  A fivefold greater laboratory turnover is thus a conservative estimate. 
290 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
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Modern biotechnology-related diagnostics 
are generally faster than conventional methods 
and at least as accurate, and may be the only 
option in some cases (e.g. for BSE monitoring or 
GMO traceability). Overall turnover on modern 
biotechnology kits (test kit sales) is about EUR 
300 million. The indirect use of these test kits by 
laboratories generates an estimated additional 
turnover of EUR 1.5 billion, contributing only 
marginally to agro-food sector turnover (0.15%).
Social implications of modern biotechnology in 
diagnostics291
Diagnostics are essential for assuring the 
functioning of the food chain through early and 
quick identification of pathogens, thus avoiding 
animal suffering from diseases and ensuring 
food safety as well as enabling compliance with 
regulatory obligations and consumer choice, 
e.g. in the case of GMO traceability. Contagious 
diseases such as foot-and-mouth disease (FMD) are 
of minor danger to humans but, if not controlled, 
spread rapidly and involve the suffering of many 
animals, apart from significant economic losses. 
In a recent outbreak in the EU in 2001 (mainly 
in the UK, but also in Ireland, France and the 
Netherlands), about 4 million animals were 
culled. Rapid and specific diagnostic tests could 
facilitate detection and control of the disease.
In the case of BSE, modern biotechnology 
provides the only method for the rapid processing 
of samples and diagnosis, thus enabling the level 
of surveillance required by EU legislation292. 
Thirteen different immunoassays have been 
approved by the EU for BSE testing of slaughtered 
animals before they enter the food chain, 
reducing the risk of contamination and increasing 
consumer trust in beef. However, food safety and 
consumer confidence come at a price. Between 
2001 and 2004, around 44.7 million cattle were 
tested at a cost of EUR 1835 million. About 
EUR 1.56 million were spent for every BSE case 
identified in healthy animals, and EUR 70 000 for 
every BSE case in at-risk animals.
Bovine spongiform encephalopathy (BSE) 
is a zoonotic disease affecting cattle, first 
confirmed in the UK in 1985. BSE is a 
neurological disease the symptoms of which 
may last several weeks, are progressive and 
fatal. The disease belongs to the family of 
Transmissible Spongiform Encephalopathies 
(TSEs), which also appear in other mammals, 
including humans. Most recorded BSE 
cases have occurred in the UK, peaking at 
37 301 in 1992 and falling to 561 in 2005 
(EU-wide data)293. The risk of nvCJD (new-
variant Creutzfeldt-Jakob Disease) from 
the consumption of BSE-infected meat was 
identified in 1996, and so far approximately 
162 cases of nvCJD have been found in the 
UK and 36 in the rest of the world (of which 
30 in the EU). The impact of the disease 
is multifaceted and, besides human and 
animal losses, has also brought with it a loss 
of consumer confidence, trade implications, 
and the large and long-term costs associated 
with control measures, the drop in the value 
of beef animals, the safe disposal of waste 
material, animal testing and extra procedures 
in the slaughtering industry. The cost of the 
epidemic to the EU has been calculated 
at 10% of the annual value of the EU beef 
sector, while the discounted present value 
has been estimated at EUR 92 billion294.
A new generation of modern-biotechnology 
diagnostic methods could also enable faster 
291 For details on the case studies see: ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food 
Applications.
292 Regulation (EC) No 999/2001 of the European Parliament and of the Council laying down rules for the prevention, control and 
eradication of certain transmissible spongiform encephalopathies. OJ L147/1, 31.5.2001. 
293 Report on the monitoring and testing of ruminants for the presence of Transmissible Spongiform Encephalopathy (TSE) in the 
EU in 2005. European Commission, DG Health and Consumer Protection, 2006.
294 Cunningham, E.P. (ed.) (2003). After BSE: a future for the European livestock sector. EAAP Series no. 108, Wageningen Academic 
Publishers, Wageningen. 
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detection of the food pathogen salmonella. 
Salmonella causes food poisoning and is the 
second most prevalent pathogen in food and 
the most frequent cause of food-borne bacterial 
gastroenteritis in the EU. In 2004, an average 42.2 
cases per 100 000 inhabitants were registered 
in the EU. Early and quick identification of 
contaminated raw material and food could help 
avoid or control such cases.
Modern biotechnology also enables the 
identification and quantification of genetically 
modified (GM) ingredients in raw material and 
food. It thus facilitates compliance with EU 
regulation regarding traceability and the labelling 
of food295 and also increases transparency and 
consumer choice regarding GM food.
Environmental implications of modern 
biotechnology in diagnostics
In environmental terms, the adoption 
of modern biotechnology-based diagnostics 
brings about improvements (efficiency and/or 
accuracy) in avoiding potential environmental 
contamination (e.g. Salmonella) and/or animal 
culling in the case of outbreaks (e.g. BSE, 
FMD). Moreover, modern biotechnology-based 
diagnostics for tracing GMOs in the food chain 
also permit the long-term monitoring of GMOs 
in the environment, which is crucial for the post-
marketing environmental monitoring and general 
surveillance that supplement the environmental 
risk assessments of GMOs under current EU 
legislation.
2.2.3	 Emerging	 biotechnology	 applications	 in	
primary	production	and	agro-food
Emerging applications in plants
The production of plants as raw material for non-
food purposes
An emerging issue in agriculture and forestry 
is the increasing emphasis on the development 
and use of plants for non-food purposes, mainly 
for industrial applications, such as the production 
of energy, biofuels and other bio-based materials 
(such as bio-polymers, plant oils, etc.)296. These 
developments are relevant for the primary sector 
providing the raw material, but also for the 
industrial sector involved in processing it into 
the various final product forms, and may also 
have consequences for the agro-food sector in 
that resources (such as arable land or even the 
final raw material produced) may need to be 
shared among different users. The potential of 
bio-based resources to provide alternative raw 
materials has been recognised in the EU and 
globally297. Modern biotechnology plays a dual 
role in this context: i) industrial biotechnologies 
are important for transforming the raw material 
into the final product (e.g. in bio-refineries), 
and ii) modern biotechnologies applied in plant 
breeding are important for the development 
of plants optimised for industrial purposes. 
In the latter case, modern biotechnologies 
such as molecular markers and/or GM-based 
technologies are already being explored for the 
development of plants with traits optimised 
for industrial applications. Examples include 
a higher yield from plants suitable as feedstock 
295 Regulation (EC) No 1829/2003 of the European Parliament and of the Council on genetically modified food and feed, OJ L 
268/1, 18.10.2003; Regulation (EC) No 1830/2003 of the European Parliament and of the Council concerning the traceability 
and labelling of genetically modified organisms and the traceability of food and feed products produced from genetically 
modified organisms and amending Directive 2001/18/EC. OJ L268/24, 18.10.2003.
296 For example, see http://www.epobio.net/overview.htm, http://www.biofuelstp.eu/overview.html or http://www.epsoweb.org/
Catalog/TP/index.htm.
297 For example, see http://ec.europa.eu/research/biotechnology/ec-us/docs/ec-us_tfws_2004_april_albany_proceedings.pdf.
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in industrial applications, plants with optimal 
composition, plants with novel traits, etc.298. In 
general, modern biotechnology is considered 
a critical factor for the future development of 
plant production for industrial purposes299, with 
considerable economic (knowledge-based bio-
economy), environmental (especially in terms of 
energy saving and GHG emissions) and social 
(e.g. in terms of energy security or alternative 
activities for farmers) implications300.
Genetically modified plants
Currently commercially available genetically 
modified (GM) crops are mainly ‘first-generation’ 
GM plants, i.e. with modified agronomic 
input (production) traits. Emerging GM crops 
(second- and third-generation GM plants) mainly 
involve301:
i) the insertion of more than one trait in a plant 
(stacked traits),
ii) the insertion of novel and/or more complex 
traits, such as output traits (i.e. improved 
quality) and abiotic stress-resistance traits 
(e.g. drought or salt tolerance), and
iii) the production of novel products through 
molecular farming.
Overall, there are a large number of products 
in the pipeline, given that the period from 1991 
to 2006 saw 2121 notifications of deliberate field 
trials302, many of which concern novel traits303. 
Also of particular interest is the production 
of GM plants through metabolic engineering 
(engineering the metabolism of organisms) to 
express complex traits304.
The most recent developments target 
plant molecular farming, i.e. the production 
of pharmaceuticals, functional proteins and 
industrial enzymes in plants. Over the last 
decade, plants have emerged as convenient and 
economic alternative-expression systems, and 
plant molecular farming is expected by some to 
challenge established production technologies 
that currently use bacteria, yeast or cultured 
mammalian cells. To date, over 20 plant-derived 
pharmaceuticals have been submitted for 
clinical trials, including recombinant antibodies, 
human- and animal-edible vaccines (in 2006 
FDA authorised the first plant-derived animal 
vaccine), and other proteins such as gastric lipase 
for the treatment of cystic fibrosis. Additionally, 
six plant-derived technical proteins are already 
available (avidin, trypsin, ß-glucuronidase, 
aprotinin, lactoferrin, and lysozyme). R&D is 
currently dominated by not-for profit research 
organisations. Patent analyses for the years 2000-
2003 have revealed the strong position of the 
USA in the field, with EU organisations holding 
70% fewer patents than the USA305.
The major technological challenge to be 
addressed by researchers is to ensure that the 
298 For example, Syngenta is developing a genetically modified strain of corn that expresses high levels of a Diversa alpha amylase 
enzyme, called internally amylase-T, to increase the cost-effectiveness of ethanol production from corn starch. http://www.
diversa.com/Pages/Products/AlternativeFuels/AltFuelsAmylaseT.html.
299 For example, see http://www.biomatnet.org/publications/us-ec0605strategy.pdf.
300 For example, see http://ec.europa.eu/research/conferences/2005/kbb/.
301 It should be noted, however, that there are no strict borderlines between current and emerging applications, nor among 1st, 2nd 
and 3rd generation GM plants.
302 http://biotech.jrc.it/deliberate/dbcountries.asp.
303 Two products expressing novel traits are in the pipeline for authorisation, namely potato with altered starch composition 
and fodder maize with increased lysine content (http://efsa.europa.eu/science/gmo/gm_ff_applications/catindex_en.html). 
Moreover, several products that combine herbicide resistance with pest resistance or different types of pest resistance (stacked 
traits) have already been authorised. (For example see http://gmoinfo.jrc.it/gmc_browse.asp and http://ec.europa.eu/food/dyna/
gm_register/index_en.cfm).
304 Examples of such products under development include “golden” rice (Paine J.A. et al. (2005). Nature Biotechnol. 23: 482-487), 
which contains two transgenes to produce pro-vitamin A (β-carotene) and which has already undergone the first field trials in 
the USA, or leaf mustard (Brassica juncea), which has been engineered with three to nine structural genes to express high levels 
of ω-3 poly unsaturated fatty acids (PUFAs) (Wu, G. et al. (2005). Nature Biotechnol. 23: 1013-1017). These applications are 
among the first of their kind, with prospects for providing nutritional solutions for both developing and developed countries.
305 Arcand, F. and P.G. Arnison (2005). Development of novel protein-production systems and economic opportunities & regulatory 
challenges for Canada. Discussion paper. http://www.cpmp2005.org/Plant-factories.aspx.
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structure of the engineered protein results in 
a functionality equivalent to that of the native 
form. However, the cost-efficiency of plant 
production is controversial. Other factors that 
add to the uncertainty are limited clinical data, 
public debate on transgenic technology, and the 
uncertainty as to regulatory approval for such 
plant-produced drugs.
Emerging biotechnology applications in animals306
Genetically modified animals
While genetic modification (GM) technology 
has so far mainly been applied to microorganisms 
and plants, GM animals, including fish, have 
been receiving increasing interest in recent years. 
The first GM mammal was produced in 1985 and 
GM pigs, sheep, cattle, goats, rabbits, chickens 
and fish have all been reported. Currently, the 
majority of GM mammals are mice used for R&D 
purposes. In the UK, for example, the number of 
GM animals increased from 50 000 in 1990 to 
900 000 in 2004307.
There are several possible applications of GM 
animals (though so far relatively little commercial 
activity):
Production of novel compounds (mainly 
pharmaceuticals) in the milk, eggs and blood 
of animals (molecular farming): between 
5–10 products produced in GM animals are 
progressing through human clinical trials as 
part of the regulatory procedures required for 
pharmaceutical products. The production of 
proteins in animals has several advantages over 
various other methods that are currently used 
for the industrial production of proteins. ATryn® 
(GTC Biotherapeutics, Inc), a human antithrombin 
product produced in the milk of genetically 
modified goats, became the first product to 
receive market authorisation by the European 
Commission in August 2006.
Food production (including fish): The 
lead product is probably GM fish, including 
faster-growing GM salmon developed in North 
America, which is awaiting regulatory approval 
for use in the food chain. Other applications are 
at the experimental stage, but it seems unlikely 
that any will be in general use before 2010. No 
companies developing GM animals for food were 
identified in the EU.
Production of organs for transplant into 
humans (xenotransplantation): The production of 
GM pigs to supply organs for human transplants 
has been the subject of considerable research. 
However, no examples of xenotransplantation 
products from GM livestock are currently on the 
market or available for treatments. Various degrees 
of optimism are expressed about the prospects for 
xenotransplantation, but most proponents suggest 
that it will be 10 years or more before GM pig 
organ transplants become available.
Production of specific types of pets: GM 
ornamental fish have been available commercially 
in the USA since late 2003. Research is reportedly 
also being conducted to produce GM cats with 
reduced allergenicity for humans. However, 
reduced-allergenicity cats have just recently been 
produced by Allerca (USA) through the use of a 
patented technology based on directed evolution 
and not GM.
The most contentious issues with regard to the 
use of GM animals are welfare and ethical issues. 
As there may be adverse animal welfare effects 
related to GM animal production, GM animal 
welfare may need a case-by-case assessment. 
The extensive ethical discussion has shown that 
there is no universal agreement on the ethical 
considerations. Other issues raised by some in the 
animal welfare and ethical debate as regards both 
cloning and GM include the potential to interfere 
with “animal integrity”, which refers to the 
naturalness, wholesomeness, and independence 
306 The information herein is mainly based on a study developed and coordinated by the JRC/IPTS and carried out through the 
European Science and Technology Observatory (ESTO): “Animal cloning and genetic modification: a prospective study”. 
Publication in preparation. 
307 Home Office, Statistics of Scientific Procedures on Living Animals, Great Britain (1990-2004).
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of animals, and the potential increase in the 
perception of animals as commodities, such as 
research tools or units of production.
Animal cloning308
The first mammalian species cloned using 
somatic cell nuclear transfer (SCNT) was sheep, 
in 1996. Since then several species have been 
cloned, including cattle, goat, pig, horse, cat and 
most recently dog.
Animal cloning may be used in a variety of 
commercial contexts including:
Food production309: Cloned livestock 
(especially pigs and cattle) are currently being 
developed for use in the food chain, the main 
barriers being regulatory approval and public 
acceptance. At least in the beginning, cloned 
animals are likely to be used just for breeding 
purposes, as it will not be economic to use them 
directly for food or milk production. Cloned 
animals for the food sector are being developed 
primarily in the USA, Australia/New Zealand 
and Asia. No company was found in the EU to 
be developing this technology for use in the food 
chain.
Pets and sports animals: Commercial services 
for cloning cats were available in the USA310. 
Similar services exist for various sports animals 
in the USA and there is a company offering a 
commercial service to clone horses in France. 
Dogs have been cloned on an experimental basis 
in South Korea. The total number of cloned pets 
or sports animals worldwide is currently very 
small.
Endangered species: Commercial companies 
offering to clone endangered species exist in 
the USA, Brazil and France. Cloning to preserve 
endangered species offers a chance to regain 
genes lost through the death of an animal but 
will not increase the amount of genetic diversity 
and does not address other issues such as loss of 
habitat. Individuals from some endangered species 
have been cloned, e.g. the mouflon, banteng and 
African wildcat, and cloning technology has been 
used to restore endangered breeds of cattle.
The welfare of cloned animals and the 
ethics of cloning, particularly where the benefits 
perceived by citizens are small, are likely to be 
controversial. Many cloned animals display a 
range of physiological disorders (collectively 
known as Large Offspring Syndrome), which in 
some cases can have a severe impact on welfare. 
Some claim that these welfare problems have 
been overcome, but others remain sceptical.
Nutrigenomics - Nutrigenetics
The basic goal of both nutrigenomics and 
nutrigenetics311 is to match nutrition to individual 
human genotypes (looking at genes and/or other 
biological measurements) in order to delay the 
onset of disease or to optimise and maintain 
human health (i.e. personalised nutrition). In 
commercial terms, this involves the provision of 
a new service in the form of nutritional advice 
tailored to the needs and particular characteristics 
of individuals (or populations). Similarly, the 
technology may be applied to animals to improve 
livestock production and companion animal 
nutrition. The genetic testing companies with 
or without nutritional expertise (e.g. through 
hospitals and dieticians) are the main players 
currently involved in the provision of personalised 
308 Animal cloning refers to the production of genetically identical “copies” of an animal through Somatic Cell Nuclear Transfer 
(SCNT) technology. This involves the production of animals through transfer of the genetic material from one donor somatic 
cell to a recipient unfertilised oocyte that has had its nuclear DNA removed (enucleation). Through the use of several individual 
cells from a given unique source and an equivalent number of recipient oocytes, several cloned animals can be produced. 
SCNT can also be used as a tool in the production of GM animals.
309 Suk, J. et al. (2007). Nature Biotechnology 25: 47-53.
310 The only company offering this service has closed.
311 As a scientific endeavour, nutrigenomics is the study of the response of organisms to food and food components using 
genomics, proteomics and metabolomics approaches. Nutrigenetics, in turn, refers to genetically determined differences in 
how individuals react to specific foods.
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nutrition advice. GeneWatch UK312 identified 12 
mainly small biotech companies operating (or 
in the planning phase) worldwide, most of them 
with their headquarters in the USA, although 
some also claim to be marketing in the EU313.
Genetic testing followed by dietary advice 
for monogenic nutrient-related diseases may 
be considered as an elementary application of 
nutrigenomics. This is the case for phenylketonuria 
and haemochromatosis testing and for another 
approximately 50 genetic diseases in humans 
caused by variants in enzymes, where changing 
the substrate (nutrient) concentration may be 
the general approach for dietary intervention314. 
While today almost 1 000 human disease genes 
have been identified and partially characterised, 
97% of which are known to cause monogenic 
diseases315, most chronic diseases are due to 
complex interactions between several genes 
and environmental factors, which makes 
directed dietary intervention more challenging. 
Nutrigenomics is expected to have an impact 
primarily in the prevention (but also mitigation 
and curing) of chronic diseases such as obesity, 
diabetes type II, cardiovascular diseases (CVD) 
and cancers, and is therefore expected to have a 
beneficial effect on human health and wellness.
While nutrigenomics is considered 
promising by some, it is still in its infancy and 
the benefits are not expected to be realised in 
the short term. A number of concerns regarding 
the commercialisation of nutrigenomics and 
personalised nutrition have been raised316, 
questioning the potential of the commercial 
application of nutrigenomics.
Nanobiotechnologies in agriculture and food
Nanotechnology may converge with 
biotechnology and enable new and/or improved 
applications not only in primary production, but 
also throughout processing, packaging, distribution 
and preparation processes, such as317:
Improved diagnostics, biosensors and 
surveillance/monitoring systems, e.g.: improved 
microarrays based on nano-scale materials 
(e.g. silica-based chips); nanosensors utilising 
nanotubes or nano-cantilevers that are small 
enough to trap and measure individual proteins 
or other small molecules; nanoparticles or 
nanosurfaces that can be engineered to trigger an 
electrical or chemical signal in the presence of a 
contaminant such as bacteria; other nanosensors 
that work by triggering an enzymatic reaction or 
by using nano-engineered branching molecules 
(dendrimers) to bind target chemicals and 
molecules. For example, BioMerieux launched 
the first high-density DNA multi-detection test 
for food and animal feed testing (FoodExpert-ID) 
in 2004318. Other improved sensors are currently 
being developed for sensing and signalling 
microbiological and biochemical changes, e.g. 
those relevant to food safety and quality during 
packaging and storage and relevant to improving 
food appearance (such as colour, flavour and 
consistency).
Improved delivery systems, e.g.: encapsulation 
and controlled release methods for the precise 
and targeted delivery of fertilisers, pesticides 
and herbicides in crop farming, of veterinary 
treatments to animals, as well as of nutrients to 
animals and humans. For example, Syngenta is 
312 Wallace, H. (2006). Your diet tailored to your genes: preventing diseases or misleading marketing? GeneWatch, Buxton. 
313 Besides these biotech companies, larger food manufacturing companies, such as Nestlé, Unilever, Kraft and Cargill seem to 
have expressed interest in investing in research on nutrigenomics applications, while the International Life Sciences Institute 
(ILSI) has also engaged in related activities (From footnote 312). 
314 Kaput J. and R.L. Rodriguez (2004). Physiological Genomics 16: 166-177.
315 Jimenez-Sanchez, G., B. Childs and D. Valle (2001). Nature 409: 853-855.
316 Wallace, H. (2006). Your diet tailored to your genes: preventing diseases or misleading marketing? GeneWatch, Buxton. 
317 Joseph T. and M. Morrison (2006). Nanotechnology in agriculture and food. Nanoforum Report. nanoforum.org, Düsseldorf. 
318 http://industry.biomerieux-usa.com/news/pressreleases/food_expert_id_pr.htm.
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using nanoemulsions in its pesticide products, 
has marketed a quick-release microencapsulated 
insecticide under the name Karate ZEON, 
which breaks open on contact with leaves319, 
and holds a patent for a “gutbuster” insecticide 
that breaks open to release its contents when it 
comes into contact with alkaline environments, 
such as the stomach of insects320. In the food 
sector, an example is “Tip Top Up” bread, on sale 
in Australia, which has incorporated ω-3 fatty 
acids in nanocapsules designed to break up only 
upon reaching the stomach, thus avoiding the 
unpleasant taste of fish oil321.
The application of nanotechnology in the 
agriculture and food sectors was first addressed 
in the USA by the USDA322. The European 
Commission published a Nanosciences and 
Nanotechnologies Action Plan in June 2005, 
in support of its Nanotechnology Strategy for 
Europe323. Claims of potential benefits from 
the application of nanotechnology have been 
coupled with concerns, which include potential 
risks to human health and the environment. 
Under the Nanosciences and Nanotechnologies 
Action Plan, the Commission will aim to identify 
and address safety concerns associated with the 
application of nanotechnology, become involved 
in the development of terminology, guidelines, 
models and standards for risk assessment and, 
where appropriate, propose adaptations of EU 
regulations in relevant sectors.
2.2.4	 Summary
Economic significance
Modern biotechnology is applied in most 
areas of primary production and the food chain, 
ranging from applications in breeding to the 
provision of diagnostic tools for food safety and 
food ingredient identification. The combined 
economic contribution of the application of 
modern biotechnology in the input sectors has 
been estimated at between EUR 3-5.6 billion 
or 13%-23% of turnover in these sectors. This 
represents only a small share of the overall agro-
food sector (0.26%-0.47%) or total EU gross 
value added (GVA) (0.01%-0.02%324). Overall, 
and based on a conservative estimate, the largest 
turnover share among the various applications 
is held by veterinary products (30%), followed 
by feed additives (28%), food enzymes (13%), 
and diagnostics (10%), while breeding and 
propagation-related activities altogether (plants, 
livestock and fish) account for the remaining 
19% (Figure 2-13). An estimation based on the 
upper limits of the turnover values calculated 
for these applications indicates a larger relative 
economic significance for molecular marker-
based technologies in plants.325 This reflects 
the large uncertainty in the actual adoption of 
molecular marker-based technologies in plant 
breeding. The role of modern biotechnologies in 
the different applications may differ as well, and 
so may their relative importance for the turnover 
obtained with these applications. For example, 
modern biotechnologies may have a core or a 
supporting role in production processes. From 
the product perspective, modern biotechnology 
may be the only technology available for 
reaching a certain objective (e.g. in diagnostics 
applications), may provide a more cost-effective 
option (e.g. riboflavin production) or may provide 
better-quality though more expensive products 
for optimising benefits in downstream uses (e.g. 
breeding).
319 http://www.syngentacropprotection-us.com/prod/insecticide/Karate/.
320 Syngenta’s US Patent No 6,544,540: Base-Triggered Release Microcapsules.
321 http://www.tiptop.com.au/driver.asp?page=main/products/bread/up+white+omega+3+dha.
322 Nanoscale science and engineering for agriculture and food systems, Department of Agriculture, US, 2003.
323 ‘Nanosciences and nanotechnologies: An action plan for Europe 2005-2009’ (COM(2005) 243).
 http://europa.eu.int/comm/research/industrial_technologies/lists/list_108_en.html.
324 The turnover values were multiplied by 0.3 to obtain an estimate in GVA terms.
325 For example, assuming that 100% of maize seed is derived from molecular marker-assisted breeding increases the relative 
share of this application to 10%, while the assumption that 1/3 of all plant breeding uses molecular markers further increases 
its share to 37% of the total.
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Figure 2‑13: Relative economic values of 
biotechnology applications in input sectors 
(conservative estimate) 
The use of biotechnology-derived products 
provided by the input sectors, mainly in 
primary production and food processing, also 
contributes to the economic performance of 
these “user” sectors. The turnover of the sectors 
using modern biotechnology-derived products 
has been estimated at EUR 382-453 billion326, 
which accounts for 32%-38% of agro-food sector 
turnover and 1.3%-1.55% of total EU GVA327. 
Based on a conservative estimate, the largest 
turnover share is accounted for by the use of 
modern-biotechnology-derived products in the 
food processing sector (80%), followed by the 
livestock sector (19%) and the plant sector (1%) 
(Figure 2-14). However, an estimation based on 
the upper limits of the turnover values calculated 
for these applications indicates a higher 
relative economic significance for molecular 
marker-based technologies in plants328. Thus 
modern biotechnology indirectly has economic 
implications for at least a third of the agro-food 
sector. The economic scale of these indirect 
effects is approximately two orders of magnitude 
larger than the direct contributions of the input 
sectors. This estimate is not, however, an absolute 
measure of the indirect impacts per se: modern 
biotechnology-derived products provide varying 
economic advantages to the user sectors, 
generally related to improvements in productivity, 
production efficiency, and therefore overall 
competitiveness.
Figure 2‑14: Relative economic values 
of applications of biotechnology‑derived 
products in primary production and food 
processing (conservative estimate) 
As far as global competitiveness in 
concerned, apart from the production of GM 
seeds and the cultivation of GM crops, where the 
EU lags behind, the EU has an important share in 
the markets where biotechnology-based products 
play a role. This can be seen from its considerable 
share in the export market for breeding and 
propagation material as well as in the markets 
for veterinary products, diagnostics and feed 
additives.
Note: LS = livestock, Pl = plants, F = fish.
326 Not including the indirect impacts of feed additives and veterinary products, although as the indirect impacts will relate mainly 
to livestock production, they are already partially covered by other applications relating to livestock (as the users of the various 
inputs may overlap).
327 The turnover values were multiplied by 0.3 to obtain an estimate in GVA terms.
328 For example, assuming that 100% of maize production is derived from seeds produced via molecular marker-assisted breeding 
increases the relative share of this application to 2%, while the assumption that 1/3 of all plant breeding uses molecular 
markers further increases its share to 12% of the total.
Note: LS = livestock, Pl = plants, F = fish.
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Contribution to employment
Data on employment are largely missing, 
while complex interactions and unknown 
substitution effects limit any attempt to arrive 
at a comprehensive assessment. In general, the 
contribution of modern biotechnology is seen 
mainly in the creation of “more qualified jobs” in 
sectors that use modern biotechnologies directly. 
Moreover, the share of direct employment that may 
be attributed to modern biotechnology probably 
corresponds to that calculated for the adoption 
of biotechnology applications in general. As with 
biotechnology applications overall, a proportion 
of the newly generated jobs can be assumed to 
replace existing employment. Results along these 
lines were obtained in a previous study329 focusing 
on seed biotechnology, which also indicated 
that most of the future growth potential for direct 
employment lies in the success of EU companies 
on foreign markets (where the future growth 
in “users” lies) and that indirect employment 
opportunities in the agro-food chain are much 
greater than the direct prospects, not least because 
of the large differences in current employment 
numbers (e.g. while the EU seed sector has more 
than 30 000 employees, total employment in food 
processing alone is over 3 million).
Social implications
The social implications of modern 
biotechnology in the agro-food sector mainly relate 
to public health issues, including animal health and 
welfare. As with biotechnology in the health field, 
the public health benefits of modern biotechnology 
applications in the agro-food sector derive from 
the availability of new and better diagnostics and 
vaccines. In particular, the monitoring and control 
of some of the most important zoonoses and food 
safety concerns (e.g. Salmonella and BSE) help 
in ensuring EU-wide food safety and consumer 
confidence in the food chain. The cost-effectiveness 
of modern biotechnology applications is also 
relevant for applications in the agro-food sector 
with a potential indirect impact on public health. It 
has been reported, for example, that the use of the 
modern biotechnology-based vaccine for Aujeszky’s 
disease in pigs is the most cost-effective option 
for eradication of the disease. Similarly, modern 
biotechnology-based diagnostics are crucial for the 
surveillance of several of the major communicable 
livestock diseases in the EU, though achieved at 
a high monetary cost. Yet a general assessment 
is not feasible, especially if social and ethical 
costs are taken into account. Ensuring optimal 
animal health and welfare is important both from 
a social and an economic perspective. Modern 
biotechnology may have contrasting implications 
for animal health and welfare. On the one hand, 
some modern biotechnologies present new issues 
in terms of animal welfare, necessitating a case-
by-case assessment of the potential adverse affects 
and perceived benefits. This is especially the case 
with what are perceived as intrusive techniques or 
techniques that may involve novel risks for animal 
welfare, such as pain, suffering or distress in the 
short or long term. On the other hand, modern 
biotechnology provides solutions that improve 
animal health and welfare in a variety of ways, 
for example by replacing the use of animals in 
chemical safety testing or through the provision 
of novel animal health management tools that 
decrease animal suffering.
Environmental implications
The agro-food sector is a major contributor 
to a number of environmental pressures, such 
as the use of natural resources (e.g. land, water) 
as well as emissions of harmful substances (e.g. 
nutrients, pesticides). Therefore, improvements in the 
environmental performance of the agro-food sector 
may be very important from a global perspective. 
A quantitative analysis of the environmental 
implications of biotechnology was hampered by 
the lack of data, so a more qualitative approach was 
329 Tait, J., J. Chataway and D. Wield (2001). PITA project: Policy influences on technology for agriculture: chemicals, biotechnology 
and seeds. Final report. Scottish Universities Policy Research and Advice Network (SUPRA), Edinburgh. 
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followed, except in cases where data were available. 
Modern biotechnology applications in the agro-
food sector may affect both the eco-efficiency of 
manufacturing-related activities (e.g. food processing) 
as well as activities in the primary sector. The use of 
modern biotechnologies by the manufacturing sector 
in general leads to eco-efficiency improvements, 
mainly in energy use and associated greenhouse gas 
emissions, but also in water use and waste generation 
(see also Chapter 0). In the primary sector, modern 
biotechnologies supplement other technological 
innovations that predominantly target improvements 
in production efficiency, thereby reducing resource 
use or emissions of harmful substances per unit 
output. Yet, while these impacts are mostly of an 
indirect nature, there are direct impacts as well, for 
example the replacement of drug and antibiotic 
treatments with the use of vaccines in animal 
production, many of which are produced using 
modern biotechnology, and the reduction of harmful 
emissions due to the use of improved crop varieties or 
biotechnology-based feed additives. However, some 
modern biotechnology applications may also raise 
new challenges, requiring a case-by-case evaluation 
to consider specific aspects or potential risks. To 
this end, the EU has put in place specific legislation 
making it obligatory to carry out comprehensive risk 
assessments before placing such products on the EU 
market.
2.3 Modern biotechnology in industrial 
production processes, energy and 
environment
2.3.1	 Modern	 biotechnology	 in	 industrial	
production	processes
Many industrial manufacturing sectors have 
long-standing traditions in using biotechnology, 
e.g. pancreas extracts containing an enzyme 
mix were used in detergents at the beginning of 
the 20th century. The use of isolated enzymes or 
microorganisms in industrial production processes 
is also referred to as industrial biotechnology. The 
term biocatalysis330 is mainly used to describe the 
application of isolated enzymes in production 
processes, but also covers non-growing whole-
cell systems. For processes using growing 
microorganisms, the term fermentation is used.
Industrial biotechnology is nowadays used 
to manufacture a wide range of products in 
many different industrial sectors, including those 
that traditionally did not use biotechnological 
processes. It often replaces chemical processes 
because of several advantages:
− Improved process efficiency through 
highly substrate- and reaction-specific 
activity. Enzymes and microorganisms 
have the ability to catalyse reactions with 
a high selectivity, including stereoselective 
reactions331. Biotechnological production 
yields purer products (fewer by-products) 
and consequently requires less extensive 
purification steps compared to complex 
chemical production. This is for example 
important in the production of pharmaceutical 
intermediates.
− Reduced energy consumption through the 
ability of most enzymes to work at room 
temperature. The discovery of extremophilic 
microorganisms, which find optimal 
living conditions in comparatively harsh 
surroundings (high-pressure, very hot, very 
cold, alkaline or acidic environments), 
has broadened the application areas of 
enzymes.
− Less waste production, because the use of 
microorganisms in fermentation processes 
often replaces several chemical production 
steps with one biotechnological production 
step (e.g. production of riboflavin).
330 Catalysts increase the rate of a chemical reaction without being consumed, i.e. without becoming part of the product.
331 Stereoselective reaction refers to the preference for one 3-D form of a specific molecule out of the different forms this molecule can have. 
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− Manufacturing of products with improved 
or novel characteristics, e.g. biologically 
degradable biotechnology-based polymers 
or detergents with better performance.
Modern biotechnology widens the 
application of industrial biotechnology, for 
example by enabling the identification of new 
enzymes using modern screening techniques, 
the large-scale production of enzymes using 
improved fermentation processes and more 
efficient microbial producer strains, the 
tailoring of enzymes to specific reactions and 
environments through directed evolution and 
genetic modification, and the conversion of 
microorganisms into “cell factories” using 
metabolic engineering. More than 50% of 
all enzymes currently in commercial use are 
produced by genetically modified organisms332.
Industrial biotechnology is applied in a variety 
of industrial manufacturing sectors, ranging from 
chemicals to pulp and paper production (see 
below under enzyme production). Furthermore, 
it is used to produce a large variety of different 
products, including bulk chemicals such as 
bioethanol or citric acid, which are produced 
in large quantities at low prices, but also fine 
chemicals such as Vitamin B12 or the amino acid 
methionine, which are high-price products with 
comparatively low production volumes. Table 2.6 
gives an overview of some of these products.
2.3.1.1 Enzyme production
Enzyme production can be considered a 
subsector of the chemical manufacturing sector. 
It uses modern biotechnology in production 
processes and produces the biotechnological 
products, i.e. enzymes, needed for applications in 
other industrial sectors. As such, it plays a crucial 
role for the latter, described in this chapter as 
users of biotechnological processes. In Table 2.7 
the main enzyme groups are shown together with 
the reactions catalysed and the user industries. 
Enzymes are very versatile tools, each of which 
can be applied in different industrial processes. 
Users range from the pharmaceutical industry to 
food producers.
332 Gavrilescu, M. and Y. Chisti (2005). Biotechnology Advances 23: 471-499. 
333 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik und Biotechnologie, 
Frankfurt a.M. 
Table 2.6 Examples of biotechnology‑based products, annual global production volumes and prices
Source: DECHEMA.333
Product Annual production (tonnes) World market prices (e/kg)
Bulk chemical
Bioethanol >18.5 million 0.40
Amino acids
L-Glutamic acid 1 500 000 1.20
L-Lysine 700 000 2
L-Threonine 10 000 6
L-Methionine 400 20
Acids
Citric acid 1 000 000 0.80
Lactic acid 150 000 1.80
Gluconic acid 100 000 1.50
Vitamins
Vitamin C 80 000 8
Vitamin B12 20 25 000
Riboflavin 30 000 NA
Antibiotic derivatives
6-aminopenicillanic acid 10 000 NA
D-p-hydroxyphenylglycine 7 000 NA
7-Aminocephalosporinic acid 4 000 NA
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Most of these enzymes are used in the food 
sector (30%-45%) and the detergents sector (33%). 
The textile and pulp and paper industries account 
for about 8%-14% and 1%-3%, respectively. 
Enzymes for fine chemical production account 
for another 5% of the world market335.
Economic significance
In this study, about 117 enzyme-producing 
companies were identified worldwide. 75 (64%) 
are located in the EU, with France, Spain and 
Germany having more than 10 companies each, 
representing more than 50% of all EU enzyme 
companies (Figure 2-15). 18% of the companies 
are situated in the USA. However, the main 
enzyme producers by volume can be found 
in Denmark, with 47% of worldwide enzyme 
production in 2001. Since the acquisition of one 
of the major US enzyme producers (Genencor) 
by Danisco (Denmark) in 2005, this share has 
most probably increased even further. The most 
important companies in terms of production 
volumes are Novozymes (Denmark), Chr. Hansen 
(Denmark), DSM (Netherlands), AB Enzymes 
GmbH (Germany), and DIREVO Biotech AG 
(Germany). Other major producers in volume 
terms are in the USA (Genencor – part of Danisco 
since 2005) and Japan. World production volume 
was estimated at 53 000 tonnes per year in 2001, 
with the EU’s share being about three quarters. 
With an estimated 5% growth for the enzyme 
market, a production volume of around 65 000 
tonnes for 2005 can be assumed336,337.
Table 2.7 Different groups of enzymes and reactions
Source Lievonen334, adapted by IPTS.
334 Lievonen, J. (1999). Technological opportunities in biotechnology. VTT Group of Technological studies, Espoo, p. 24. 
335 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications. And DECHEMA (2004). Weiße 
Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik und Biotechnologie, Frankfurt a.M. 
336 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik und Biotechnologie, 
Frankfurt a.M.
337 Gavrilescu, M. and Y. Chisti (2005). Biotechnology Advances 23: 471-499.
Type of enzyme Substrate Reaction catalysed by the enzyme User sectors
Proteases 
(proteolytic 
enzymes)
Proteins Hydrolysis of proteins into shorter fragments, peptides and amino acids
Detergents, food, 
pharmaceuticals, chemical 
synthesis
Carbohydrases Carbohydrates Hydrolysis of carbohydrates into sugar Food, feed, pulp and paper, textiles, detergents
Lipases Fats (triglycerides)
Hydrolysis of fats into fatty acid and glycerol 
molecules
Food, effluent treatment, 
detergents, pharma
Pectinases Pectins Mix of enzymes to degrade pectin, a complex polysaccharide present in fruits 
Food, beverages (clarification 
of fruit juices)
Cellulases Cellulose Hydrolysis of cellulose into sugar Pulp, textiles, feed, detergents, energy
Amylases Poly-saccharides
Hydrolysis of starch into smaller 
carbohydrate molecules such as glucose and 
maltose
Food, textiles
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The market value of the global enzyme 
market for 2004/2005 was estimated at around 
EUR 1.8 billion339. Assuming an EU share of 75% 
in enzyme production and an even distribution of 
enzyme price levels, it can be concluded that EU 
companies earned around EUR 1.3 billion from 
enzymes in 2005. Based on the gross value added 
(GVA) share that the biggest enzyme producer 
Novozymes (Denmark) declares for its activities 
(57%340), EU enzyme production created a GVA 
of EUR 684 million, which represents 0.05% 
of the GVA produced by the EU manufacturing 
sector in 2002.
It is estimated that the sector employs between 
4000 and 6000 staff341, representing 0.015%-
0.02% of all employees in EU manufacturing. Its 
GVA/employment ratio (share of all economic 
activity in the EU compared with the share of 
EU employment) reveals a labour productivity 
of 2.8-4 (0.0084% of EU GVA is created by 
0.002%-0.003% of EU employment). Enzyme 
production thus has a higher labour productivity 
than the chemical sector (2.0) and the average for 
EU economic activities (1.0), indicating a mature 
industry with a high degree of automation.
Environmental implications
The production of enzymes as an intermediate 
chemical product has environmental implications 
in terms of energy use and process-related 
greenhouse-gas and other emissions. Generally, 
little information is available on these aspects 
of enzyme production. However, environmental 
assessments of individual products carried out by 
one of the main enzyme-producing companies 
(Novozymes) provide an indication. A lifecycle 
Figure 2‑15 Enzyme‑producing companies and worldwide production shares in 2001, by country
RoW: rest of the world
Source: ETEPS.338
338 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
339 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik und Biotechnologie, 
Frankfurt a.M., p.43. And: Novozymes (2005). The Novozymes report 2005. Novozymes, Bagsværd, p. 11 (conversion: 1 DKK 
= 0.135 Euro). 
340 Novozymes (2005). The Novozymes report 2005. Novozymes, Bagsværd, p. 22 (turnover DKK 6024m, GVA DKK 3424m).
341 Estimation based on data from a fruit juice enzyme business (200 employees) and the share of fruit juice enzymes in all 
enzyme production (3.5%), and on information from the Novozymes homepage, which indicate 2 250 EU based employees, 
with Novozymes holding 60% of the enzymes market.
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assessment comparing phytase342 production with 
the production of the feed additive monocalcium 
phosphate (replaced by phytase) revealed that 
the production of the enzyme consumes about 
90% less energy, which also leads to reductions 
in greenhouse gas emissions343. A comparison of 
enzyme production processes using conventional 
or genetically modified microbial production 
strains revealed that the use of genetically 
modified organisms has environmental benefits 
along all the environmental dimensions analysed, 
such as global warming, energy consumption and 
others344.
In the following, the application of industrial 
biotechnology, in particular biocatalysis, in 
different sectors will be described and analysed: 
detergents, food processing, textile finishing, 
pulp and paper processing, and fine chemicals. 
Bioethanol fuel production will be described in 
Chapter 2.3.2 under energy. There are also other 
sectors applying industrial biotechnology, such as 
mining (bioleaching), which however have only 
minor significance in the EU and therefore will 
not be taken into account in this analysis.
2.3.1.2 Biocatalysis in detergents
Biocatalysis in detergents is different from 
enzyme applications in other sectors, because 
the biocatalysts, i.e. enzymes, form part of 
the end product, the detergent, to improve its 
performance when used by the consumer. Hence, 
biotechnology is not used here to improve the 
manufacturing process of detergents. Enzymes 
have been used in detergents since the beginning 
of the 20th century, when crude pancreatic 
enzymes were added to laundry detergents. 
Commercial large-scale utilisation of enzymes 
produced by microorganisms in detergents began 
in the 1960s, and the range of enzymes used 
nowadays includes different proteases, amylases, 
cellulases and lipases (see Table 2.7). By 1968, 
a few years later, 80% of all laundry detergents 
in Germany contained enzymes345. Advantages 
are the ability to reduce washing time and 
temperature, thus reducing energy consumption, 
improving cleaning performance, and reducing 
the environmental impact due to biodegradability. 
Accordingly, the improved quality of the product 
and environmental considerations, rather than 
lower production costs, are the driving factor 
for the application of enzymes in detergents346. 
Today, enzymes are mainly used in detergents for 
washing machines and dishwashers.
Economic significance
Detergent enzyme sales in 2005 were about 
EUR 592 million, 33% of the world enzyme 
market. The leading detergent enzyme producers 
are Novozymes (Denmark) and Danisco/
Genencor (Denmark), with 50% and 20% of 
the world market, respectively. Two thirds of 
enzyme detergents are sold in the EU (32%), the 
USA (23%) and Japan (10%). The market grows 
by about 4.5% per year, due to growing enzyme 
markets for dishwasher and liquid detergents. The 
high share of detergent enzymes among industrial 
enzymes and the continuous growth along with 
low volatility indicate a well-established market. 
It represents a considerable share of the business 
of the world market leaders: 32% of Novozymes’ 
sales in 2005 (EUR 273 million) and 47% of 
Genencor’s sales in 2004 (EUR 142 million347; 
since 2005 part of Danisco, Denmark)348.
342 Phytase is an enzyme degrading phytate, a phosphorus-rich plant ingredient not digestible for monogastric animals. It is a feed 
additive. See also box in Chapter 2.2.1.1 
343 Nielsen, P.H. and H. Wenzel (2006). International Journal of Life Cycle Assessment, online first,
 http://dx.doi.org/10.1065/lca2006.08.265.2.
344 Nielsen, P.H., K.M. Oxenbøll and H. Wenzel (2006). International Journal of Life Cycle Assessment, online first,
 http://dx.doi.org/10.1065/lca2006.08.265.1.
345 Braun, M., O. Teichert and A. Zweck (2006). Übersichtsstudie: Biokatalyse in der industriellen Produktion. VDI 
Technologiezentrum, Düsseldorf. 
346 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
347 Conversion: 1 U.S. Dollar = 0.776 Euro.
348 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
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Overall sales of soap, detergents, and 
maintenance products in the EU (here including 
Norway, Iceland and Switzerland) amounted to 
about EUR 30 billion in 2005349. About 30%-50% 
of all detergents sold in 2005 contained enzymes, 
equivalent to about EUR 9 to 15 billion. Based on 
the GVA of the relevant industrial manufacturing 
sector (Manufacture of soap, detergents, cleaning 
and polishing — NACE DG 24.51) in 2003 and 
the market share of 30%-50%, the contribution of 
enzyme-containing detergents to GVA in the EU 
is estimated at EUR 2.5 to 4.0 billion, or 0.03%-
0.05% of overall EU GVA (see Table 2.15 at the 
end of this chapter).
Following the same approach, it is estimated 
that about 36 000 to 60 000 employees work in the 
manufacturing of enzyme-containing detergents. 
The contribution to overall EU employment is 
0.02%-0.03%. Labour productivity is similar for 
all detergent manufacturing, and at 1.5-1.7 is 
higher than the average labour productivity for 
the EU (1.0).
Environmental implications
The environmental impact of enzymes in 
detergents can only be qualitatively described 
due to the lack of data. The use of enzymes in 
household detergents results in lower washing 
temperatures, reduced water consumption, 
reduced washing times, and a reduced load of 
toxic substances in waste water (enzymes replace 
chemical substances in detergents). Reducing 
the washing temperature from 95oC to 40oC 
reduces energy consumption by 70%. However, 
it is not possible to quantify this effect as the 
overall energy used by the washing process is not 
known. The amount of toxic substances such as 
benzoapyrene, lead, cadmium, or sulphur oxide 
can be reduced by 5%-60%. However, exposure 
to enzymes can result in allergic reactions. 
This used to be the case for workers handling 
the enzyme powders for detergent production 
and inhaling air with enzyme particles. Today, 
enzymes are encapsulated to avoid allergic 
reactions. Still, because of risk of inhalation and 
allergic reactions, enzyme-based detergents are 
not used for cleaning open surfaces in either 
households or industry.
2.3.1.3 Biocatalysis in food production
Biotechnology in food production has 
a long history, e.g. in beer, wine, bread and 
cheese production. The significance of modern 
biotechnology (i.e. the use of biocatalysis) in food 
processing nowadays is illustrated by the large 
share of food enzymes in the enzyme market: 
30%-45%350,351. Table 2.8 provides some examples 
of enzyme applications in food processing and 
illustrates the diversity of the processes involved. 
Since the early 1960s, all glucose production 
based on starch has been carried out by enzymatic 
rather than acid hydrolysis, reducing steam cost 
by 30%, ash by 50% and by-products by 90%352. 
Laccases are used in the clarification of juices as 
well as in baking for the treatment of dough353. 
Amylases, proteases and xylanases also play 
important roles in baking, cheese production, 
sweetener production and other food production 
processes.
349 AISE (2005). Market data. International Association for Soaps, Detergents, and Maintenance Products, Brussels. http://www.
aise-net.org/go_withsub.php?pid=14&topics=4. 
350 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik und Biotechnologie, 
Frankfurt a.M., p. 30.
351 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
352 Novozymes (2004). Enzymes at work. Novozymes, Bagsværd, p. 27.
353 Rodríguez Couto, S. and J.L. Toca Herrera (2006). Journal of Biotechnology Advances 24: 500-513.
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Enzymes are used in food production to 
improve the production processes and the 
product quality. In juice production, for example, 
the application of enzymes such as pectinases, 
amylases and proteases, which also occur 
naturally in the fruit ripening process, helps 
to soften the fruit cell walls and to reduce the 
viscosity of the material. This results in
− Increased juice yield (fruits 15%-20%)
− Decreased filtration times, up to 50%,
− Clarification and cloud stabilisation of juice 
and juice concentrates,
− Decreased risk of jellification.
The treatment is supposed to improve taste, 
colour stabilisation and oxidative stability355.
Economic significance
The dairy, starch and sugar, and bakery segments 
are the main users of enzymes in food processing, 
each representing about a quarter of enzyme sales 
in 2006 (Table 2.9). Fruit juice, wine and brewing 
together represent about 20%, and supplements 
about 5%. The analysis will thus concentrate on 
these food manufacturing segments356, which 
represented about 40% of the overall GVA of the 
food manufacturing sector (NACE DA 15) in 2002 
according to Eurostat data357.
Table 2.8 Examples of enzymes used in food processing
Source: Kirk et al354, adapted by IPTS.
354 Kirk, O., T.V. Borchert and C.C. Fuglsang (2002). Current Opinion in Biotechnology 13: 345-351.
355 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
356 NACE codes: DA15.3 Fruit and vegetables, DA 15.4 Vegetable and animal oils and fats, DA15.5 Dairy products, DA 15.62 
Starch and starch products, DA 15.7 Prepared animal feed, DA 15.81 Bread, pastry, cake, DA 15.83 Manufacture of sugar, DA 
15.93 Wine making, DA 15.94 Cider and fruit wines, DA 15.96 Manufacture of beer.
357 The calculations focus on industrial food production. In the bakery segment, therefore, the figures have been adjusted to take 
only large-scale industrial bread manufacturing into account, disregarding the large share of family owned businesses. They 
thus cover about 18% of the employees in this food manufacturing segment (224 000), producing 32% of its GVA (EUR 8.5 
billion). See Table 2.15 at the end of this chapter.
Food processing Enzyme Effect
Dairy Protease (chymosin) Milk clotting
Lipase Cheese flavour
Lactase Lactose removal (milk)
Bakery Amylase Bread softness and volume, flour adjustment
Xylanase Dough conditioning
Lipase Dough stability and conditioning (in situ emulsifier)
Phospholipase Dough stability and conditioning(in situ emulsifier)
Glucose oxidase Dough strengthening
Lipooxygenase Dough strengthening, bread whitening
Beverage Pectinase De-pectinisation, mashing
Amylase Juice treatment, low calorie beer
Beta-Glucanase Mashing
Acetolactate decarboxylase Maturation (beer)
Laccase Clarification (juice), flavour (beer), cork stopper treatment
Starch Amylase, Amyloglucosidase, Pullulanase Starch liquefaction, saccharification 
Glucose isomerase Glucose to fructose conversion
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Many enzymatic processes have been 
universally taken up by the industry and are state-
of-the-art technology, which makes a comparison 
with conventional alternatives impossible. The 
entire output of the food production processes 
concerned is therefore considered for calculating 
the impact of modern biotechnology. The 
contribution of the segments listed above to EU 
GVA is 0.8% (EUR 70 billion, 2002), or 4.8% of 
manufacturing sector GVA (2002). With 1 375 082 
employees, these segments also account for 0.69% of 
overall EU employment and 4.2% of employment 
in the manufacturing sector. Labour productivity 
in the food sectors applying enzymes is 1.2, or 
about 30% higher than the average for the overall 
food sector (0.9) and 20% higher than the EU 
average for all economic activities (1.0).
Environmental implications
The analysis of the environmental impacts of 
biocatalysis in food processing faces challenges 
similar to those posed by the measurement of 
economic impacts. As most enzymatic processes 
have a diffusion of 100% in the sector, no other 
process is available for comparison. The only 
conclusion that can be drawn is that about 50% 
of the food processing segments apply enzymes 
to a large extent, and that the contribution of 
food and feed manufacturing to CO2 emissions of 
all manufacturing sectors is about 7% (excluding 
agriculture) and 0.35% to overall greenhouse 
gas emissions. The potential for reducing 
greenhouse gas emissions, water and energy use 
and chemical inputs by using enzymes in other 
food segments might be limited as biocatalysis is 
already widespread in food production.
2.3.1.4 Biocatalysis in pulp and paper
Paper and board are made of cellulose 
sourced from wood. In the production process, 
there are several steps in which enzymes 
are applied (Figure 2-16). However, enzyme 
application has not been taken up on a large 
scale in pulp and paper production since its first 
introduction in the 1980s. Some processes are 
now established, but others have only recently 
entered production scale.
Xylanases are the major enzyme class used 
in pulp and paper production. They are used 
in the pulp bleaching process to enhance the 
extractability of lignin. According to expert 
estimates, xylanases are applied in about 20 
mills throughout Scandinavia, North America 
and Russia, where about 10% of kraft pulp is 
manufactured using xylanase treatment with 
cost savings of 5%-6%359. Kraft pulp (chemical 
Table 2.9 Share of enzyme sales per application area in the food sector358
358 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
359 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
Food application area Enzyme sales in 2006
Dairy 26%
Starch and sugar 25%
Bakery 24%
Fruit juice 7%
Wine making 7%
Brewing 6%
Nutrition and dietary supplements 5%
Total 100%
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pulp) has a share of about 60% of all the pulp 
manufactured in the EU361.
Apart from xylanases, the use of other 
enzymes such as pectinases in raw material 
treatment or cellulases and lipases in the pulping 
process has become established in the pulp and 
paper industry.
The recycling rate of paper in the EU was 
55% in 2004362. Pulp from recycled paper needs 
to be cleaned of dirt and ink. Cellulases and 
hemi-cellulases can be used in enzyme-aided de-
inking. This process is already used in mills but is 
not yet widespread.
Wood contains esters of fatty acids (‘pitch’) 
that can lead to sticky depositions in paper-
making machines, thus disturbing the production 
process. These substances are usually removed 
using chemicals. Enzymes such as lipases can 
be used in mechanical pulps to reduce pitch 
problems. Mechanical and semi-chemical pulp 
represents about 34% of all pulp manufactured in 
EU countries in 2005363.
Paper making is a water-intensive process. 
The prevailing conditions (temperature, nutrients, 
pH) favour the growth of microorganisms 
and the development of biofilms on surfaces. 
The application of biocides, together with 
biodispersants, and enzymes to remove and 
prevent biofilms is common practice. Another 
biotechnology application in paper making 
is the enzyme-aided removal of fines and 
polysaccharides on fibres to improve the drainage 
of water, thus increasing the efficiency of pressing 
Figure 2‑16 Enzymes used in an integrated mill (chemical pulping, bleaching and paper production)
Source: EPA360, modified by IPTS.
360 US Environmental Protection Agency EPA Office of Compliance Sector Notebook Project (2002), Profile of the pulp and paper 
industry, 2nd edition, p.17. Washington DC.
361 CEPI (2006). Annual statistics 2005. Confederation of European Paper Industries, Brussels. (Covering 17 EU countries and 
Norway and Switzerland.)
362 CEPI (2006). Annual statistics 2005. Confederation of European Paper Industries, Brussels.
363 CEPI (2006). Annual statistics 2005. Confederation of European Paper Industries, Brussels.
WOODYARD AND CHIPPING
(ENZYME: Pectinase)
PULPING (ENZYME: Cellulase, Lipase)
BLEACHING (ENZYME: Xylanase) SCREENING 1 WASHING
SCREENING 2 DRYING MACHINE FINISHING DEPARTMENT
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and drying processes364. No data on the actual 
uptake of these processes or their impact were 
available. Paper making will therefore not be 
considered in the following analysis.
Economic significance
Overall, the adoption rate of enzyme-
aided processes in pulp manufacture, including 
bleaching, de-inking, and pitch reduction, was 
assumed to be 15%. Sales figure for pulp enzymes 
show that xylanases used for pulp bleaching 
dominate (67%), followed by lipases (8%) for 
pitch control and cellulases (8%) for de-inking 
and fibre modification (Figure 2-17). The overall 
pulp enzyme market was about EUR 46.6 million 
in 2004, or about 2.6% of the overall enzyme 
market. Sales in Northern America and Western 
Europe are similar, representing 36% and 33% of 
the world market, respectively.
The main pulp producers worldwide in 2004 
were the EU (23%), the USA (30%), and Canada 
(15%), with Finland (8%) and Sweden (7%) being 
the largest producers within the EU (Figure 2-18). 
Russia, China and Japan have comparatively 
small production volumes. In 2005, pulp and 
paper was produced in the EU by about 214 pulp 
mills and 1005 paper mills. The number of mills 
decreased between 1991 and 2005 by 20%–
24%366. Comparing the regional distribution of the 
sales of the enzymes mainly used in the pulping 
process with the regional distribution of pulp 
manufacturing, it seems that the use of enzymes 
in pulp manufacturing is greater in the EU (23% 
of pulp manufacturing and 33% of enzymes) than 
in North America (45% of pulp manufacturing 
and 36% of enzymes).
364 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
365 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
366 CEPI (2006). Annual statistics 2005. Confederation of European Paper Industries, Brussels. 
Figure 2‑17 Distribution of pulp enzymes, by value (left panel) and regional sales (right panel) in 2004
Data: ETEPS365; RoW: rest of the world.
Lipase 8%
Xylanase 67%
Cellulase 8%
Other 17%
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The EU pulp, paper and paperboard sector 
(NACE sector DE 21.1) generated a turnover 
of EUR 75 billion in 2002. Of that figure, the 
turnover on pulp production was about EUR 6.8 
billion (9%). Assuming a GVA rate of 29% (based 
on data from the pulp, paper and paperboard 
manufacturing sector), the GVA is estimated at 
EUR 2 billion or 0.13% of the GVA of overall 
manufacturing. Assuming furthermore that 
15% of all pulp is processed using enzymes, 
the GVA of pulp manufacturing using enzymes 
would be around EUR 300 million or 0.02% 
of all manufacturing (0.0034% of EU GVA). 
Following the same approach, it is estimated that 
the 22 000 employees in pulp manufacturing 
include about 3000 active in enzyme-aided pulp 
production, only a small share (0.0015%) of EU 
employment. The labour productivity of enzyme-
aided pulp manufacturing is 2.3, or about 10% 
higher than conventional production (2.1). In 
total, pulp manufacturing as such seems to be a 
comparatively efficient, automated process, with 
a labour productivity well above the EU average 
for all economic activity (1.0).
Environmental implications
The pulp and paper industry produces 
emissions to air and water as well as solid waste 
as a by-product. The main air pollutants are NOx, 
SO2, CO, CO2 and particulate matter. Wastewater 
contains adsorbable, organically bound halogens 
(AOX) and is characterised by high biological and 
chemical oxygen demand (BOD and COD368). 
Chlorine emissions from bleaching processes 
have been reduced over the past decades: today, 
most pulp and paper production uses elementary-
chlorine-free (ECF) or totally chlorine-free (TCF) 
processes.
A recent study using model processes369 
identified the following environmental benefits 
Figure 2‑18 Share of pulp production in 2004, by country
RoW: rest of the world
Source: Verband Deutscher Papierfabriken367.
367 Verband Deutscher Papierfabriken, Papier Kompass 2006, Bonn. 
368 BOD: biochemical (biological) oxygen demand is a test used to measure the concentration of biodegradable organic matter 
present in a sample of water. COD: chemical oxygen demand is a test commonly used to indirectly measure the amount of 
organic compounds in water. Both tests are used to determine water quality.
369 Kvistgaard, M. and O. Wolf. (eds) (2002). The assessment of future environmental and economic impacts of process integrated 
biocatalysts. European Commission, DG JRC/IPTS, EUR 20407, p. 24.
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of enzyme applications: xylanase application in 
chemical pulping reduces the need for elemental 
chlorine by 90% and thus the AOX content in 
wastewater streams by 15%-20%. Cellulase 
(and fungi) applications in mechanical pulping, 
an energy- and water-intensive process, reduce 
energy use by about 32% and indirectly lead 
to savings in greenhouse gas emissions. Direct 
average greenhouse gas emission savings are 
around 5%. Furthermore, the use of enzymes in 
de-inking and pitch control results in less use of 
additives, surface-active chemicals, and other 
chemicals. However, no quantitative data are 
available. Overall, it can be assumed that enzyme 
application leads to reductions in CO2 emissions 
and the pollutant load of wastewater streams.
2.3.1.5 Biocatalysis in textile finishing
The textile sector in the EU includes the 
production of fibres and yarns, the production 
of knitted and woven fabrics, and finishing 
activities such as bleaching, printing, dyeing, etc. 
Biocatalysis is applied in the last step, in textile 
finishing, in particular for cotton fabrics. The use 
of amylases to remove starch from cotton fabric 
after weaving370 (de-sizing) is the oldest process, 
in use for about 100 years (Figure 2-19). This 
enzymatic process is used in almost all textile 
manufacturing. “Bioscouring” (the removal of 
remaining cell-wall components such as waxes 
and oils in the cotton fabric by pectinases) is a 
comparatively new process. This application 
could replace an alkaline cooking process but 
is most probably not yet widely used. Catalases 
are applied to remove superfluous hydrogen 
peroxide used in the bleaching step, replacing 
repeated rinsing of the fabric in hot water. The 
take-up of this enzyme application, available 
since the 1980s, is about 40%-50%371. In the 
biopolishing process, the aim of which is to 
improve the quality of the fabric, cellulases 
370 Cotton threads are covered with starch to make them more resistant to mechanical stress during weaving.
371 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
372 Kirk, O., T.V. Borchert and C.C. Fuglsang (2002). Current Opinion in Biotechnology 13: 345-351. 
Figure 2‑19 Enzymes used in cotton fabric processing
Source: Kirk et al.372
-Amylase Pectinase
Peroxidase
(removal of excess dye)
Laccase (mediator)
Acid cellulase
biopolishing
De-sizing Scouring Bleaching Dyeing Finishing
Raw fabric
Catalase
(bleach clean-up) Finished fabric
Stone-wash Bleaching Finished blue jeans
Neutral cellulase
De-sizing
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modify the surface of the fibres to prevent pilling 
and increase softness and smoothness. Cellulases 
are also used in the finishing of denim garments 
to create a washed-out appearance by replacing 
the stone wash process by “biostoning”. This 
process was applied to 80% of jeans trousers in 
the 1990s373. Cellulases account for about 2/3 of 
textile enzyme sales.
Economic significance
Enzymes applied in the textile industry 
represent about 8% of the worldwide enzyme 
market (EUR 140 million). The Western European 
market accounts for about 33%, while North 
America represents 36% of the textile enzyme 
market. Other countries including China and 
India account for about 31%, reflecting the 
importance of these regions in terms of textile 
manufacturing374. The growth rates of the enzyme 
markets in non-EU regions, e.g. 3.9% in Asia 
compared to 2.7% in the EU, indicates the 
growing importance of these regions in textile 
manufacturing375.
The textile sector in the EU comprises about 
70 000 companies (EU15, 2002), mainly small 
and medium-sized enterprises376. The sector has 
been shrinking continuously in recent years, 
with the contribution to EU GVA decreasing by 
35% between 1995 and 2005377. Textile finishing 
contributed 12% to the GVA of EU textile 
manufacturing in 2002 (EUR 4.3 billion) and 
0.05% to overall EU GVA. Assuming an average 
adoption rate of 40% for enzymes in textile 
finishing processes, enzyme applications thus 
contributed EUR 2 billion or 0.02% of EU GVA. 
Furthermore, they reduced costs on average by 
about 25% based on model calculations378.
Again based on the share of 40% of 
enzymatic processes in textile finishing, about 48 
480 employees (out of 121 200) can be assumed 
to have biotechnology-related jobs. Overall 
labour productivity in textile finishing is low 
(0.8) compared to the EU average (1.0). Enzyme-
based textile finishing processes have a slightly 
higher labour productivity of 0.9, indicating 
some technological optimisation through the 
application of enzymes.
Environmental implications
The textile industry is known for its energy- 
and water-intensive processes, resulting in 
wastewater streams with high and diverse 
pollutant loads. In textile wetting, 100 litres of 
water are used for every kilogram of textile fabric. 
Processes often require high temperatures, and 
cleaning, bleaching, dying and other finishing 
processes generate a variety of pollutants. The 
effects of enzyme applications in different textile 
finishing steps are summarised in Table 2.10. 
However, quantitative information is scarce.
Overall, it can be concluded that enzymatic 
processes in textile finishing reduce water and 
energy usage (and thus the emission of greenhouse 
gases) and the chemical load in wastewater as 
well as ensure increased biodegradability.
373 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
374 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
375 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
376 European Commission SEC(2003) 1345 Commission staff working paper: Economic and competitiveness analysis of the European 
textile and clothing sector in support of the Communication “The future of the textiles and clothing sector in the enlarged Europe”. 
377 Eurostat data.
378 Kvistgaard, M. and O. Wolf. (eds) (2002). The assessment of future environmental and economic impacts of process integrated 
biocatalysts. European Commission, DG JRC/IPTS, EUR 20407, p. 46.
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2.3.1.6 Industrial biotechnology in the   
 production of chemicals
Modern biotechnology is applied in the 
production of many chemical substances 
(for examples, see Table 2.6), using either 
microorganisms or enzymes, or a combination 
of both. Often several chemical production 
steps are replaced by one biotechnological 
step, with potential advantages ranging from 
less material input to fewer by-products and 
reduced waste and energy use. Further below, 
the biotechnological production of specific 
intermediates in antibiotic production, vitamins, 
amino acids and biotechnology-based polymers 
will be described as examples for bulk and fine 
chemical production.
Economic significance of industrial biotechnology 
for the chemical industry
The chemical industry in the EU comprises 
about 60 000 companies, of which 56 can 
be identified as producers of biotechnology-
based chemicals381. Disregarding bioethanol 
producers, about 38 companies (0.1%) produce 
biotechnology-based chemicals. In the USA 
and Japan, the share seems to be significantly 
higher: 1.7% of US chemical companies use 
biotechnological processes (266 out of 16 000), 
and 2.5% in Japan (127 out of 5000)382. The EU 
chemical sector has a strong position compared 
to other countries. In 2003, 16 out of the top 30 
chemical companies by sales worldwide (without 
pharmaceuticals) were EU companies, 7 were 
situated in Japan and 5 in the USA (3 of those 
within the top 10). Overall, the manufacturing 
of chemicals and chemical products (including 
pharmaceuticals) accounted for 11% of the GVA 
of the manufacturing sector in 2002, and nearly 
2% of overall EU GVA.
No data are available regarding production 
volumes and sales of biotechnology-based 
chemicals or regarding employment. Due to the 
lack of information, a quantitative analysis of 
the economic relevance of these products is not 
meaningful. Nevertheless, a selection of case 
studies can illustrate the nature and magnitude of 
their environmental and economic impacts.
Example: Biotechnological production of 7-ACA, 
a cephalosporin antibiotic intermediate
Naturally occurring antibiotics are mostly 
produced by fermentation: due to their complex 
379 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
380 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
381 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
382 ETEPS (2006). Bio4EU Task 2 Main report.
Table 2.10 Overview of the effects of enzyme applications in textile finishing 
NA: Not available.
Textile finishing step Chemical use Water use Energy consumption Time consumption
De-sizing (starch) Reduction NA NA NA
Bioscouring379 Reduction Reduction
Reduction (lower 
temperature of 60°C 
instead of 100°C)
Reduction
Bleach clean-up380 Reduction of 80% Reduction of 50% Reduction of 20% Reduction of 33%
Denim bleaching NA Reduction of 17% Reduction of 9%-14% Reduction of 10%
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structure, chemical production is not as efficient. 
This group includes the broad-spectrum beta-lactam 
antibiotics penicillin and cephalosporin. However, 
the natural form is often not sufficiently potent 
or not orally stable, so what are known as semi-
synthetic antibiotics have been developed. They are 
chemically or, more recently, biotechnologically 
modified versions of the naturally occurring form. 
In 1999/2000, beta-lactam antibiotics accounted 
for about 65% of the world antibiotic market of 
around EUR 12 billion383.
Cephalosporin C, produced by the fungus 
Acremonium chrysogenum on a commercial 
scale, is the starting point of semi-synthetic 
cephalosporin production. The removal of a 
side chain results in the compound 7-ACA384, 
which is the nucleus for further modification and 
production of different types of cephalosporin 
antibiotics. In all, two thirds of commercial 
cephalosporin antibiotics are derived from 7-ACA385. 
The conversion can be carried out chemically, 
which is the conventional process, or, more 
recently, using two recombinant enzymes. In 
particular, recombinant enzyme production has 
cut the costs of the biotechnological production 
step and made it economically competitive386. 
The production volume of 7-ACA is about 4000-
5000 tonnes/year, while cephalosporin antibiotics 
amount to about 30 000 tonnes/year for human 
and veterinary uses387. About 20% of 7-ACA is 
produced using enzymatic conversion388, i.e. 
about 1250 tonnes. Major producers are Sandoz 
(Switzerland, but with its production facilities 
in Germany), Antibioticos (Italy), and DSM 
(Netherlands). Sandoz and Antibioticos account 
for about 60-70% of biotechnology-based 7-ACA 
and 14%-17% of global 7-ACA production. 
Overall, about 35% of 7-ACA is produced in the 
EU.
One third of cephalosporin antibiotics are 
derived from another precursor, 7-ADCA. 7-ADCA 
can be produced chemically, based on penicillin 
G as a precursor, or directly in a one-step 
fermentation process using genetically modified 
microorganisms389. Recently, DSM (Netherlands) 
has introduced a fully biotechnological production 
process for Cephalexin, a cephalosporin-based 
antibiotic, including one fermentation step and 2 
enzymatic steps, replacing a 10-step conventional 
production process and reducing costs by about 
50%390. DSM is the world’s largest producer of 7-ADCA 
with a production capacity of several 100 tonnes. 
According to expert opinion, the share of the EU 
in production and sales is around 50%391.
In the case of 7-ADCA, the switch from 
chemical to biotechnological synthesis has 
reduced wastewater by 90%. Emissions of CO2 
have decreased by 75% and substantial energy 
savings have been made (37% less electricity 
and 92% less steam)392. In 7-ACA production, the 
biotechnological process has reduced by almost 
100% the use of solvents and the production of 
waste needing to be incinerated, and has cut the 
amount of wastewater by 10%.
Compared internationally, the EU is 
competitive in the production of 7-ACA and 
7-ADCA in terms of production volumes. This 
is true both for market volume as a whole and 
for the share of biotechnological processes. 
383 Elander, R.P. (2003), Appl. Microbiol. Biotechnol. 61(5-6): 385-392.
384 7-aminocephalosporanic acid.
385 Elander, R.P. (2003), Appl. Microbiol. Biotechnol. 61(5-6): 385-392.
386 Bayer, T. and D. Wullbrandt (1999). Enzymatische Herstellung von 7-Aminocephalosporansäure. In: Heiden, S., C. Bock and G. 
Antranikian (eds). Industrielle Nutzung von Biokatalysatoren: Ein Betrag zur Nachhaltigkeit. 15. Osnabrücker Umweltgespräche. 
Initiativen zum Umweltschutz, vol. 14, Erich Schmidt Verlag, Berlin. 
387 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik und Biotechnologie, 
Frankfurt a.M., p. 51.
388 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
389 OECD (2001). The application of biotechnology to industrial biotechnology. OECD, Paris
390 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik und Biotechnologie, 
Frankfurt a.M., p. 34.
391 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
392 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
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Worldwide, only a few producers are active. The 
uncertain factor here is the rapid development of 
production capacity in China. The North China 
Pharmaceutical Corporation NCPC and the 
Harbin Pharmaceutical Group (8000 employees) 
produce several 1000 tonnes of antibiotics, 
including 7-ACA and 7-ADCA. It is known that 
NCPC is developing biotechnological production 
routes for future production processes. It cannot 
be predicted how this will influence the current 
world market structure.
Example: Biotechnological production of 
riboflavin
Riboflavin (Vitamin B2) is a water-soluble 
vitamin that is an essential nutritional ingredient 
for humans and animals. Deficiency can lead 
to skin disorder, retarded growth, diarrhoea, 
and, in animals, to poor feed utilisation and 
impaired reproduction. Commercial riboflavin 
is primarily used as a feed additive (70%), rather 
than for dietary purposes (30%). The worldwide 
production volume is about 4000 tonnes/year 
(2000393). The biotechnological production 
process (fermentation processes partly using 
genetically modified microorganisms) has 
now largely replaced the intensive, multi-step 
chemical production process since it was first 
introduced in 1990 (accounting for more than 
75% of production in 2002)394. According to the 
industry experts interviewed, about 3000 tonnes 
are produced using a fermentation process (30% 
in the EU and 70% in Asia). On average, the 
fermentation process yields 80% pure riboflavin, 
which is sufficient for feed applications, while 
the chemical process yields 96% pure riboflavin, 
which corresponds better to the purity needs for 
food applications, in particular for baby food with 
its particularly high purity standards395.
In the EU, two companies produce 
riboflavin by fermentation processes. BASF in 
Germany produces about 1000 tonnes or 25% 
of the world market. However, the production 
site was moved to South Korea in 2003. DSM, 
Netherlands, has a production capacity of about 
2000 tonnes. Recently, other major producers 
have been emerging in China. The world market 
for riboflavin is estimated at about EUR 55-60 
million, which indicates an average price of 
EUR 15/kg riboflavin396. Asia accounts for about 
30% of the market, North America and Mexico 
for about 50%, and the EU for about 20%397. 
Chinese manufacturers seem to have increased 
their production and exports of riboflavin and 
increased their share of the EU market, from 4% 
in 1999 to about 24% in 2003398.
The substitution of the conventional chemical 
process by the fermentation process seems to have 
resulted in significant cost reductions of between 
40% and 50%399, due to higher efficiency, lower 
material input costs and less waste production.
Example: Biotechnological production of the 
amino acid lysine
In contrast to riboflavin, the amino acid 
lysine, also a feed additive, is produced in much 
larger quantities: yearly production is estimated 
at about 1 million tonnes in 2006, up from 850 000 
tonnes in 2005400. Lysine is an essential amino acid 
393 Schmid, R.D. (2002). Taschenatlas der Biotechnologie und Gentechnik. Wiley-VCH, Weinheim.
394 BIO (2004). New biotech tools for a cleaner environment. Biotechnology Industry Organization, Washington, D.C., p. 48. 
395 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
396 Producers did not disclose current prices, and prices also seem to be rather volatile. Other sources give a range between EUR 
14/kg and EUR 32/kg (http://www.feedinfo.com/).
397 According to industry experts interviewed; other sources give a range between 27-35% (ETEPS (2006). Bio4EU Task 2 Case 
studies report – Industrial Biotechnology Applications).
398 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
399 OECD (2001). The application of biotechnology to industrial biotechnology. OECD, Paris. EuropaBio (2003). White 
biotechnology: gateway to a more sustainable future. EuropaBio, Brussels. 
400 Ajinomoto (2005). FY2005 market and other information. Materials for the analysts’ meeting for the interim period ended 
September 30. Ajinomoto, Tokyo. http://www.ajinomoto.com/ar/i_r/ir_event.html.
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that has to be taken with food or feed in sufficient 
amounts to meet the nutritional requirements 
of animals and humans. The limited availability 
in cereal-based feed requires the addition of 
lysine rich-soy beans or pure lysine to the feed. 
Livestock would otherwise have to ingest more 
feed to satisfy their lysine needs, resulting in less 
efficient overall feed use. Lysine nowadays is 
produced exclusively by fermentation processes, 
which have now completely replaced chemical 
production.
The world market for lysine is about EUR 1.0–1.2 
billion (based on a product price of EUR 1.2/
kg401). Lysine is an important product in the feed 
sector, representing about 80% (by value) of all 
amino acids produced for feed (approx. EUR 1.5 
billion) and 26% of the feed additives market 
(EUR 4.8 billion, including amino acids, vitamins, 
acidifiers, antibiotics, enzymes, and minerals). 
More than one third of the feed additives market, 
even if only amino acids are considered, is based 
on modern biotechnology. Vitamins, enzymes, 
and antibiotics add to that share.
Four companies in the EU represent about 
40% of world production, although the production 
itself takes place to a large extent in non-EU 
countries (South Korea, USA). Only three factories 
produce lysine within the EU, in France, Italy and 
Denmark, with an output of 130 000 tonnes (13% 
of world production). As with riboflavin, Asia 
seems to be an important market and production 
location for feed additives with about 43% of 
world production in Indonesia, South Korea and 
China, the latter alone accounting for 25%.
Based on feed consumption data for Western 
Europe, it is estimated that the EU requires 
about 268 000 tonnes of lysine. This is twice the 
amount of EU production. While the EU is the 
largest market (27%), EU companies are however 
moving production to low-cost countries (with 
low wage and/or raw material costs) and turning 
to higher-value products such as the amino acids 
threonine or tryptophane402.
Production of biotechnology-based polymers
Plastics or polymers are currently the most 
used materials worldwide, in packaging materials 
(37% of the plastics market), in building and 
construction (20%), in the electrical industry 
(8%), for automotive uses (8%), in furniture 
(4%), in household goods (9%), or in agriculture 
(2%)403. The worldwide production volume 
in 2004 was 224 million tonnes. However, 
production is based on petrochemicals, i.e. non-
renewable resources, and the raw materials and 
products are mostly not biodegradable (although 
biodegradable polymers can also be produced 
using fossil sources). In contrast, the production 
and use of biotechnology-based polymers could 
reduce the use of oil-based products and waste. 
The analysis here focuses on polymers whose 
production includes a biotechnological step. 
Starch- and cellulose-based polymers developed 
from plant material, already known and used for 
several decades, are not included404. In contrast 
to the other biotechnology processes described 
above, the production of biotechnology-based 
polymers is still in an early development phase.
There are several types of biotechnology-
based polymers:
− Lactic-acid based: Starch or sugar is 
fermented to produce lactic acid, which can 
be dried and extruded to obtain thermoplastic 
properties, e.g. Solanyl®, based on potato 
waste, produced by Rodenburg Biopolymers, 
the Netherlands (40 000 tonnes/year). Other 
401 Ajinomoto (2005). FY2005 market and other information. Materials for the analysts’ meeting for the interim period ended 
September 30. Ajinomoto, Tokyo. http://www.ajinomoto.com/ar/i_r/ir_event.html.
402 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
403 PlasticsEurope (2007). Plastic demand by end-use application sector 2004 (W. Europe). PlasticsEurope, Brussels. http://www.
plasticseurope.org/content/default.asp?PageID=103.
404 A comprehensive overview of biobased polymers including all types of products is given in: Patel, M., M. Crank and O. Wolf 
(eds) (2005). Techno-economic feasibility of large-scale-production of bio-based polymers in Europe. European Commission, 
DG JRC/IPTS, EUR 22103, pp. 35-36. 
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EU producers are: PURAC, the Netherlands 
(80 000 tonnes/year) and Galactic, Belgium 
(25 000 tonnes/year). Lactic acid can also be 
chemically polymerised to form poly-lactic 
acid (PLA), which can be further used to 
make fibres, films, etc. (e.g. Nature Works®, 
using maize starch — Nature Works LLC, 
USA, 140 000 tonnes/year405). Applications 
include food packages, carpets, or PC body 
components.
− Polyhydroxyalkanoates (PHA) are natural 
polymers produced by bacteria through 
fermentation from sugar or lipids as feed 
stock. The company Metabolix (USA) 
has developed an enzyme-catalysed 
polymerisation process for the production 
of very pure PHA for medical applications. 
Further process development includes the 
use of whole-cell biocatalysis to reduce 
production costs and improve purification406. 
Metabolix currently produces about 1000 
tonnes per year in a pilot plant (Biopol®). 
Procter&Gamble (USA) reports production 
capacities of about 250 tonnes/year of 
PHA407.
− Bio-PDO (1,3-propanediol) produced via 
fermentation of maize-derived sugar is 
used for the production of polytrimethylene 
terephthalate (PTT), a new type of 
polyester fibre (Sorona®), which is not 
biodegradable. The fibre can be used e.g. 
for carpet and clothing manufacturing. A 
genetically modified bacterium is used for 
the fermentation process. In a joint venture 
with Tate&Lyle (UK), DuPont (USA) will 
increase production in the USA in 2006 
to about 23 000-45 000 tonnes.
− The oldest process using biocatalysts in 
polymer production is the conversion of 
acrylonitrile to acrylamide with the help of 
a recombinant enzyme. Acrylamide can be 
further polymerised to polyacrylamide. This 
is one of the first large-scale biotechnological 
applications of enzymes in bulk chemical 
production. Mitsubishi Rayon Co. LTD (Japan, 
formerly Nitto Chemical Industry) is the 
largest producer of acrylamide (about 20 000 
tonnes/year). Overall worldwide production 
of biotechnology-based acrylamide is about 
100 000 tonnes/year, produced mainly in 
Japan.
Economic significance
In the EU, eight companies were identified 
as active in bio-based polymer production 
(Table 2.11). Overall production volumes of 
biotechnology-based polymers have been 
estimated to be around 148 000 tonnes per year 
in the EU. Compared to 32.5 million tonnes of 
oil-based polymers, this is a marginal share of 
0.13%408. EU producers are still few in number, 
and are mostly operating on a pilot scale. 
The market value is estimated at about EUR 
55.3 million, 7% of the world production of 
biotechnology-based polymers409. The GVA is 
estimated at about EUR 11.3 million, or 0.0001% 
of EU GVA.
The world production of biotechnology-
based polymers is estimated to be around at 
least 390 000 tonnes/year (148 000/year tonnes 
in the EU, 140 000 tonnes/year NatureWorks 
in the USA, 100 000 tonnes/year biotechnology-
based acrylamide mainly in Japan). Compared 
to the combined plastics output in the EU, the 
USA and Japan of 98 million tonnes/year, this 
amounts to a share of 0.45%, indicating a higher 
share of biotechnology-based polymers in Japan 
405 Natureworks maintains two production facilities in Blair, Nebraska (US). One produces lactic acid, which is used in different 
food and non-food applications. Most of the output feeds into the second plant, which produces 140kt PLA/year.
406 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
407 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
408 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
409 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
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and the USA. This is partly due to national policy 
initiatives to support non-petrochemical-based 
product development.
While biotechnology-based polymers are still 
more expensive than their oil-based counterparts, 
the competitiveness threshold also depends 
on technical requirements and the end-user 
market and thus might differ strongly between 
different applications. Due to low production 
volumes the current impact of biotechnology-
based polymers is marginal in the EU. However, 
production capacities are growing worldwide, 
and price reductions are expected for nearly all 
biotechnology-based polymers in the near and 
mid-term future. The average price of oil-based 
polymers today is around 0.75 EUR/kg. It seems 
that Solanyl®, with a relatively high current 
production volume, is the only biotechnology-
based polymer that comes near the price of oil-
based polymers (1.13 EUR/kg410).
The competitiveness gap is expected to shrink 
in the future with increasing production volumes, 
but in the coming five years biotechnology-
based polymers are not expected to contribute 
massively to the market for primary plastics, apart 
from highly specialised applications.
No evidence is available on the employment 
effects of biotechnology-based polymers, 
but based on current production volumes, 
the employment effects can be regarded as 
negligible.
Environmental implications
The production of biotechnology-based 
polymers could lead to reductions in energy 
consumption and greenhouse gas production 
(CO2) (Table 2.12). The impact depends on 
the polymer in question and the polymer it is 
compared to. A PLA-based polymer such as 
Solanyl® or NatureWorks® uses 20%-50% 
less energy compared to polyethylene or other 
bulk plastics, and has about 50%-70% lower 
CO2 emissions (in the case of NatureWorks®). 
Table 2.11 EU companies producing biotechnology‑based polymers
410 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
Company Product Production volume
Rodenburg BioPolymers, The 
Netherlands
Solanyl® (lactic-acid based 
polymer) 40 000 tonnes/year
Tate & Lyle, UK 1,3 Propanediol
Joint venture with DuPont, USA; 
planned production in the USA
23 000 to 45 000 tonnes/year
Hycail (taken over by Tate & Lyle in 
2006), The Netherlands/UK Poly-lactic acid Pilot plant
Uhde Inventa-Fisher, Germany Poly-lactic acid Pilot plant
PURAC, Netherlands Poly-lactic acid 80 000 tonnes/year
Galactic, Belgium Poly-lactic acid 25 000 tonnes/year
Biomer, Germany Biomer ® (Poly-hydroxy-butyrate) 
Boehringer Ingelheim, Germany Poly-lactic acid (Resomer®)
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Additionally, an indirect reduction in CO2 
emissions can be expected from the lower 
energy consumption. In the case of acrylamide 
production, the enzymatic process yields a 30% 
reduction in energy consumption and a 25% 
reduction in CO2 emissions
411. For Bio-POD, 
energy savings of about 16% have been identified, 
thus also indirectly reducing CO2 emissions. 
There is no difference in the CO2 emissions of the 
production process.
Ongoing research will influence the 
environmental impacts of biotechnology-based 
polymer production. The use of plants to produce 
PHA could replace the current fermentation process 
with potentially positive effects on energy use and 
CO2 emissions. The use of lignocellulosic biomass 
as a raw material for PLA production instead of 
maize starch is expected to reduce the fossil energy 
requirements for production by 80%413.
The advantage of biotechnology-based 
polymers such as PLA is that they can be 
composted, incinerated, or re-used in pre-
consumer recycling or post-consumer recycling/
recovery. In the case of composting, tests have 
shown that PLA polymers can be composted in 
full compliance with DIN, ISO, CEN and ASTM414 
regulations. When incinerated, PLA produces 
fewer by-products than traditional polymers and 
also has a lower energy content. Pre-consumer 
recycling studies show that PLA can be used 
in thermoforming like any other polymer. In 
post-consumer recycling, a separate collection 
system needs to be put in place415, which implies 
that these polymers need to be distinguishable 
from oil-based polymers. Normally, however, 
end consumers cannot be expected to tell the 
difference, so they will not be in a position 
to collect biotechnology-based polymers 
separately. As a result, oil- and biotechnology-
based polymers could enter the same waste 
streams. Biotechnology-based polymers are not 
compatible with the existing oil-based polymer 
recycling system and could negatively impact on 
the product quality of recycled polymers.
411 OECD (2001). The application of biotechnology to industrial sustainability. OECD, Paris, p. 74. 
412 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
413 OECD (2001). The application of biotechnology to industrial sustainability. OECD, Paris, p. 88.
414 DIN: Deutsches Institut für Normung, Germany; ISO: International Organization for Standardization; CEN: European Committee 
for Standardisation; ASTM: American Society for Testing and Materials.
415 OECD (2001). The application of biotechnology to industrial sustainability. OECD, Paris, p. 89.
Table 2.12: Environmental impacts of biotechnology‑based polymers: energy consumption and CO2 
emissions412
Polymer Energy consumption Direct CO2 emissions
Production of Solanyl® compared to 
conventional oil-based plastics
40% less than bulk plastics such as 
polyethylene No data available
Production of NatureWorks® compared 
to conventional oil-based plastics
20%-50% less than other plastics (PET, 
HDPE, Nylon-6) 50%-70% less
Production of BioPDO-based 
polytrimethylene terephthalate compared 
to conventional oil-based plastics
16% less than polyethylene terephthalate
No difference
(indirect effects not 
included) 
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2.3.2	 Modern	biotechnology	in	the	production	
of	biofuel	-	bioethanol
Rising oil prices, dwindling fossil fuel reserves 
and concerns about climate change due to increasing 
CO2 levels in the atmosphere have put renewable 
energy sources on the agenda worldwide. One 
important alternative energy source is biomass, and 
bio-based fuels in particular have received wide 
attention recently. Bioethanol, which is produced 
by conversion of plant biomass into ethanol by 
biocatalysis and can be used as a transport fuel, is the 
most important application of modern biotechnology. 
For all energy production from biomass, modern 
biotechnology could also play a role on the biomass 
production side, with an impact on development of 
energy crops. However, this analysis will focus on 
the biomass processing side.
Bioethanol is the product of a fermentation 
process usually using yeasts, with glucose sugar 
as a substrate. In the EU bioethanol is produced 
mostly from wheat, sugar beet and grapes. Wheat 
is the most important raw material. Conversion 
of wheat starch into glucose requires enzymatic 
hydrolysis. The enzymes – recombinant amylases 
– account for only a small fraction of the costs 
of bioethanol production.416 R&D efforts are 
focusing on improving the fermentation process 
in order to be able to use other raw materials, 
such as wood, straw or grass (lignocellulosic 
material) (see also Chapter 2.3.4) 417. In the USA 
bioethanol is produced from maize by means of 
a similar process as in the EU. In Brazil, currently 
the largest bioethanol producer in the world, 
sugar cane is used, which requires no enzymatic 
pre-treatment.
Economic significance
Worldwide, 79% of the bioethanol produced 
is used as transport fuel.418 Between 1975 and 
2005 world fuel ethanol production increased 
steadily. It has more than doubled in the last five 
years. Up until now Brazil has been the largest 
bioethanol producer; it has by far the highest 
share of bioethanol in national liquid transport 
fuel consumption (14%). The USA has increased 
its production considerably over the last six 
years and now has a worldwide share of 45% 
(see Figure 2-20). The EU’s share of worldwide 
production in 2005 was 2.6%, making it a small 
international player compared with China, for 
example, which increased its share from 1.2%-
5.5% of world production in three years. Japan 
does not produce bioethanol as a transport fuel, 
but imported around 400 000 tonnes in 2004 and 
2005.
Figure 2‑20 Global bioethanol fuel 
production (thousand tonnes) by year and 
country
RoW: rest of the world.
Source: ETEPS, BMELV and IEA419.
 
In contrast to fossil fuel production, 
bioethanol production is a young industry 
which is undergoing rapid economic and, in 
particular, technological development. Table 2.13 
shows basic figures on the eco-nomic impact of 
416 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
417 Herrera, S. (2006). Nature Biotechnology 24(7): 755-760.
418 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
419 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications, Report prepared by the Worldwatch 
Institute for the German Federal Ministry of Food, Agriculture and Consumer Protection (2006), Biofuels for transportation, 
Washington D.C., and International Energy Agency (2004), Biofuels for transport-An international perspective. Paris.
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bioethanol production in comparison with fossil 
fuel production. By volume, in 2005 bioethanol 
production was equivalent to about 0.1% of 
fossil fuel production. Large-scale fossil fuel pro-
duction facilities produce, on average, 60 times 
more than biofuel production plants. In 2005, 
525 people were employed directly (and around 
5 000 indirectly) in fuel ethanol production, 
which corresponds to around 0.015% of all EU 
employment in manufacturing or 0.0003% of EU 
employment.
Table 2.13 also shows that the average 
production costs of bioethanol exceeded fossil 
fuel production costs by 60% in 2005.420 Due 
to the lower energy content of bioethanol, the 
production costs per unit energy equivalent 
were about 130% higher than for fossil fuel in 
2005. However, compared with 2004, the cost 
differences have narrowed (in 2004 production 
costs per litre of bioethanol were 150% higher 
and production costs per unit energy equivalent 
270% higher). Future cost trends for biofuels can 
be predicted, on the basis of past experience, 
only within certain limits. Growth of production 
volumes from individual crops is limited due 
to geographical dependence on raw material 
supplies (biomass). And, related to that, large-
scale production of biofuels has repercussions for 
the raw material price itself, which might offset 
any cost reductions as a result of efficiency gains.
Bioethanol production in the EU shows large 
differences in output from year to year, but overall 
strong growth, by more than 100% between 2002 
and 2005. This is reflected in the increase in the 
number of biofuel refineries in the EU, from 16 
in 2004 to 23 in 2005, with eight more planned. 
There are several reasons for this development, 
such as technological progress, recent changes in 
the market price for crude oil and, in reaction to 
that, a changing legal framework at both national 
and EU levels. The EU set a target of 5.75% for 
biofuel’s share of all road transportation fuel in 
the EU,421 which was recently increased to 10% 
by 2020.422 Some Member States are already 
designing their national policies accordingly, such 
as the Netherlands or Germany, which recently 
420 The price per unit for biofuel is indicative and differs slightly, depending on the raw material and production pathways. The 
cost comparison with fossil fuel should, however, give an idea of the approximate range.
421 Directive 2003/30/EC of the European Parliament and of the Council on the promotion of the use of biofuels or other renewable 
fuels for transport, OJ L 123, 17.5.2003, p. 42.
422 Brussels European Council, 8 and 9 March 2007, Presidency conclusions.
Table 2.13 Comparison of the contribution of fossil fuel and bioethanol to the EU economy
Fossil fuel in the EU Bioethanol in the EU
Share of GVA 0.25% 0.0002%*
Share in manufacturing (NACE D) 1.10% 0.00231%
Employment: direct
   
indirect
40 000 525 
approximately 100 000 approximately 5 000
Contribution to employment in Europe (based on 
direct employment) 0.05% 0.0003%
Turnover per employee e5 300 000 e800 000
Production cost per litre e0.33 e0.53
Production cost per litre gasoline equivalent r0.33 e0.76
Total production 600 000 000 t* 750 000 t
Average output per plant 6 000 000 t/year 100 000 t/year*
Number of refineries 104 (2005) 16 (2005), 23 (2006)
Sales e139 billion e192 million
Imports 13% 
Data from the most recent year available in each case (i.e. 2002-2006). *Estimate.
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announced an obligatory share of 10% for biofuel 
by 2014.423 The USA has announced that biofuels 
will cover 30% of its national fuel supply by 
2030.424 Availability of a bioethanol production 
process based on lignocellulose instead of sugar 
is the precondition for reaching the US target 
of 30%. Accordingly, research funds and other 
subsidies are being made available for that area 
in particular. Total subsidies for bioethanol in the 
USA have reached USD 5.1 billion to 6.8 billion 
a year and are expected to rise further during the 
next five years.425 As a result, companies such as 
Novozymes (enzyme development) and Broin 
(the largest dry mill ethanol producer in the USA) 
have announced that they are collaborating to 
speed up development of cellulosic ethanol.426
Environmental implications
Production of bioethanol and substitution of 
fossil transport fuels have an impact on several 
dimensions of the environment, mainly less 
depletion of non-renewable fossil fuel resources 
and a reduction of greenhouse gas (GHG) 
emissions. The environmental impact differs in 
scale, depending on the production path chosen. 
Further factors influencing the environmental 
impact are the share of imports from non-EU 
regions, the mix between diesel and gasoline, the 
blending and the (future) shift from first-generation 
to second-generation fuel, i.e. to lignocellulosic 
biomass.
Table 2.14 shows that, for both diesel and 
gasoline (petrol) alike, substitution by biofuels 
reduces GHG emissions. As biodiesel production 
does not involve modern biotechnology, only the 
implications of bioethanol production are taken 
into consideration here. Bioethanol produced 
from wheat reduces GHG emissions by about 
50%, from 3.62 tCO2eq/toe to 1.85 tCO2eq/
toe. Wheat is the main raw material used for 
bioethanol production in the EU. The table also 
shows that biofuel production from lignocellulosic 
biomass (straw or wood) reduces GHG emissions 
by up to 90%.
Table 2.14 GHG emissions from different biofuels427
BTL: biomass to liquid; toe: tonne of oil equivalent; n.a.: not available; *chemical transformation.
423 FTD (2006). “Koalition zwingt Ölkonzernen zehn Prozent Biosprit auf.“ Financial Times Deutschland (Hamburg), online 
version 24 October. 
424 DOE (2006). DOE publishes roadmap for developing cleaner fuels. Press release, 7 July. U.S. Department of Energy, Washington, 
D.C. http://www.doe.gov/news/3804.htm.
425 Koplow, D. (2006). Biofuels – at what cost? Government support for ethanol and biodiesel in the United States. The Global 
Subsidies Initiative, International Institute for Sustainable Development, Geneva. 
426 Novozymes (2006). Broin and Novozymes to collaborate on development of ethanol from cellulosic biomass. Press release, 
26 October. Novozymes, Bagsværd.  http://www.novozymes.com/en/MainStructure/PressAndPublications/PressRelease/2006/
NzBroinBiomass.htm.
427 European Commission SEC (2006) 1721/2: Commission Staff Working Document Review of economic and environmental data 
for the biofuels progress report, p. 20. 
Greenhouse gas emissions
(tCO2eq/toe)
Savings (%)
Diesel (3.65)
Biodiesel from rape* 1.79 51
Biodiesel from soy* 2.60 29
Biodiesel from palm* 1.73 53
BTL from straw n.a. n.a.
BTL from farmed wood 0.27 93
Petrol (3.62)
Ethanol from sugar beet 2.17 40
Ethanol from wheat 1.85 49
Ethanol from sugar cane 0.41 89
Cellulosic ethanol from straw 0.333 91
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The EU has set out to replace 5.75% of fossil 
transport fuels by biofuels or renewable fuels 
by 2010 and 10% by 2020.428 Currently 7.9% 
of GHG emissions are generated by oil-based 
gasoline. Hypothetical substitution of 100% of 
gasoline by ethanol from wheat would lead to 
a 4% reduction in all GHG emissions, given the 
50% CO2 reduction achievable with bioethanol 
(assuming unchanged demand for transport 
fuel). In all, applying a share of only 5.75% for 
bioethanol produced from wheat would lead to 
a reduction in GHG emissions of about 0.23%. 
This calculation takes into account the whole 
lifecycle. There are other production pathways, 
one of which is estimated to lead to higher 
GHG emissions than the fossil fuel it replaces. In 
absolute terms, real CO2 savings in the EU due to 
ethanol were 0.7 MtCO2eq in 2005.
429
However, the potential GHG reduction 
depends on several factors. As discussed above, 
savings of CO2 emissions can be offset if raw 
materials for biofuels are grown on inappropriate 
land, for example if wetlands are chosen. The CO2 
balance could be neutralised or even reversed to 
negative. Another relevant environmental issue 
to be considered is biodiversity, which might be 
threatened by large-scale growth of raw materials 
for biofuels. However, according to the European 
Environment Agency, enough biomass can be 
produced in the EU to cover even high demand 
for biofuel production.430 Accordingly, the 
challenge seems not to be a bottleneck in land 
availability, but to identify appropriate land for 
growing raw materials for biofuels.
2.3.3	 Modern	biotechnology	in	bioremediation
Bioremediation is the collective term for 
treatment of contaminated water, soil, air and 
solid waste with living organisms, mostly micro-
organisms, to degrade or transform hazardous 
organic contaminants. These end-of-pipe 
applications of biotechnology were developed 
from the 1970s and 1980s onwards.
Amongst the different applications, 
biotechnological waste water treatment has the 
longest tradition, whereas biotechnological air 
filters and specific waste treatments are more 
recent. The mechanism is similar in all these 
applications, in that micro-organisms adapted 
to degradation of specific pollutants are used to 
decontaminate environmental media. This can be 
done on-site, which is usually the more economic 
solution, or off-site, which entails transporting 
contaminated material to a decontamination 
site. Often the most suitable micro-organisms 
are found in the direct environment of the 
contaminated material.
Bioremediation has been thoroughly 
reviewed by the OECD, which collected a number 
of examples.431 For air and off-gases, micro-
organisms in peat and compost beds are able to 
break down simple volatile organic compounds 
and reduce odours; at the same time these 
processes are often simpler and cheaper than the 
alternative chemical approach. Contaminated 
soils can be treated “in situ” by injecting 
nutrient solutions and/or air to support microbial 
activity (“biostimulation”). Bioaugmentation 
– introduction of specific strains or consortia of 
micro-organisms on the contaminated site to 
improve the capacity for pollutant degradation – is 
at a comparatively early stage of development.432 
Another biological soil remediation method is “ex 
situ”, which ranges from simple composting to 
soil-flushing techniques. Solid waste treatment is 
similar to soil clean-up techniques. Solid organic 
waste can be degraded in the presence of oxygen 
428 Directive 2003/30/EC of the European Parliament and of the Council on the promotion of the use of biofuels or other renewable 
fuels for transport, OJ L 123, 17.5.2003, p. 42; Brussels European Council, 8 and 9 March 2007, Presidency conclusions.
429 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
430 EEA (2005). How much biomass can Europe use without harming the environment? Briefing, European Environment Agency, 
Copenhagen. 
431 OECD (1994). Biotechnology for a clean environment. OECD, Paris. 
432 El Fantroussi, S. and S.N. Agathos (2005). Current Opinion in Microbiology 8: 268-275.
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in landfills and during composting. Degradation 
in an oxygen-depleted environment produces 
usable methane. Waste water treatment has the 
longest record of applying micro-organisms 
for clean-up purposes with several different 
technologies.433
Currently, limited use is made of modern 
biotechnology in bioremediation. It is used, 
for example, to support efficient production 
of enzymes,434 which are employed, inter alia, 
to clean up pesticide residues. In this case, 
the enzyme is isolated from bacteria in the 
environment of the pollutants, cloned into a 
common bacterium, produced by industrial-
scale fermentation and then applied in 
decontamination.435
The fact that micro-organisms are able 
to adapt to degradation of a wide range of 
problem pollutants, such as chlorinated solvents, 
sparked expectations in the 1980s that modern 
biotechnology would make it possible to 
modify micro-organisms in a way which would 
increase their degradation capacity, both by 
improving the degrading rate, i.e. enabling them 
to clean material faster, and also by making them 
applicable to a larger variety of pollutants. Steps 
have been taken in that direction, resulting in 
the first-ever patenting of a living organism, a 
Pseudomonas strain able to degrade a series of 
recalcitrant compounds.436
Use of modified micro-organisms in 
bioremediation technologies, however, faced 
several challenges. With the exception of a 
few cases, modified micro-organisms have 
performed poorly in degrading pollutants 
compared with their naturally occurring 
counterparts. One exception are transgenic 
plants for decontamination of soil, for example 
modified tobacco plants for phytodetoxification 
of explosives (TNT) in soil.437 However, this 
application is not actually being used to remove 
explosives residues from soil. In addition, the 
interaction of modified micro-organisms with the 
natural environment is difficult to predict, and 
newly introduced micro-organisms have often 
turned out to be less fit than their competitors and 
been eliminated.438 The potential risks associated 
with uncontrolled growth and proliferation of the 
GMOs in the environment and gene transfer to 
other organisms have limited the applications of 
GMOs in bioremediation up to now.
Another example of use of modern 
biotechnology in environmental applications 
is development of biosensors. Biosensors are 
analytical devices incorporating biological 
material, such as micro-organisms, enzymes, 
antibodies, etc., which are associated with or 
integrated into a physiochemical transducer 
system, which may be optical, electrochemical, 
etc.439 The system is introduced into environmental 
media, e.g. water, and gives a signal once it detects 
a specific pollutant. However, no evidence could 
be found that biosensor systems which do not 
need additional physical translation of signals are 
currently on the market – an additional readout 
system is still attached to biological systems.
2.3.4	 Emerging	 biotechnology	 applications	 in	
industrial	processes	and	energy
Recent developments, such as rising oil 
prices and growing concerns about environmental 
pollution and global warming, are turning 
increasing attention to industrial biotechnology, in 
view of the potential environmental and energy-
related benefits. The availability of advanced 
433 Gaugitsch H. and M. Schneider (1997). “Einleitung, Zusammenfassung und Bewertung.” In: Umweltbiotechnologie in 
Österreich, Schwerpunkt: Nachsorge, Monographien Band 85B, Bundesministerium für Umwelt, Jugend und Familie, Vienna, 
p. 501-510.
434 Alcalde, M. et al. (2006). Trends in Biotechnology 24(6): 281-287. 
435 Sutherland, T. and R. Russell (2002). Pesticide Outlook 13: 149-151.
436 Cases I. and V. de Lorenzo (2005). International Microbiology 8: 213-222.
437 Hannink, N. et al. (2001). Nature Biotechnology 19: 1168-1172.
438 Cases I. and V. de Lorenzo (2005). International Microbiology 8: 213-222. 
439 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.
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modern biotechnology tools, such as high-
throughput screening, metabolic engineering, 
metagenomics and synthetic biology, combined 
with genome sequence information for a growing 
number of organisms, are supporting development 
of better or new applications of industrial 
biotechnology. The main targets of research 
activities are identification of new biocatalysts 
or microorganisms for production processes and 
optimisation of enzymes and production strains 
for certain tasks, including development of new 
biocatalytic pathways in microorganisms.
New and improved approaches to industrial 
biotechnology
Currently more than 35 000 enzyme 
reactions are known440. Adding the vast number 
of microorganisms that cannot be isolated with 
current culturing techniques (it is estimated 
that only 1% of bacteria can be cultured441) 
and which are likely sources of as yet unknown 
enzymes, this provides a potentially large pool 
of enzymes for industrial purposes. Access to 
unculturable microorganisms can be opened up 
by metagenomics, i.e. isolating genetic material 
from natural sources such as soil or seawater and 
introducing it in well-known organisms such as 
Escherichia coli442.
One of the main fields for biocatalysis are fine 
chemicals, including pharmaceutical compounds. 
The high selectivity of enzymes facilitates 
synthesis of these compounds, which is otherwise 
difficult to achieve due to the highly complex 
functional groups and their localisation within 
the molecule443. Metabolic pathway engineering 
allows production not only of different complex 
compounds (e.g. polyketide, isoprenoide and 
alklaloide) but also of compounds that would 
otherwise be inaccessible because the organisms 
cannot be cultured (e.g. the cytotoxic substance 
patellamide). Modification of biosynthetic 
pathways also facilitates production of compound 
analogues and promising drug candidates (e.g. 
analogues of the substance rapamycin)444. Further 
research efforts are looking into biotechnological 
production of small molecule drug precursors. 
One example is production by recombinant 
bacteria of shikimic acid, an intermediate of the 
antiviral product Tamiflu (targeting avian flu), 
which is mostly extracted from plants445.
Wider availability of new classes of enzymes 
for industrial purposes (e.g. transaminases, 
monooxygenases and nitrilases), in addition to 
the currently most used enzymes (e.g. esterases, 
proteases and lipases), will have an impact on 
use of biocatalysis in industrial production446. 
The enzymes will catalyse reactions impossible 
to achieve by other methodologies as key steps 
in multi-step syntheses of new drugs and other 
fine chemicals. Apart from the availability of 
sufficient and inexpensive enzyme stocks, 
the enzyme activity and its robustness and 
adaptation to process conditions play a major 
role in biocatalysis. Hence, enzymes are 
subjected to optimisation processes using 
modern biotechnology tools, for example to 
increase thermostability, to reduce the optimum 
temperature or to increase their activity447. 
Enzymes from extremophilic microorganisms 
(extremozymes) are expected to play a significant 
role in industrial biotechnology due to their 
unique stability at high or low temperatures, high 
pressure, high salt concentrations and extreme 
440 Straathof, A.J.J. et al. (2002). Current Opinion in Biotechnology 13: 548-556.
441 Tringe, S.G. and E.M. Rubin (2005). Nature Reviews Genetics 6: 805-814.
442 Gewin, V. (2006). Nature 439: 384-386.
443 Pollard, D.J. and J.M. Woodley (2007). Trends in Biotechnology 25(2): 66-73.
444 Wilkinson, B. and B.O. Bachmann (2006). Current Opinion in Chemical Biology 10: 169-176.
445 Panke, S. and M. Wubbolts (2005). Current Opinion in Chemical Biology 9: 188-194.
446 Pollard, D.J. and J.M. Woodley (2007). Trends in Biotechnology 25(2): 66-73. Faber, K. and W. Kroutil. (2005). Current Opinion 
in Chemical Biology 9: 181-187.
447 Cherry, J.R. and A.L. Fidantsef (2003). Current Opinion in Biotechnology 14: 438-443.
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pH, plus their high organic solvent and metal 
tolerance448. New “natural” biopolymers (e.g. 
poly-lactic acid analogues) will be made available 
by appropriate engineering of microorganisms, 
while enzymes will be employed to produce and 
modify “non-natural polymers”.449
Bioethanol production
Biofuels, notably bioethanol, are the focus 
of efforts to diversify energy sources, increase the 
share of renewable energy sources and reduce 
greenhouse gas emissions. The current bioethanol 
production process, based mainly on sugar and 
starch, will most probably not be able to produce 
the required quantities of bioethanol in the long 
term and has limitations in terms of reduction 
of greenhouse gas emissions450. Research is 
therefore focusing on “second generation” 
bioethanol, based on non-food lignocellulosic 
feedstock or biomass, e.g. agricultural residues, 
wood, municipal solid waste or dedicated 
energy crops. The compactness and complexity 
of lignocelluloses poses technical and economic 
challenges with, among others, depolymerisation 
of cellulose and hemicellulose and fermentation 
of the resulting mix of sugars451.
Cellulose and hemicellulose are degradable 
by enzymes (cellulases and hemicellulases). New 
cellulases and hemicellulases have been isolated 
from microorganisms in recent years. These 
cellulases are still comparatively costly and show 
low catalytic activity.452 An alternative approach 
is focusing on plants (see also Chapter 2.2.3). 
Genetic engineering is attempting to develop 
plants that produce less lignin. This would 
reduce the need to pretreat biomass to facilitate 
cellulose depolymerisation. Another approach 
has developed cellulase- and ligninase-producing 
plant varieties as biofactories for cost-efficient 
production of these enzymes or as direct input 
into the process with the biomass. Yet another 
approach is targeted at increasing the biomass 
yield from dedicated energy crops453.
For fermentation of sugar to ethanol, yeast 
(Saccharomyces cerevisiae) is usually used. 
However, lignocellulose depolymerisation 
results in a mix of sugars, mainly glucose (hexose 
sugar) and xylose (pentose sugar). The latter is 
not metabolised by most strains of S. cerevisiae. 
Therefore, using genetic engineering, current 
research efforts are focusing on introducing 
new pentose metabolic pathways into yeast 
and other ethanologenic microorganisms or on 
improving ethanol yields in microorganisms 
that can metabolise the sugar mix454. The recent 
sequencing of the genome of a xylose fermenting 
yeast will feed into these developments455.
Currently only a few pilot plants are producing 
bioethanol from lignocellulosic feedstock using 
an enzymatic hydrolysis process456. In the long 
term, development of integrated biorefineries is 
envisaged, combining production of biofuels and 
co-products such as commodity chemicals and 
materials, thereby making the biofuel production 
process more efficient and competitive457.
Apart from bioethanol, efforts are also being 
made to apply biotechnology to production of 
other biofuels. In the case of biodiesel production, 
448 Egorova, K. and G. Antranikian (2005). Current Opinion in Microbiology 8: 649-655. Van den Burg, B. (2003). Current Opinion 
in Microbiology 6: 213-218.
449 Gross, R.A. et al. (2001). Applied Microbiology and Biotechnology 55(6): 655-660.  
450 Hahn-Hägerdal, B. et al. (2006). Trends in Biotechnology 24(12): 549-556.
451 Schubert, C. (2006). Nature Biotechnology 24(7): 777-784.
452 Hahn-Hägerdal, B. et al. (2006). Trends in Biotechnology 24(12): 549-556. Gray, K.A. et al. (2006).
 Current Opinion in Chemical Biology 10: 141-146.
453 Sticklen, M. (2006). Current Opinion in Biotechnology 17, 315-319.
454 Gray, K.A. et al. (2006). Current Opinion in Chemical Biology 10: 141-146.
455 Jeffries, T.W. et al. (2007). Nature Biotechnology 3: 319-326.
456 Lin, Y. and S. Tanaka (2006). Applied Microbiology and Biotechnology 69: 627-642. Hahn-Hägerdal, B. et al. (2006).
 Trends in Biotechnology 24(12): 549-556.
457 Biofuels in the European Union: A vision for 2030 and beyond. Final draft report of the Biofuels Research Advisory Council, 
14 March 2006. See also European Technology Platforms on Sustainable Chemistry and on Biofuels (http://www.europabio.
org/ne_WBTP.htm; http://www.biofuelstp.eu/).
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research is being carried out to replace the 
alkali-catalysed transesterification step with a 
biocatalytical step using lipases458. Biobutanol is 
the target of another initiative with sugar beet as a 
feedstock. Again the long-term objective is to use 
lignocellulosic feedstock459.
Synthetic biology
Another recently emerging approach, 
making use of the increased knowledge on 
genes and genome organisation and modern 
biotechnology tools such as DNA synthesis 
and genetic engineering, is synthetic biology. 
Synthetic biology is defined as “the engineering 
of biological components and systems that do not 
exist in nature and the re-engineering of existing 
biological elements; it is determined on the 
intentional design of artificial biological systems, 
rather than on the understanding of natural 
biology”460.
Synthetic biology is considered to have 
great potential for creating organisms to carry 
out specific tasks and reaching beyond current 
genetic engineering of existing organisms. 
However, synthetic biology is still at an early 
stage of development and largely coincides with 
recombinant DNA technology461. Related research 
activities are focusing on building living organisms 
from scratch (e.g. assembly of the infectious 
genome of a bacteriophage from synthetic 
oligonucleotides462) or on creating a minimal 
microorganism, currently through a top-down 
approach identifying the set of essential genes463.
The first building blocks for synthetic biology 
have been developed. These are DNA strands with 
certain functions and universal connectors at each 
end so that they can be linked to and integrated 
in a cell’s DNA464. Construction of a minimal cell 
based on small molecules is expected to facilitate 
the production of new proteins difficult to express 
by standard approaches and creation of useful 
microorganisms465. For example, use of non-
natural amino acids for development of proteins 
with new properties could lead to new drugs466.
Other potential applications of synthetic 
biology envisaged include molecular devices for 
tissue repair or regeneration, smart drugs, in vivo 
synthesis of small-molecule pharmaceuticals (e.g. 
complex natural products such as antibiotics), 
bulk chemical production, bioremediation, energy 
production, smart materials, biomaterials and in 
sensor and detection systems, e.g. for detection 
of chemicals or for diagnostic purposes467. One 
of the first applications considered as an example 
of synthetic biology is creation in yeast of the 
metabolic pathway for a precursor of the malaria 
drug artemisinin, which is in short supply and 
unaffordable for many malaria patients. 468
The possibility of creating artificial life forms 
raises several concerns. Apart from the potentially 
negative environmental impact, contamination 
of the natural genome pool and the risk that 
the approach could be used for bioterrorism 
attacks, creation of new life forms also raises 
ethical issues469. While the scientific community 
is discussing these issues and a self-regulating 
458 Shah, S. and M.N. Gupta (2007). Process Biochemistry 42: 409-414.
459 Sanderson, K. (2006). Nature 444: 673-676. Hatti-Kaul, R. et al. (2007). Trends in Biotechnology 25(3): 119-124.
460 SynBiology (2006). An analysis of synthetic biology research in Europe and North America.
 http://www2.spi.pt/synbiology/documents.asp. 
461 Brenner, S.A. and A.M. Sismour (2005). Nature Review Genetics 6: 533-543.
462 Smith, H.O. et al. (2003). PNAS 100(26): 15440-15445.
463 Glass, J.I. et al. (2006). PNAS 103(2): 425-430.
464 E.g. http://www.biobricks.org/ and: The Economist (2006). Life 2.0. The Economist (London), 31 August.
465 Forster, A.C. and G.M. Church (2006). Molecular Systems Biology 2: 45-.
466 Synthetic Biology – Applying Engineering to Biology. Report of a NEST High-Level Expert Group (2005). European Commission, 
DG Research, EUR 21796.
467 Synthetic Biology – Applying Engineering to Biology. Report of a NEST High-Level Expert Group (2005). European Commission, 
DG Research, EUR 21796.
468 Ro, D.K. et al. (2006): Nature 440(7086): 940-943.
469 ETC (2007). Extreme genetic engineering: an introduction to synthetic biology. ETC Group, Ottawa, O.N.  Bhutkar, A. (2005). 
Journal of Biolaw & Business 8: 2. Brenner, S.A. and A.M. Sismour (2005). Nature Review Genetics 6: 533-543.
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approach470, a coalition of 35 non-governmental 
organisations is calling for an inclusive public 
debate471.
2.3.5	 Summary
Economic significance and contribution to 
employment
Modern biotechnology has found its way 
into many different industrial manufacturing 
processes. Measured in terms of contribution to 
the EU’s GVA, about 45% of all manufacturing 
sectors use modern biotechnology. The subsectors 
where modern biotechnology is actually applied 
(excluding pharmaceuticals) account for 14.4% 
of GVA in manufacturing industry and 2.51% 
of EU GVA (see Table 2.15). Uptake of modern 
biotechnology in these subsectors differs, as does 
their economic contribution. Food processing 
(0.8% of EU GVA), detergents (0.05%) and 
textile finishing (0.02%) are the three subsectors 
considered to make the highest economic 
contribution. This also reflects comparatively 
high (and early) uptake of modern biotechnology 
Table 2.15 Contribution of modern biotechnology in industrial processes to EU gross value added 
and to employment472
Year: 2002 Share of
EU GVA (%)
Share of EU employment 
(%)
Labour productivity
EU gross value added (all economic 
activity
100.00 100.00 1.0
Manufacturing total
17.41 16.50 1.1
DG 24.66 Manufacture of other chemical 
products** 0.09 0.06 1.5
Enzyme production* 0.0084 0.0030 2.8
DG 24.51 Manufacture of soap, detergents, 
cleaning and polishing** 0.09 0,06 1.5
Enzyme-containing detergents* 0.05 0.03 1.7
DA 15 Manufacture of
food products** 2.06 2.22 0.9
Enzyme-using food production 
segments***
0.8 0.69 1.2
DE 21.11 Manufacture of pulp* 0.02 0.01 2.1
Manufacture of pulp-using enzymes* 0.0034 0.0015 2.3
DB 17.3 Finishing of textiles 0.05 0.06 0.8
Textile finishing with enzymes* 0.02 0.02 0.9
DF 23.2 Refined petroleum products 
(calculated with 0.8 ratio to focus on fuel) 0.20 0.33 3.7
Bioethanol**** 0.0002 0.0003 0.7
Total sectors 2.51 2.46 1.0
Total of enzyme–based processes 0.88 0.75 1.2
* Estimate: Upper employment estimate used for calculation of labour productivity.
** 2003 data.
*** In the NACE sector “bread, pastry cakes” only industrial production has been included.
**** 2005 data, only direct employment counted.
470 Check, E. (2006). Nature 441: 388-389. Voigt, C.A. and J.D. Keasling (2005). Nature Chemical Biology 6: 304-307.
471 Genewatch press release, 19 May 2006. http://www.genewatch.org/. 
472 Eurostat and IPTS calculation.
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(between 40% and 100%). Although the EU 
is the market leader in enzyme production, 
this field contributes comparatively little to 
the EU’s economic performance (0.008%). 
Bioethanol, because it is still at an early stage of 
development, takes a marginal share of the EU’s 
GVA (0.0002%) in economic terms. Overall, 
modern biotechnology contributes 33% to the 
GVA of the subsectors concerned and about 
0.88% to EU GVA. This is comparable to other 
sectors of manufacturing, such as rubber and 
plastic products (NACE DH 25: 0.86%) or textile 
and textile products (NACE DB 17/18: 0.77% of 
EU GVA).
The share of employees active in 
manufacturing processes based on modern 
biotechnology (without pharmaceutical 
production and chemical production) can be 
estimated at about 30% (1.5 million out of 
4.9 million employees) (see Table 2.15). Food 
processing, detergents and textile finishing 
contribute most, with the highest uptake of 
modern biotechnology. Food processing, in 
particular, accounts for 90% of biotechnology-
related jobs. Overall, modern biotechnology in 
industrial processes contributes about 0.75% to 
employment in the EU.
A look at the relation between employment 
and value added – labour productivity – reveals 
that, on average, biotechnological processes 
need one unit of labour input to generate 1.2 
units of GVA. The corresponding value for total 
EU manufacturing is 1.1. This indicates that 
modern industrial biotechnological processes are 
technologically superior to conventional methods. 
Regarding the individual subsectors, enzyme 
production seems to be the most advanced 
sector with labour productivity of about 2.6. In 
the comparable fine chemicals sector labour 
productivity is substantially lower on about 1.5. 
Bioethanol, with labour productivity of about 0.7, 
is far below the EU average of 1.0. This shows 
that this application is still at a rather early stage 
of development. By comparison, fuel production 
is a mature industry with a labour productivity 
value of 3.7, far above the EU average.
Environmental implications
In the context of modern biotechnology in 
manufacturing, energy and the environment, the 
most important environmental aspects to consider 
seem to be resource and energy use, greenhouse 
gas (GHG) emissions, other emissions and waste 
generation.
In the EU anthropogenic GHG emissions 
consist mainly of carbon dioxide (CO2: 83%), 
methane (CH4: 7.5%), nitrous oxide (N2O: 8%), 
and others (1.5%). Industrial manufacturing 
processes contribute 8% directly to GHG 
emissions (5% CO2, 1.1% N2O and only a 
negligible amount of CH4), plus an additional 
14% via industrial combustion processes (see 
Figure 2-21). Transport contributes 21% to overall 
GHG emissions; more than 90% of that is due to 
combustion of road transport fuel, of which 37%, 
or 7.9% of all GHG emissions, is due to gasoline 
combustion. Energy generation is another major 
contributor to GHG emissions with 29%. Fuel 
combustion in sectors other than manufacturing 
industry contributes an additional 17%.473
Figure 2‑21 Sectors with GHG (CO2, CH4, 
N2O) reduction potential by means of 
modern biotechnology
473 Based on: European Commission (2006). Progress report by the EU to the Intergovernmental Panel on Climate Change (IPCC). 
Submission 2006, v. 1.4. European Commission, Brussels. 
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Based on 2001 data for four EU Member 
States (Denmark, Germany, Italy and the UK),474 
GHG emissions from manufacturing industry 
were analysed. Out of the total of 5% of all GHG 
emissions generated by industrial processes 
emitting CO2, about 27% (1.3% of CO2) can 
be attributed to branches of industry applying 
biotechnological processes (the chemical industry, 
food and feed processing, pulp and paper 
production and the textile industry) and could 
potentially be further influenced by application 
of modern biotechnology. CH4 emissions are 
negligible. N2O (1.1%) is produced almost 
exclusively by the chemical industry, in particular 
in production of nitric and adipic acid. For both 
substances no large-scale use is being made of 
biotechnological production, so the direct impact 
of modern biotechnology on N2O emissions can 
be assumed to be zero.
Modern biotechnology in industrial 
processes generally leads to a decrease in energy 
use, which in turn decreases CO2 emissions. 
The degree of reduction depends on the specific 
application and on the characteristics of the 
specific process. In the examples given it ranges 
from about 10% (biobleaching in textile finishing) 
to 70% (detergents). The potential for further 
reductions due to increased use of modern 
biotechnology also varies from sector to sector. In 
food processing take-up of modern biotechnology 
is already comparatively high, whereas bio-based 
polymer production is still an emerging sector.
About one third of the GHG emissions 
from transport, or 7.9% of total GHG emissions, 
are caused by gasoline combustion. Blending 
transport fuels with bioethanol can help to 
improve the environmental impact of this 
sector. The environmental impact of bioethanol 
compared with fossil fuel depends on a variety 
of factors, such as import share (and origin of 
imports), type of biomass used and production 
pathway. First-generation biofuels, produced in 
the EU using the most economically attractive 
production method, result in greenhouse gas 
emissions 35%-50% lower than the conventional 
fuels they replace. Applied to gasoline’s 7.9% 
share in overall GHG emissions, this means that 
100% replacement of gasoline with bioethanol 
would lower GHG emissions by around 4%. 
Accordingly, compliance with the European 
Commission’s 5.75% target will lead to a 
reduction of around 0.23% in GHG emissions. 
This calculation takes into account the whole 
lifecycle. There are other production pathways, 
one of which is estimated to lead to higher GHG 
emissions than the fossil fuel it replaces.
Power generation, including energy generation 
(21%), industrial fuel combustion (13%) and 
fuel combustion in other non-energy and non-
industrial sectors, e.g. the residential sector or 
agriculture (17%), is the largest GHG emitter. GHG 
emissions from industrial fuel combustion are 
more than 50% higher than GHG emissions from 
industrial processes (8%). Application of modern 
biotechnology in power generation produces a 
dual environmental impact: a direct impact, due 
to the switch from non-renewable resources such 
as oil to renewable resources such as biomass as 
input material, and an indirect impact as a result 
of lower energy demand from industrial processes. 
This unquantifiable indirect effect emerges 
because as a general rule application of enzymatic 
processes in industrial production reduces energy 
use in the process concerned.
Overall, modern biotechnology contributes 
to sustainable production and consumption by 
reducing the necessary inputs, e.g. chemicals and 
energy, and also emissions into the air (GHG) or 
water and consumption of water.
Modern industrial biotechnology seems 
to be applied primarily in individual stages 
of specific production processes. Take-up of 
modern biotechnology in industrial applications 
appears to proceed at a slow pace, despite the 
cost-effectiveness of biotechnological processes 
(including increased labour productivity) and 
474 Data from Eurostat.
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supporting regulatory measures (e.g. biofuels). 
One factor could be that industrial biotechnology 
is often targeted at sectors where mainly chemical 
approaches are used (e.g. textiles or pulp 
production). Hence, awareness of alternative 
biotechnological approaches is often lacking, 
as is the necessary expertise.475 In addition, 
introduction of biotechnological processes 
requires investment in R&D, infrastructure and 
staff, which creates a bottleneck, in particular 
for small and medium-sized companies.476 The 
increasing awareness of the need for energy- and 
resource-efficient processes and sustainable, low-
carbon technologies might add to the interest in 
industrial biotechnology.
475 Wolf O. and P. Sørup (eds.) (2000). The introduction of process-integrated biocatalysts in companies. European Commission, 
DG JRC/IPTS EUR 19582, p. 57.
476 Wolf O. and P. Sørup (2000). The introduction of process-integrated biocatalysts in companies. European Commission,
 DG JRC/IPTS EUR 19582, p. 57.
11
JR
C
  R
EF
ER
EN
C
E 
R
EP
O
RT
11
JR
C
  R
EF
ER
EN
C
E 
R
EP
O
RT
11
C
on
se
qu
en
ce
s,
 O
pp
or
tu
ni
tie
s 
an
d 
C
ha
lle
ng
es
 o
f 
M
od
er
n 
Bi
ot
ec
hn
ol
og
y 
fo
r 
Eu
ro
pe
JR
C
  R
EF
ER
EN
C
E 
R
EP
O
RT
The competitiveness of the EU in developing 
modern biotechnology applications depends 
on the EU’s capacity for conducting research, 
generating new knowledge and converting it 
into new products and processes. Stimulating 
research, but also promoting take-up of 
innovations and encouraging entrepreneurship 
in biotechnology to reap the economic returns 
that can be generated from the research results, 
have been identified as challenges for the EU.477 
This chapter will describe the current situation 
with modern biotechnology R&D in the EU and 
worldwide in terms of research publications, 
patent applications and dedicated biotechnology 
firms.
3.1 Bibliometric analysis
Worldwide, the absolute number of biotech-
nology publications increased by 24% between 
1995-1997 and 2002-2004, with the EU 
accounting for about 38% of the publications in 
2002-2004, a similar share to the USA (see Figure 
3-1). Considering population size, however, the 
USA is more productive with 469 biotechnology 
publications per million inhabitants, followed by 
Japan with 316 publications per million and the 
EU with 297 per million. This relative success of 
the USA in terms of publication output is further 
underlined by the fact that in the USA there were 
only 17 holders of a PhD in life sciences per 
million inhabitants in 2003/2004, compared with 
27 per million in the EU.478
Figure 3‑1 Distribution of biotechnology 
publications in the period 2002‑2004 by 
country/region
Source: ETEPS.479, IPTS calculations.
RoW: rest of the world.
Nevertheless, between 1995-1997 and 2002-
2004 the share of biotechnology publications 
out of all scientific publications increased (from 
12%-14% in the EU, from 15%-17% in the USA 
and from 11%-13% worldwide), indicating the 
growing importance of biotechnology research. 
The distribution by sectors of application 
highlights the significance of health-related 
biotechnology (see Figure 3-2). Worldwide, 
health biotechnology accounted for over 50% of 
all biotechnology publications over the period 
1995 to 2004. Out of the countries analysed, 
only Brazil, India and Russia publish considerably 
less on health biotechnology (from 25%-35% of 
all biotechnology publications). Globally, agro-
food biotechnology generates around 17% of all 
biotechnology publications, with Brazil and India 
showing higher research activity in this area (29% 
and 32% respectively). Publications focusing 
3 Modern biotechnology R&D in the EU and 
worldwide
477 European Commission (2006). 2006 Report from the Competitiveness in Biotechnology Advisory Group (CBAG). DG Enterprise 
and Industry, European Commission, Brussels. http://ec.europa.eu/enterprise/phabiocom/comp_biotech_commit.htm. 
478 ETEPS (2006) Bio4EU: Task 2 Main report. 
479 ETEPS (2006) Bio4EU: Task 2 Main report.
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on manufacturing, energy and the environment 
are a minor field of research with only 4% of all 
biotechnology publications worldwide in 2002-
2004, up from 2% in 1995-1997. Only India 
shows comparatively higher activity in this field, 
with 13%. Russia focuses strongly on publications 
covering generic biotechnology topics, which are 
addressed by more than 50% of its biotechnology 
publications.480
Figure 3‑2 Distribution of biotechnology 
publications in the period 2002‑2004 by 
sector
Source: ETEPS.481
MEE: manufacturing, energy and environment.
3.2 Analysis of patent applications
Looking at biotechnology patent applications 
to the European Patent Office (EPO),482 between 
1995 and 2004 the absolute number of 
biotechnology patent applications per three-year 
period fluctuated between 18 657 and 33 189. 
Over the period 2002-2004 the EU accounted 
for 35% of all biotechnology patent applications, 
whereas 41% could be attributed to the USA 
(see Figure 3-3). Hence, while the EU generates 
as many biotechnology publications as the USA 
in absolute terms, it seems to be less successful 
at converting this scientific knowledge into 
practical and economically promising inventions. 
Although the US share of biotechnology patent 
applications decreased between 1995 and 2004, 
other countries, such as Japan, China, Singapore 
and South Korea, increased their patenting 
activities, and the EU’s share remained stable.483
Figure 3‑3 Share of biotechnology patent 
applications in the period 2002‑2004 per 
country/region
RoW: rest of the world.
Source: ETEPS.484, IPTS calculations.
When it comes to the relative importance 
of the different fields of use, the distribution of 
biotechnology patent applications mirrors the 
results of the bibliometric analysis: health is the 
most important sector, accounting for 50% of 
all biotechnology patent applications from the 
480 ETEPS (2006) Bio4EU: Task 2 Main report
481 ETEPS (2006) Bio4EU: Task 2 Main report
482 Patent applications to the EPO were taken as the basis for the patent analysis because recent data are available and because 
patent applications to the EPO are considered comparatively costly, i.e. it can be assumed that applications are filed only for 
commercially attractive and economically sustainable inventions. However, by leaving out, for example, patent applications to 
the United States Patent and Trademark Office (USPTO), this analysis could be biased in favour of the EU. A separate analysis 
by Fraunhofer ISI revealed that about 80% to 90% of the patent applications are granted, i.e. applications can be taken as a 
proxy for patents granted.  
483 ETEPS (2006) Bio4EU: Task 2 Main report. 
484 ETEPS (2006) Bio4EU: Task 2 Main report
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different countries, the only exception being 
India (see Figure 3-4). The second largest class 
are generic biotechnology patents, whose share 
has been increasing since 1995 to reach 22% 
of all biotechnology patent applications to the 
EPO in 2002-2004. Agro-food biotechnology 
patents account for about 10% of all patent 
applications with little variation across countries. 
Biotechnology in manufacturing, energy and 
the environment, in contrast to its share of 
biotechnology publications, generates about 
13% of all biotechnology patent applications in 
the EU.485 This suggests that scientific progress 
in manufacturing (measured by publications) is 
more readily converted into relevant practical 
inventions.
Looking at the role of modern biotechnology 
in R&D and inventiveness in each sector, the 
share of biotechnology patent applications 
out of all patent applications confirms, in 
particular, the significance of biotechnology for 
the health sector, where about 40% of all patent 
applications to the EPO relate to biotechnology 
(see Figure 3-5). But in the agro-food sector 
too biotechnology plays an important role in 
applied R&D, where it generates about 20%-
30% of all patent applications. By contrast, for 
manufacturing, energy and the environment, 
biotechnology seems to play a comparatively 
small role, with under 10% of all patent 
applications relating to biotechnology.486 
However, in this sector modern biotechnology 
is even less relevant in the EU than it is in the 
USA or in other countries – despite the EU 
doing quite well according to the bibliometric 
analysis.
Figure 3‑4 Distribution of biotechnology 
patent applications in the period 2002‑2004 
by sector
Source: ETEPS.487
Figure 3‑5 Share of biotechnology patent 
applications out of patent applications 
from all sectors in the period 2002‑2004 by 
country/region
Source: ETEPS.488
MEE: manufacturing, energy and environment.
485 ETEPS (2006) Bio4EU: Task 2 Main report.
486 ETEPS (2006) Bio4EU: Task 2 Main report.
487 ETEPS (2006) Bio4EU: Task 2 Main report.
488 ETEPS (2006) Bio4EU: Task 2 Main report.
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3.3 Biotechnology in the private sector
The predominance of the health sector in 
modern biotechnology is also visible from the 
distribution of dedicated biotechnology firms 
(DBF) by sector. According to Critical I (2006), 
37% of biotechnology companies in 18 European 
countries (including Norway and Switzerland) 
were active in the human health care sector 
(see Figure 3-6); another 18% were classified 
as active in biodiagnostics, which also includes 
health care diagnostics. Companies active in 
agricultural and environmental biotechnology 
make up 11% of all DBFs, and 34% of the bio-
technology companies provide services such as 
bioprocessing and screening. The distribution 
in the USA is even more focused on health care 
(53% of all DBFs there are active in this sector), 
with only 5% of companies active in agriculture 
and the environment.
Figure 3‑6 Distribution of biotechnology 
companies in 2004 by sector
Source: Critical I489.
In contrast to biotechnology patent applica-
tions, where the USA was in the lead, 2032 
DBFs were identified in the EU in 2004 (based 
on 16 EU Member States), similar to the USA 
with 1991 DBFs.490 Within the EU, most of the 
companies are located in Germany, the UK, 
France, the Netherlands and the Scandinavian 
countries (see Figure 3-7). However, DBFs are 
defined as companies whose primary activity 
depends on biotechnology. Hence, for example, 
large pharmaceutical companies for which 
biotechnology is a comparatively minor part of 
their business are not included in this definition, 
even though their biotechnology business may 
be bigger than that of many DBFs. Allowing for 
population size, the USA has a higher number of 
DBFs per million inhabitants (seven) than the EU 
with five DBFs per million (see Figure 3-8).491
Figure 3‑7 Number of dedicated 
biotechnology firms (DBFs) and average 
number of employees by country
Source: Critical I492.
489 Critical I (2006): Biotechnology in Europe: 2006 comparative study. Critical I, Banbury
490 Critical I (2006): Biotechnology in Europe: 2006 comparative study. Critical I, Banbury. 
491 ETEPS (2006) Bio4EU: Task 2 Main report.
492 Critical I (2006): Biotechnology in Europe: 2006 comparative study. Critical I, Banbury
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Figure 3‑8 Dedicated biotechnology firms in 
the EU and the USA in 2004
Data Source: Critical I493, ETEPS494.
Therefore, the number of DBFs in a given 
region is in itself only a weak indicator of the 
capacity of the region to create new companies 
and derive economic returns from the scientific 
knowledge it generates. Moreover, looking in 
more detail at these companies reveals that 
European DBFs employ, on average, about 43 
staff, while DBFs in the USA have about 2.2 
times more employees (see Figure 3-8). Big 
companies, such as Novo Nordisk in Denmark, 
may inflate the national averages considerably 
(see Figure 3-7). And while the share of R&D staff 
in both regions is similar, accounting for about 
42% of all staff, turnover and R&D expenditure 
indicate that the US biotechnology sector is both 
economically more successful and investing more 
in development of new products: on average, 
the turnover of US DBFs is about twice as high 
as the average turnover of their EU counterparts 
and US companies spend a larger share of their 
revenue on R&D than DBFs in the EU (50% vs. 
35%). Given the higher revenue of DBFs in the 
USA, this results in absolute R&D spending three 
times higher. This stronger position of US DBFs 
may also explain why they are able to raise about 
five times more equity capital per company 
than European DBFs (EUR 4 830 000 vs. EUR 
874 000). Consequently, in the case of private-
sector biotechnology, the capacity to apply this 
technology to practical and commercial ends 
seems to be higher in the USA than in the EU.
Analysis of the global modern bio-technology 
R&D landscape, with particular focus on the EU, 
and of the performance of the EU and the USA 
in converting new scientific knowledge into 
economically viable products and businesses has 
shown that even though the EU is doing well in 
terms of researchers and public biotechnology 
research centres, its output in terms of scientific 
publications is relatively lower than the output in 
the USA. And while this output is still on a par 
with the US output in absolute terms, the EU’s 
capacity to apply this knowledge to generate novel 
products, to encourage entrepreneurship and to 
create new and competitive companies is lower 
than the USA’s. Consequently, the EU still faces 
the challenge identified by the Competitiveness in 
Biotechnology Advisory Group (CBAG),495 namely 
promoting biotechnology entrepreneurship based 
on the knowledge created by scientific research.
493 Critical I (2006): Biotechnology in Europe: 2006 comparative study. Critical I, Banbury
494 ETEPS (2006) Bio4EU: Task 2 Main report
495 European Commission (2006). 2006 Report from the Competitiveness in Biotechnology Advisory Group (CBAG). DG Enterprise 
and Industry, European Commission, Brussels, cf above.
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In this chapter the economic, social 
and environmental implications of modern 
biotechnology will be summarised and discussed 
in the context of two horizontal European 
strategies, namely the Lisbon Strategy and 
the Sustainable Development Strategy. In the 
following, these EU strategies will be briefly 
described and the contributions of modern 
biotechnology to the achievement of the 
respective objectives will be presented.
The policy context
The	Lisbon	Strategy
In March 2000, the Lisbon European Council 
committed the EU to becoming the world’s most 
competitive and dynamic knowledge-based 
economy within ten years, capable of sustainable 
economic growth, with more and better jobs and 
greater social cohesion496. This initiative, called 
the Lisbon Strategy, was launched against the 
background of high unemployment and economic 
challenges, not only from the USA but also from 
Asian countries. Biotechnology was considered to 
be one of the new technologies with the potential 
to support the Lisbon Strategy497. Consequently, the 
Commission was requested to examine measures 
to harness the full potential of biotechnology 
and to strengthen the biotechnology sector’s 
competitiveness. The Strategy for Life Sciences and 
Biotechnology was developed in 2002498, together 
with an Action Plan.
An assessment of the achievements of the 
Lisbon Strategy in 2004 revealed that progress 
in meeting the goals was too slow499. As a result, 
the strategy was revised in 2005, with the focus 
on “stronger, lasting growth and more and 
better jobs” while striving for high social and 
environmental standards500. A mid-term review of 
the Strategy on Life Sciences and Biotechnology 
was also considered in this context, to which this 
Bio4EU study provides a major input501.
The Sustainable Development Strategy
In 2001, the Lisbon Strategy was 
complemented by the Sustainable Development 
Strategy (SDS), strengthening the environmental 
dimension502. Sustainable development means 
meeting the needs of the present generation 
without compromising the ability of future 
generations to meet their own needs503. The 
SDS is broader in scope and takes a longer-
term perspective than the Lisbon Strategy. It was 
reviewed in 2005 and the key issues refocused. 
These are climate change and clean energy, public 
health (handling health threats, health promotion 
and disease prevention), management of natural 
resources (biodiversity and resource efficiency), 
sustainable transport, and global poverty and 
development challenges.
The SDS, like the Lisbon Strategy, is also 
implemented through other, more sector-
4 Contribution of modern biotechnology to European 
policy objectives
496 Presidency conclusions, Lisbon European Council, 23 and 24 March 2000.
497 Presidency conclusions, Stockholm European Council, 23 and 24 March 2001.
498 European Commission COM(2002)27: Communication of the Commission to the European Parliament, the Council, the 
Economic and Social Committee and the Committee of the Regions - Life sciences and biotechnology – a Strategy for Europe. 
499 European Commission (2004). Facing the challenge: the Lisbon strategy for growth and employment. Report from the High 
Level Group chaired by Wim Kok. European Commission, Brussels. 
500 European Commission (2005). Growth and jobs: working together for Europe’s future. Communication to the Spring European 
Council. European Commission, Brussels. 
501 European Commission COM(2005)286 final: Sciences and biotechnology – a strategy for Europe. Third progress report and 
future orientations. 
502 Presidency Conclusions, Gothenburg European Council, 15 and 16 June 2001. 
503 World Commission on Environment and Development (1987). Our common future. Oxford University Press, Oxford. 
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specific policy initiatives, such as the 6th 
environment action programme504 and the 
Environmental Technology Action Plan505, while 
the EU’s Common Agricultural and Common 
Fisheries Policies include Lisbon and SDS policy 
objectives.
Due to recent increases in oil prices and 
high import dependency, energy supply security 
receives more attention, over and above the 
environmental and climate change aspects of 
using fossil energy sources. Alternative energy 
sources such as biofuels are gaining in importance, 
as reflected in several policy initiatives506.
EU policy objectives regarding public 
health are also described in the programme of 
Community action in the field of public health507 
508. In addition to addressing SDS objectives, this 
programme goes hand in hand with the Lisbon 
strategy, as good health is crucial to economic 
growth. Moreover, the general principles and 
requirements of food law must also be considered 
in the context of “health and food safety”509, 
as should the protection of animal health and 
welfare, and the European Environment and 
Health Strategy.510
The prerequisite for any contribution of 
modern biotechnology to the achievement 
of EU policy objectives is the availability and 
uptake of modern biotechnology applications. 
The Bio4EU study confirms the considerable 
uptake of modern biotechnology within the EU 
economy in three main areas: medicine and 
health care, primary production and agro-food, 
and industrial production processes, energy 
and the environment. Modern biotechnology 
products and processes are used, for example, in 
the cultivation of crops and animal husbandry, in 
food processing, in the manufacturing of textiles, 
paper and chemicals, in fuel production, in the 
production of pharmaceuticals and in health 
care. In the following, the implications of modern 
biotechnology are described in terms of major EU 
policy objectives.
Contributions of modern biotechnology 
to the Lisbon Agenda
In the context of the Lisbon Strategy, the 
analysis focused on:
• economic significance of modern 
biotechnology products and processes,
• employment related to modern biotechnology 
and quality of jobs, and
• labour productivity and international 
competitiveness.
Economic	significance	of	modern	biotechnology	
applications
The analysis confirmed that modern 
biotechnology applications are important 
contributors to the EU economy. Taking the 
production and use of modern biotechnology 
applications in medicine and health care, primary 
production and agro-food, industrial production 
504 European Commission COM(2001)31 final. Communication from the Commission to the Council, the European Parliament, 
the Economic and Social Committee and the Committee of the Regions on the sixth environment action programme of the
 European Community ‘Environment 2010: Our future, Our choice’ - The Sixth Environment Action Programme. 
505 European Commission (COM(2004)38): Communication from the Commission to the Council and the European Parliament 
- Stimulating Technologies for Sustainable Development: An Environmental Technologies Action Plan for the European Union.
506 European Commission (2005). Doing more with less: green paper on energy efficiency. European Commission, Brussels. 
Directive 2003/30/EC of the European Parliament and of the Council on the promotion of the use of biofuels or other renewable 
fuels for transport, OJ L 123/42, 17.5.2003.
507 Decision No 1786/2002/EC of the European Parliament and of the Council adopting a Community programme in the field of 
public health (2003-2008), OJ L 271/1, 9.10.2002.  
508 Amended proposal for a decision of the European Parliament and of the Council establishing a Programme of Community 
action in the field of Health 2007-2013 - COM(2006)234 final. 
509 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general 
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures of food 
safety, OJ L 31/1, 1.2.2002. 
510 European Commission COM(2003)338 final: Communication from the Commission to the Council and the European Parliament 
and the European Social and Economic Committee - A European Environment and Health Strategy. 
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processes, energy and the environment, modern 
biotechnology contributes to about 1.43%-1.69% 
of the EU’s gross value added (based on 2002 
GVA data). Further induced economic effects, 
such as improved health status and applications 
not included (modern biotechnology in R&D of 
small molecule drugs or in chemical production), 
would add to this estimate. This is in the range 
of entire economic sectors such as agriculture 
(1.79%) or chemicals (1.95%).
Yet, within the EU, the adoption rates of 
biotechnology-based products and processes in 
the various sectors and fields of application vary 
considerably. In the area of medicine and health 
care, where biotechnology is widely applied, 
biotechnology applications contribute about 30% 
to the overall turnover of in vitro diagnostics in 
the EU, whereas biopharmaceuticals have a share 
of 9% in the total turnover of pharmaceuticals. 
In the field of industrial manufacturing, modern 
biotechnology adoption is even more divergent: 
turnover shares of individual applications range 
from less than 1% in the case of biotechnology-
based polymers, 10% in pulp and paper, 30% in 
detergents and to up to 100% in the production 
of specific fine chemicals. Finally, in the agro-
food sector modern biotechnology is estimated 
to directly contribute 13%-23% to the overall 
turnover of the input sectors, such as breeding or 
feed additive production, while the use of these 
biotechnology-based inputs affects about 32%-
38% of the agro-food sector’s total turnover.
However, given the different degrees of 
adoption of individual applications, there is further 
growth potential insofar as modern biotechnology 
enables the provision of new or improved 
products or enhances efficiency. For instance, 
dynamic developments of this kind can be seen 
in health biotechnology, where the EU market 
for biopharmaceuticals has grown twice as fast 
as the overall EU pharmaceuticals market. Patent 
data also highlight the significance of modern 
biotechnology for medical and agro-food-related 
developments: in the time period 2002-2004, 
39% and 21%, respectively, of all sector patent 
applications were biotechnology-related.
Effects	of	modern	biotechnology	on	employment
The contribution of modern biotechnology 
to employment is mainly seen in the creation of 
“better jobs” (i.e. more higher qualified jobs), due 
to the higher level of training often necessary to 
develop and deal with biotechnology products 
and processes. Measuring the quantitative impact 
(i.e. “more jobs”) is hampered by limited data 
availability and the difficulties of integrating 
indirect employment effects. Nevertheless, the 
order of magnitude of direct employment effects 
is probably in line with the overall uptake of 
biotechnology applications, although some of 
the newly generated jobs can be assumed to 
substitute existing ones.
Effects	 of	 modern	 biotechnology	 on	
competitiveness
Modern biotechnology may improve 
competitiveness through efficiency gains that 
lead to higher labour productivity. For instance, 
labour productivity in industrial manufacturing 
processes where modern biotechnology is 
applied is estimated to be 10% to 20% higher 
than conventional processes. However, other 
countries, especially the USA, were often 
quicker or more pro-active in adopting modern 
biotechnology applications and they did so more 
comprehensively, i.e. they were able to increase 
their competitiveness vis-à-vis the EU. While the 
USA had embarked late on the production of 
bioethanol, for example, they provided policy 
support that helped its enterprises to gain a large 
share of world production within a few years’ 
time. Similarly, developments in China and India 
indicate that, at least in terms of market size, 
these countries may soon outpace the EU, too. 
In the field of health biotechnology, only 15% 
of the biopharmaceuticals on the market were 
developed by EU companies, compared to over 
50% developed by US companies. That said, in 
the agro-food sector – if GM seeds and GM crops 
are disregarded – the EU has significant shares 
in the markets for which biotechnology-based 
products are relevant.
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The predominance of the USA in modern 
biotechnology is also visible in terms of R&D 
activities, namely scientific publications and 
patent applications. Although the EU has a 
similar number of scientific publications in 
absolute terms, the output of the USA is about 
60% higher per million capita. In addition, as 
regards patent applications, the EU is doing less 
well in translating the scientific knowledge that it 
has gained into patents.
Contributions of modern biotechnology 
to environmental sustainability
In the context of the environmental aspects 
of the Sustainable Development Strategy, the 
analysis considered:
• resource productivity,
• emission reduction, including greenhouse 
gas emissions and waste prevention, and
• energy supply security.
In the agro-food sector, biotechnology 
applications are mostly aimed at improving 
production efficiency. Thus, modern 
biotechnology contributes to reducing the use of 
resources and the emission of harmful substances 
per unit output. More direct impacts include, for 
example, the reduction of drug and antibiotic 
treatments in animal production due to the use of 
(recombinant) vaccines. However, some modern 
biotechnology applications may also raise new 
challenges, requiring a case-by-case evaluation 
of specific aspects or potential risks (e.g. in 
relation to GMOs or feed additives). To this 
end, the EU has put in place specific legislation 
making it obligatory to carry out comprehensive 
risk assessments before placing such products on 
the market.
In the case of industrial production processes, 
modern biotechnology applications reduce 
the use of crucial inputs like energy, water or 
chemicals in production processes. Consequently, 
modern biotechnology applications reduce 
greenhouse gas emissions, waste generation and 
the use of non-renewable resources. For instance, 
given that energy production for industrial use 
generates over 50% more greenhouse gases than 
the industrial production processes themselves, 
reduced energy demand could lead to a 
substantial decrease in related emissions.
Another, indirect impact of modern 
biotechnology could emerge from the use of 
biofuels in the transport sector, which is responsible 
for 21% of total greenhouse gas emissions. 
Because more than a third of this share (7.9%) is 
due to the combustion of gasoline, the blending 
of gasoline with bioethanol, which results in 
comparatively lower greenhouse gas emissions, 
could help to reduce the environmental impact 
of this sector. In addition, the use of renewable 
biomass for energy generation could also help to 
diversify the energy portfolio and improve energy 
supply security. However, emerging issues such 
as potentially increasing land use intensity and 
the large-scale use of food and feed products for 
non-food purposes, such as maize and wheat in 
the case of bioethanol, need to be considered.
While the overall contribution of modern 
biotechnology to the different environmental 
objectives is impossible to quantify in absolute 
terms, the fact that modern biotechnology 
applications lead, in general, to improvements in 
the eco-efficiency of production processes, while 
being themselves a new source of economic 
activity, underscore its role in decoupling 
economic growth from environmental pressures.
Contributions of modern biotechnology 
to public health and food safety
In the context of public health, including 
food safety, the analysis focused on:
• improved warning, monitoring and control 
of communicable diseases,
• reduction of disease burden, and
• reduction of health care and social costs.
The analysis was based on case studies of 
modern biotechnology-based medicinal products 
and diagnostics. The case studies indicate that 
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modern biotechnology may provide various 
benefits, such as better clinical interventions and 
treatment options, potentially safer products, and a 
higher quality of life of the individuals concerned. 
Health biotechnology thus contributes to progress 
in the monitoring and control of communicable 
diseases, to increases in the effectiveness of 
medical intervention, to reductions in the burden 
of disease and to improvements in the quality of 
life of those suffering from disease. Seen in this 
light, modern biotechnology will help to keep 
an ageing population healthier, thus facilitating 
active ageing, in the context of other measures, 
not least disease prevention.
Its contribution to reducing health care and 
social costs is less clear: in some cases, modern 
biotechnology applications increase efficiency 
in the health care sector, thus contributing to the 
objective of reducing health care costs, while in 
other cases a new drug puts an overproportional 
strain on health care resources. While the latter 
case is not specific to biotechnology-based 
therapies, and also applies to conventional 
approaches, it emphasises the ethical question of 
how to allocate scarce resources in health care. A 
more general assessment of the cost-effectiveness 
of health biotechnology applications is still 
pending, given that in many cases the results of 
pertinent studies are only preliminary and further 
studies are needed. Moreover, as the technology 
matures and generic biopharmaceuticals 
(biosimilars) reach the market, product prices may 
come down, thus improving cost-effectiveness.
The public health effects of modern 
biotechnology applications in the agro-food 
sector build on the availability of new and 
better diagnostics and vaccines. In particular, 
the monitoring and control of some of the most 
important zoonoses and food safety concerns 
(e.g. Salmonella and BSE) help to safeguard food 
EU-wide and to ensure consumer confidence in 
the food chain. However, as some biotechnology 
applications may raise new issues relating to 
animal welfare, a case-by-case assessment may 
be needed. Nevertheless, modern biotechnology 
also provides solutions that improve animal 
health and welfare in a variety of ways, such as 
through replacing the use of animals as tools in 
chemical safety testing or through the provision 
of novel animal health management tools that 
decrease animal suffering.
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Nucleic-acid-related technologies
Nucleic acids consist of polymerised 
nucleotides. Two forms of nucleic acids are 
known: DNA (deoxyribonucleic acid) and RNA 
(ribonucleic acid). For all higher organisms, 
including humans, DNA constitutes the genome, 
which includes all the necessary information for 
proteins and the functioning of the body. Nucleic 
acids exist in linear or circular forms, single- or 
double-stranded (the “double helix”).
High-throughput sequencing of nucleic acids 
(DNA, RNA) is used to determine the sequence 
of the different individual building blocks of 
nucleic acids (nucleotides) in the most efficient 
way, i.e. automatically, quickly and at low cost. 
Micro-arrays are the basic component in this 
approach. The time taken to sequence a genome/
gene/certain amount of DNA has decreased since 
1995 when traditional sequencing methods were 
replaced by high-throughput technologies.
Nucleic acid sequencing is used to identify 
genome structures, compare gene sequences and 
predict protein structures.
DNA synthesis and amplification. Polymerase 
chain reaction (PCR) is an essential technology 
for copying and amplifying DNA. It makes use 
of specific enzymes, namely DNA polymerases 
that are capable of synthesising new DNA using 
a DNA template and copying it. If this process is 
repeated several times, small amounts of DNA can 
be amplified. PCR was developed in the 1980s 
and was awarded the Nobel Prize in 1993.
Genetic fingerprinting or genotyping is 
used for identification or distinction between 
individuals of one species based on their DNA. 
The technique is often used in forensic analyses, 
Annex 1: Modern biotechnologies
The basic technologies used in modern biotechnology (see Table A.1) are described below.
Table A.1 Technologies used in modern biotechnology
Nucleic-acid (DNA/RNA)-
related technologies
• High-throughput sequencing of genome, gene, DNA
• DNA synthesis and amplification
• Genetic engineering
• Anti-sense technology
• siRNA technology
Analysis and modification of 
genetic material
Protein-related technologies
• High-throughput protein/peptide identification,
quantification and sequencing
• Protein/peptide synthesis
• Protein engineering and biocatalysis
Analysis and modification of 
proteins
Metabolite-related
technologies
• High-throughput metabolite identification and
quantification
• Metabolic pathway engineering
Analysis of metabolites (small 
molecules)
Cellular-/ subcellular-related 
technologies
• Cell hybridisation/fusion
• Tissue engineering
• Embryo technology
• Stem-cell-related technologies
• Gene delivery
• Fermentation and downstream processing 
Cell manipulation for various 
applications 
Supporting tools • Bioinformatics
Application of computational 
tools in analysis and storage of 
biological data
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but also in plant and animal breeding. If PCR 
is used for amplification, only small amounts 
of DNA are needed. Restriction enzymes are 
applied to cut the DNA at specific sequences. 
The resulting pattern of DNA fragments is specific 
to an individual.
Genetic engineering is used to modify the 
genome of an organism by adding or deleting a 
gene or modifying the nucleotide sequences of 
existing genes. The modified organism thus gains 
or losses certain abilities, such as producing a 
specific enzyme. In micro-organisms, mainly 
for use in industrial production processes but 
also for bioremediation, metabolic pathways 
are modified or new ones are introduced by 
genetic engineering, called “metabolic pathway 
engineering”. Genetic engineering is also called 
transgenesis, recombinant DNA technology or 
genetic modification.
Anti-sense technology means use of anti-
sense RNA to block translation of mRNA into 
the respective amino acid chain and thus 
prevent gene expression. It is applied mainly in 
research to study gene function, but recently this 
principle has also been applied for therapeutic 
approaches.
siRNA technology: RNA interference 
(RNAi) is a mechanism invented by nature to 
protect the genome. In the past few years this 
field has emerged at a surprisingly rapid pace. 
The underlying molecular mechanism of gene 
silencing provides short interfering RNAs (siRNAs), 
which can target any gene with high specificity 
and efficiency. Successful knock-downs of 
disease-related genes indicate that siRNAs open 
the door for novel therapeutic procedures.
Protein-related technologies
Proteins consist of varying numbers of 
polypeptides, which consist of amino acid 
chains. Genetic information encodes amino acid 
sequences of proteins.
High-throughput identification,  quantifica-
tion and sequencing. High-throughput technolo-
gies for proteins are not yet as far advanced as 
those for nucleic acids due to the complex struc-
ture of proteins. Classic technologies, such as gel 
electrophoresis, mass spectroscopy and nuclear 
magnetic resonance, are being developed further 
to produce high-throughput versions.
Protein/peptide synthesis is the chemical 
creation of proteins and peptides. Natural 
proteins and peptides can be produced this 
way (particularly if they are difficult to produce 
using other tools), but modified proteins (using, 
for example, non-natural amino acids) can also 
be synthesised. Nowadays, solid-phase synthesis 
is used. The growing amino acid chain is linked 
to a bead in a reactant solution. Amino acids are 
added one by one to the polypeptide backbone. 
The process can be automated.
Biocatalysis. Catalysts are substances 
which have the ability to increase the speed 
of a chemical reaction. Enzymes (which are 
proteins) are natural catalysts and are used in 
transformations of organic compounds, e.g. 
natural fibres or food. Enzymes can be used in 
isolated form or within a cell line or an organism, 
usually bacteria, yeasts or fungi. The process 
to optimise enzymes for the desired function is 
also called protein engineering. The “rational 
design” approach requires detailed knowledge 
of the structure and function of the enzyme and 
its amino acid sequence to introduce targeted 
changes at DNA level. The “directed evolution” 
approach uses randomly introduced mutations 
and a selection system to develop enzymes/
organisms with the desired qualities.
Metabolite-related technologies
Metabolites are compounds of low molecular 
weight that are intermediate or end-products of 
metabolism. The metabolome includes the whole 
set of metabolites of a given organism, tissue or 
cell under certain conditions.
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High-throughput technologies for 
identification, quantification and analysis. 
The metabolome can be analysed by a range 
of techniques, including high-performance 
mass spectrometry, high-performance liquid 
chromatography, liquid chromatography/mass 
spectrometry, nuclear magnetic resonance 
spectroscopy and others. High-throughput 
techniques are attracting increasing attention as 
an emerging tool for identification of metabolic 
pathways and of biomarkers associated with 
diseases.
Cellular- and subcellular-related 
technologies
Modern biotechnologies are applied in 
manipulation of cells and microorganisms for 
various purposes. Cell-based technologies include, 
for example, tissue engineering, i.e. application of 
cells to regenerate biological tissue. In addition, 
cells can be manipulated to generate a specific 
protein which can be easily extracted. Stem cells 
are unspecialised cells which have the capacity 
to differentiate into various cell types under 
given conditions, providing a promising tool for 
development of new therapies. So far they have 
been applied in bone marrow transplantation.
Bioinformatics
Bioinformatics means application (and 
development) of computational tools and 
approaches for retrieval, analysis and storage of 
biological information.511 Bioinformatics may be 
applied, for example, in analysis of genomes, 
protein structures or entire biological systems 
(e.g. neural networks).
511 The NIH working definition of bioinformatics and computational biology is available at: http://www.bisti.nih.gov/CompuBioDef.pdf.
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512 OECD (2006). Biotechnology Statistics. OECD, Paris.
513 ETEPS (2006) Task 1 – Mapping of modern biotechnology applica-tions and industrial sectors, identification of data needs and 
development of indicators. Final report. http://bio4eu.jrc.es/documents/Bio4EU-Task1.pdf. 
514 The case studies cover: therapeutics, preventives and diagnostics in medicine and health care; diagnostics and preventives 
in animal health; diagnostics, breeding and propagation techniques in primary production and the agro-food chain; and 
processing of biomass, use of enzymes, production of exemplary fine chemicals and bioremediation systems in industrial 
processes, energy and the environment. 
Annex 2: Methodology
Scope
Modern	biotechnologies
Biotechnology can be defined as “the 
application of science and technology to living 
organisms, as well as parts, products and models 
thereof, to alter living or non-living materials for the 
production of knowledge, goods and services”.512 
This definition includes both traditional processes 
that have been used for a very long time, e.g. in 
the food and drinks industry, and also modern 
biotechnological processes. This study focuses on 
major modern biotechnologies. These encompass 
DNA-, protein-, metabolite- and cell-based 
technologies, together with supporting tools, used 
for modification of living or non-living materials for 
production of goods and services. This definition 
does not include traditional biotechnologies, such 
as fermentation and conventional animal and plant 
breeding. However, modern biotechnologies used 
in combination with traditional biotechnologies, 
e.g. fermentation processes using recombinant 
organisms, are considered modern biotechnology. 
Major modern biotechnologies were identified in 
a preparatory stage of the study (see Annex 1).513
Biotechnology	applications	included
Modern biotechnology applications were 
subdivided into three main fields of application:
• Medicine and health care;
• Primary production and agro-food;
• Industrial production processes, energy and 
the environment.
Geographical	area
The analysis focuses on EU-25 and its 
competitors, in particular the USA and Japan; for 
specific applications, additional countries have 
been included. Companies were allocated to a 
country or region on the basis of the location of 
their headquarters.
Assessment
General	approach
The impact of biotechnology was subdivided 
into direct or indirect: in the context of this 
study, direct impact means effects on the users of 
biotechnology, while indirect impact means the 
effects resulting from use of products derived from 
biotech-nology (downstream sectors). Therefore, 
the direct impact (at sector and EU level) covers 
the various effects arising from the activities of 
producers of modern biotechnology products, 
such as pharmaceutical companies, breeders, 
enzyme manufacturers, etc. The indirect impact 
relates mainly to the effects arising from use of 
these products and may affect several links along 
the production chain.
The aim of the analysis was to provide 
results at the most aggregated level possible in 
terms of both indicators and sectors. In addition, 
a representative set of 29 case studies was used 
to analyse in depth the current economic, social 
or environmental impact. The case studies 
were selected to cover all relevant applications 
of modern biotechnology, particularly those 
considered to have the greatest impact, whether 
economic, environmental or social.514
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The preliminary phase of the study assessed 
the availability of data for potential indicators.515 In 
the second stage, indicators were selected based 
on their relevance to major EU policy objectives. 
While there is no standard methodology for 
linking the indicators to EU policy objectives, 
a structured approach was developed that first 
identified the major policy objectives and then 
related the indicators to these objectives, where 
possible on a quantitative basis. The approach is 
illustrated in Figure A-2.516
A cost-benefit analysis in the strict sense 
of the term517 was not carried out, for a number 
of several reasons. Firstly, for many modern 
biotechnology applications there is a significant 
lack of data regarding adoption and the 
economic, social and environmental impacts. It 
was not possible to fill these data gaps within the 
framework of this study. Thus it is impossible to 
quantify in a meaningful way costs or benefits of 
modern biotechnology applications. Secondly, 
modern biotechnology is a comparatively new 
technology and so many of the applications 
identified are fairly recent. Major technologies 
such as modern biotechnology often develop over 
long time horizons, and cost-benefit analysis can 
be very sensitive to when it is performed. Thus 
for many applications, and for the technology as 
such it is too early to assess conclusively the costs 
and benefits. Thirdly, modern biotechnology, 
due to its enabling character, has effects over 
wide areas of the EU economy involving a large 
number of actors and stakeholders, rendering any 
cost-benefit analysis a hugely complex task, and 
unfeasible in the framework of this study.
Data
Data were obtained from a number of 
sources. Depending on availability and based 
on data quality, the following descending order 
of priority was applied for data compilation 
purposes: official statistics and reports 
(provided by public institutions), peer-reviewed 
publications, surveys and interviews of industrial 
and technical experts, market reports and other 
publications and, finally, web-based information 
from validated sources. This information was 
obtained either from direct desk research or 
from the ETEPS network.518 Overall, data quality 
was highest for the medicine and health care 
sector, followed by manufacturing, and lowest 
for primary production and the agro-food sector. 
Where no robust data were available, an effort 
was made to provide estimates for illustrative 
purposes. In any case, at least a qualitative 
analysis was performed. All conversions to euro 
used this rate: 1 Dollar = 0.7765 Euro.
A lack of data on many applications of 
modern biotechnology limited the quantitative 
analysis. Future assessments would benefit from 
improvements in the basic statistics.
515 ETEPS (2006) Task 1 – A preparatory study mapping modern biotechnology applications and industrial sectors, identifying data 
needs and developing indicators. Final report http://bio4eu.jrc.es/documents/Bio4EU-Task1.pdf. 
516 For further details and, in particular, a list of the indicators used, see the Analysis Report: DG JRC/IPTS (2007). Analysis Report: 
contributions of modern biotechnology to European policy objectives, http://bio4eu.jrc.es/documents.html. 
517 Cost-benefit analysis is an approach to investment appraisal which takes a broad view of locating and quantifying the costs and 
benefits of a project, including external costs and benefits. 
518 See also http://bio4eu.jrc.es/tasks.html. 
Figure A‑2. Approach for selection of indicators based on policy objectives and the final assessment
EU strategy or 
policies
Ë
Derivation
of policy
objectives
Ë Assessment Á
Development
of policy
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Methodological remarks
Sector	classification
The sectors in which modern biotechnology 
is known to be applied were identified, based on 
the NACE classification,519 where feasible. For 
primary production and the agro-food sector, 
the sector classification provided by Eurostat 
was mainly used. Where needed, sectors were 
further disaggregated. For each biotechnology 
application the closest matching sector category 
was chosen as a benchmark, e.g. “manufacture of 
soap, detergents, cleaning and polishing” (NACE 
24.51) for “enzyme-containing detergents”. 
The data for each individual biotechnology 
application were then put into context alongside 
the benchmark data for the sector.
Economic	and	employment	indicators
Gross value added (GVA) for the most recent 
year (2002, with some exceptions) is the main 
economic indicator used throughout this analysis. 
Value added was chosen because it is equally 
as good as GDP or turnover as an economic 
measure, but more information is available in 
public databases. Turnover was used only for 
the analysis of primary production and the agro-
food sector, especially at more disaggregated 
levels, due to limited availability of GVA data. 
Where available, other economic indicators were 
also used, e.g. to show the changes induced by 
adoption of modern biotechnology in terms of 
efficiency increases. If no solid estimates could 
be obtained, the information was omitted. 
Competitiveness is discussed in qualitative terms 
throughout the analysis.
The number of direct employees was 
used as the main employment indicator. If this 
number is not known for a specific application 
of biotechnology, but the number of employees 
and rate of diffusion in the benchmark sector are, 
then “number of employees x diffusion rate” is 
applied to calculate employment numbers for the 
relevant application.
The figures obtained are linked to the 
corresponding statistics for the economy as a 
whole in order to learn (i) the contribution of 
biotechnology applications to GVA in EU-25 and 
(ii) the contribution of biotechnology applications 
to GVA (or turnover) of the various benchmark 
sectors used.
For the analysis of industry the labour 
productivity of biotechnology was also estimated as:
This figure was then used to determine (i) how 
the labour productivity of manufacturing sectors 
using enzymes relates to labour productivity in 
the relevant NACE sector and (ii) how their labour 
productivity relates to overall labour productivity 
in manufacturing.
This analysis was carried out for both the 
direct and the indirect impact by calculating 
the economic output and employment using 
biotechnology. Therefore, the analysis of the 
contributions made by modern biotechnology 
to the EU economy is static in that it does 
not calculate the change, in economic or 
employment terms, induced by adoption of 
modern biotechnology.
Where modern biotechnology (direct) or 
derived products (indirect) are used at some 
steps of a production process, the entire output is 
calculated as the impact of modern biotechnology, 
even if the modern biotechnology-based process 
is only one amongst several non-biotechnological 
steps in production. Therefore the indicator 
calculated provides a relative measure of the 
take-up and importance of modern biotechnology 
in the EU-25 economy rather than an absolute 
measure of the positive or negative effects on the 
economy. An additional reason for taking this 
approach can be found in the basic assumption 
that modern biotechnology production has 
519 NACE is the statistical classification of economic activities in the European Community. In this report version 1.1 of 2002 is used. 
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been taken up by producers in order to remain 
competitive on the relevant product market.
Environmental,	 energy	 and	 public	 health	
indicators
The assessment of the contribution made by 
modern biotechnology to the environment, energy 
and public health is based on a range of indicators. In 
the case of the environment and energy these include 
mainly resource productivity, waste prevention, 
air/soil/water quality, biodiversity, greenhouse gas 
emissions and security of supply; in the case of 
public health they include protection against health 
risks, disease prevention and health care and social 
costs. Yet, due to the inherent differences between 
the individual sectors and applications in the context 
of the environment and public health, the exact 
assessment varies between the three sectors. Where 
necessary, further details of the assessment are 
provided in the relevant chapters.
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A 
acrylamide (acrylic amide): readily polymerised Ë amide derived from acrylic acid used, for example, 
for manufacturing water-soluble thickeners and dyes, wastewater treatment, papermaking or in synthetic 
fibres; it is a carcinogen.
ADR: adverse drug reaction (can be reduced by Ë pharmacogenetics). 
agent: force or substance which has the power to produce an effect (to achieve an end). 
AI: artificial insemination.
AMI (acute myocardial infarction): heart attack.
amide: nitrogen-containing organic compound.
amylase: Ë enzyme that catalyses Ë hydrolysis of starch, glycogen and dextrin to sugar. 
anthropogenic: caused or produced by human activities.
antigen: substance that stimulates the immune system.
anti-sense technology: use of a specific Ë nucleic acid to inactivate a gene with complimentary sequence 
(the nucleic acid is called anti-sense and is designed to bind the intermediate à RNA derived from the 
respective gene).
autologous cell: cell that is re-implanted in the same individual as it came from.
B
bibliometrics: the study or measurement of texts and information, e.g. content analysis.
biocatalysis: use of Ë enzymes or Ë micro-organisms to perform chemical transformations on organic 
compounds (in industrial production processes). 
biocidal agent: Ë agent that is destructive to living organisms.
bioethanol: ethanol derived from Ë biomass by fermenting its sugar components, to be used as an 
alternative to gasoline.
bioinformatics: research, development or application of computational tools and approaches for expanding 
use of biological, medical, behavioural or health data.
biomass: renewable organic material (mostly plant matter but also animal or microbial waste) which can 
be used for fuel or industrial production.
biomolecule: chemical compound that naturally occurs in living organisms.
biopharmaceuticals: pharmaceuticals derived from biotechnology.
bioremediation: process that uses biological Ë agents (e.g. Ë micro-organisms) to break down, neutralise 
or remove contaminants (e.g. in polluted soil or water), to overcome environmental problems or to return 
the environment to its former state.
biosensor: device that detects or analyses a physiological change or a chemical or biological substance in 
the environment; it integrates a biological Ë agent with a physicochemical detector component.
Annex 3: Glossary of terms and acronyms
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biotechnology active firm: firm engaged in key biotechnology activities, such as application of at least one 
biotechnology technique to produce goods or services (or perform biotechnology R&D).
biotechnology: application of science and technology to living organisms and to parts, products and models 
thereof, to alter living or non-living materials for the production of knowledge, goods and services.
biotransformation: Ë biocatalysis.
Bt crop: crop that has been genetically engineered to be resistant to certain types of insects (the gene 
conferring resistance comes from the soil bacterium Bacillus thuringiensis).
C
CAGR: compound annual growth rate.
catalyst: substance that accelerates a chemical reaction.
cell culture: process by which cells are grown under controlled conditions.
cell-based therapy: therapeutic approach (which is in the development phase, e.g. Ë tissue engineering).
cellulase: Ë enzyme that catalyses Ë hydrolysis of cellulose (i.e. breaks down fibre to sugar).
cloning: reproduction of genetically identical “copies” of an organism.
corticoid (or corticosteroid): steroid Ë hormone produced by the cortex of the adrenal glands.
cost-utility analysis: economic analysis in which the effect of consumption of a good or service is measured 
in terms of the happiness, satisfaction or gratification gained (by a patient, society, etc.) relative to the cost 
of provision.
CVD (cardiovascular disease): disease affecting the heart or blood vessels.
D
DBF (dedicated biotechnology firm): Ë firm active in biotechnology whose predominant activity involves 
application of biotechnology techniques to produce goods or services (or perform biotechnology R&D).
DNA: Ë nucleic acid.
E
EMEA: European Agency for the Evaluation of Medicinal Products.
endotoxin or intracellular toxin: toxic compound within certain micro-organisms that is released upon 
destruction of the micro-organism.
enzyme: protein that accelerates a chemical reaction (catalyst). 
EPO: European Patent Office.
ESA: European Seed Association.
ESC (embryonic stem cell): Ë stem cell that is derived from the inner cell mass of embryos at the 
blastocyst stage; in contrast to somatic (adult) stem cells, ESCs are pluripotent, i.e. they have the capacity 
to differentiate into any one of the more than 200 cell types found in the body and they can replicate 
indefinitely in culture.
ET (embryo transfer) technique: one of a number of techniques, such as embryo transfer from donor to 
recipient, embryo sexing (through microsurgery on the embryo), embryo freezing and embryo splitting (to 
produce identical siblings).
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F
fermentation: whole cell Ë biocatalysis; process that allows cells to obtain energy from molecules 
anaerobically, by splitting complex organic compounds into simpler substances.
FMD: foot and mouth disease.
G
gene silencing: inactivation of genes (at the level of transcription or translation).
gene therapy: introduction of a gene into a cell to achieve a therapeutic goal through its product (protein).
genetic engineering: modification of the genome of an organism by adding or deleting a gene or modifying 
the nucleotide sequences of existing genes; the modified organism thus gains or loses certain abilities, 
such as producing a specific enzyme.
genetic fingerprinting: = genotyping. 
genetic modification: = genetic engineering.
genetic testing: in this report genetic testing is defined as DNA-based testing to identify variations in the 
DNA sequence that correlate with a disease or higher risk of developing a disease. It is often defined 
more broadly as analysis of human DNA, RNA, chromosomes, proteins and certain metabolites to detect 
heritable disease-related genotypes, mutations, phenotypes or karyotypes for clinical purposes or to 
establish family relationships.
genome: hereditary information of an organism, which is encoded in the Ë DNA.
genomics: study of an organism’s genome and the function of the genes.
genotype: specific genetic makeup (Ë genome) of an organism, which determines its hereditary 
characteristics.
genotyping: identification of or distinction between individuals of the same species based on their DNA.
GHG (greenhouse gas): gaseous component of the atmosphere that contributes to the greenhouse effect 
(i.e. to a rise of global temperatures); the three main Ë anthropogenic GHGs are carbon dioxide (CO2), 
methane (CH4) and nitrous oxide (N2O).
GM: genetically modified (Ë genetic engineering).
GMO: genetically modified organism (Ë genetic engineering).
GVA (gross value added): value of all newly generated goods and services minus the value of all goods 
and services consumed in producing them (i.e. minus the value of intermediate consumption).
H
herbicide tolerance (HT): ability of a crop to withstand a particular herbicide (which can therefore be used 
for weed management); HT is achieved by selective breeding, mutagenesis and Ë genetic engineering.
high-throughput technology: large-scale analysis (including identification, quantification and sequencing) 
of Ë nucleic acids, proteins or Ë metabolites.
hormone: chemical substance that controls and regulates the activity of certain cells or organs.
hybrid vigour (heterosis, outbreeding enhancement): superior qualities in Ë hybrids or increase in their 
performance over that of purebreds, most noticeably in Ë traits like fertility and sterility.
hybrid: plants or animals resulting from a cross between two genetically dissimilar parents
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hybrid: plants or animals resulting from a cross between two genetically dissimilar parents
(Ë hybrid vigour). 
hydrolysis: chemical reaction of a compound with water, in which one or more new compounds are 
formed through an exchange of functional groups. 
I
IETS: International Embryo Transfer Society.
immunoassay: biochemical test that uses antibodies to measure the level of a specific protein in a sample.
immunochemistry testing: detection of immune reactions by measuring the body’s reaction to foreign Ë agents.
immunostimulant: Ë agent that enhances the response of the immune system.
interferon: protein produced by cells of the immune system.
IVD (in vitro diagnostic): reagents and instruments for testing specimens taken from the body and intended 
for use in a broad spectrum of health care applications, including evaluation of an individual’s risk of 
developing specific diseases, their early detection, identification and monitoring of treatment, etc. 
IVF: in-vitro fertilisation.
IVP: in-vitro embryo production (part of Ë ET techniques).
L
labour intensity: the degree to which labour is used relative to capital (and land) in the production of a 
good or service.
labour productivity: measure for the amount of output (here Ë GVA) produced per unit of labour used. 
lignocellulose: strengthening substance found in woody plant cells, composed of lignin and cellulose.
lipase: Ë enzyme that catalyses Ë hydrolysis of fats into glycerol and fatty acids (e.g. in the digestive tract 
it breaks down fats into individual fatty acids, which can then be absorbed). 
lysine: amino acid that is needed for the growth of protein molecules but not produced by animals 
themselves; it can be found in other protein sources or is given as feed additive.
M
MAS (marker-assisted selection): use of molecular markers (certain DNA regions linked directly or 
indirectly to specific traits) to facilitate the incorporation of desirable Ë traits into selection schemes for 
plant or animal breeding.
MEE: manufacturing, energy and the environment.
metabolic engineering: modification of genetic and regulatory processes within cells to produce desired 
substances.
metabolism: biochemical modification of chemical compounds in living organisms and cells that produces 
energy and basic materials that are necessary for life.
metabolite: compounds of low molecular weight that are intermediates or end-products of metabolism.
metabolome: set of metabolites of a given organism, tissue or cell under certain conditions.
micro-array: collection of segments immobilised on a solid surface (e.g. glass, plastic or silicon chip) that 
allows Ë high-throughput analyses through hybridisation with a set of specific probes.
microbe: = microorganism.
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microorganism: any organism of microscopic size (i.e. too small to be seen with the naked eye).
micropropagation: use of tissue culture techniques for plant propagation to produce a large number of 
progeny plants.
molecular farming: cultivation of plants for the production of pharmaceuticals, functional proteins and 
industrial enzymes.
molecular marker: fragment of DNA sequence that is associated with a part of the genome.
molecular testing: investigation of disease association with a specific genotype.
monoclonal antibody: protein produced in the laboratory from a single clone of a B cell (the type of 
cells of the immune system that make antibodies); monoclonal antibodies bind to specific molecules at a 
specific site, e.g. a disease-causing organism, allowing targeted medication.
monogenic disease: inherited disease controlled by a single pair of genes.
mRNA: messenger Ë RNA.
N
NACE (Nomenclature générale des activités économiques dans les communautés européennes): general 
industrial classification of economic activities in the European Communities.
nanomedicine: application of Ë nanotechnology in treatment and in disease diagnosis and monitoring.
nanoparticle: microscopic particle below 100 nanometres in size.
nanotechnology: engineering of atoms, molecules or materials (on a scale below 100 nanometres) to 
produce new features.
NDDS: nano drug delivery systems.
nucleic acid: two forms of nucleic acids are known, DNA (deoxyribonucleic acid) and RNA (ribonucleic 
acid); for all higher organisms DNA constitutes the genetic material responsible for all heritable traits; 
RNA is an intermediate for the synthesis of proteins.
nutrigenetics: study of the effect of genetic variation on the interaction between diet and disease.
nutrigenomics: study of the response of organisms to food and food components using Ë genomics, Ë 
proteomics and metabolomics approaches.
O
OIE (Office International des Epizooties): World Organisation for Animal Health.
OPU: ovum pick-up (part of Ë ET techniques). 
orphan drug: medicinal product to diagnose, prevent or treat a life-threatening, seriously debilitating or 
serious and chronic condition affecting fewer than five in every 10 000 persons, of which the development 
and marketing cost is not expected to be recouped from sales of the product under normal market 
conditions because of the very low incidence of the underlying condition.
P
pathogen: Ë agent that can cause disease or illness. 
PCR (polymerase chain reaction): technology for copying and amplifying DNA by using enzymes.
peptide synthesis: chemical creation of peptides.
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PHA (polyhydroxyalkanoate): natural polymer produced by bacterial fermentation of sugar or lipids and 
synthesised and accumulated as an energy storage substance in cells; used as animal feed. 
pharmacogenetics: study of the influence of genetic variation on differences in how people respond to 
medicines with the aim of tailoring therapy to individual genetic make-up.
ploidy manipulation: increase of sets of chromosomes from two to three by giving embryos a shock (heat, 
cold or pressure) shortly after fertilisation; in aquaculture triploid fish are expected to perform better than 
their conventional diploid counterparts.
polymer: material composed of large molecules that are constructed of smaller, simpler molecules, which 
usually has a high molecular weight; polymers are essential material for almost every industry.
protein engineering: modification of a protein to achieve a desired function.
protein synthesis: chemical creation of protein.
proteomics: analysis of protein expression under different conditions, including separation, identification 
and characterisation of the proteins in a cell, to explain biological processes.
PSE: pale, soft and exudative (pig meat).
PUFA (polyunsaturated fatty acid): fatty acid that contains more than one double bond.
Q
QALY (quality-adjusted life year): weighted equivalent of one healthy life year.
R
recombinant DNA technology: = genetic engineering.
riboflavin: vitamin B2; used in food processing as a colorant or for fortification.
RNA: Ë nucleic acid.
RNAi (RNA interference): use of double-stranded Ë RNA to inactivate a specific gene.
RoW: rest of the world.
S
SCID: severe combined immunodeficiency.
SCNT (somatic cell nuclear transfer): production of animals by transfer of genetic material from one 
donor somatic cell to a recipient unfertilised oocyte from which the nuclear Ë DNA has been removed 
(enucleation).
sex manipulation: creation of monosex populations by hormonal treatment and appropriate breeding 
techniques; in aquaculture this results in increased productivity due to faster growth, reduced aggression 
and later maturation.
siRNA technology: = RNAi.
stacked trait: insertion of more than one Ë trait in a GMO.
stem cell: unspecialised cell that has the capacity for self-renewal and the ability to differentiate under 
certain physiological or experimental conditions into various types of specialised cells.
T
tissue engineering: regeneration of diseased tissues and organs by use of cells and with the aid of supporting 
structures or biomolecules.
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toe (tonne of oil equivalent): unit of energy; the amount of energy released by burning one tonne of crude oil.
trait: one of the many characteristics that define an organism.
transgene: genetic material that has been transferred by Ë genetic engineering from one organism to 
another.
transgenesis: = genetic engineering.
X
xenotransplantation: transplantation of cells, tissues or whole organs from one species to another.
Z
zoonose: infectious disease that can be transmitted from animals to humans or vice versa.
Note: These definitions are partly based on online sources: http://www.accessscience.com/, http://wordnet.
princeton.edu/, http://www.bartleby.com/, http://www.fao.org/biotech/, etc.


